

```

chain nodes :
  7  8  9 11
ring nodes :
  1  2  3  4  5  6
chain bonds :
  1-11  2-7  4-9  6-8
ring bonds :
  1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
  2-7  4-9  6-8
exact bonds :
  1-11
normalized bonds :
  1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
  containing 1 :

```

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 11:CLASS
Generic attributes :
  8:
    Saturation      : Unsaturated
  9:
    Saturation      : Unsaturated

```

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840



L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10582704.str



chain nodes :

7 9 10

ring nodes :

1 2 3 4 5 6

chain bonds :

4-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

4-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom

11:Atom

Generic attributes :

9:

Saturation : Unsaturated

10:

Saturation : Unsaturated

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2


=> d l4

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR



Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 21:21:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 105772 TO ITERATE

1.9% PROCESSED 2000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2096108 TO 2134772

PROJECTED ANSWERS: 621 TO 1493

L5 1 SEA SSS SAM L3 AND L1 NOT L2

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L6 SCREEN CREATED



10/582,704

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10582704 (a).str



chain nodes :
7 9 10
ring nodes :
1 2 3 4 5 6
chain bonds :
4-10 6-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-10 6-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
Generic attributes :
9:
Saturation : Unsaturated
10:
Saturation : Unsaturated

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7


L9 QUE L8 AND L6 NOT L7

=> d 19

L9 HAS NO ANSWERS

L6 SCR 1840

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L8 STR



Structure attributes must be viewed using STN Express query preparation.
 L9 QUE L8 AND L6 NOT L7

=> s l9 sss sam
 SAMPLE SEARCH INITIATED 21:23:21 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 105772 TO ITERATE

1.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2096108 TO 2134772
 PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L8 AND L6 NOT L7

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end



=> screen 1840

L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>
 Uploading C:\Program Files\Stnexp\Queries\10582704 (b).str



```

chain nodes :
7 9 10 12
ring nodes :
1 2 3 4 5 6
chain bonds :
4-10 6-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-10 6-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom
Generic attributes :
9:
Saturation : Unsaturated
10:
Saturation : Unsaturated

```

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12


=> d l14

L14 HAS NO ANSWERS

L11 SCR 1840

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR



Structure attributes must be viewed using STN Express query preparation.
 L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 21:25:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 105772 TO ITERATE

1.9% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2096108 TO 2134772
 PROJECTED ANSWERS: 0 TO 0

L15 0 SEA SSS SAM L13 AND L11 NOT L12

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840



L16 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L17 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10582704 (d).str



```

chain nodes :
7 8 9 11
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 2-7 4-9 6-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-7 4-9 6-8
exact bonds :
1-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 11:CLASS
Generic attributes :
8:
Saturation : Unsaturated
9:
Saturation : Unsaturated

```

L18 STRUCTURE UPLOADED

=> que L18 AND L16 NOT L17

L19 QUE L18 AND L16 NOT L17


=> d l19

L19 HAS NO ANSWERS

L16 SCR 1840

L17 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L18 STR



Structure attributes must be viewed using STN Express query preparation.
L19 QUE L18 AND L16 NOT L17

=> s l19 sss sam

SAMPLE SEARCH INITIATED 21:27:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 38110 TO ITERATE

5.2% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 750526 TO 773874

PROJECTED ANSWERS: 1001 TO 2047

L20 4 SEA SSS SAM L18 AND L16 NOT L17

=> => s l19 sss ful

FULL SEARCH INITIATED 21:28:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 766452 TO ITERATE

99.1% PROCESSED 759316 ITERATIONS

1392 ANSWERS

100.0% PROCESSED 766452 ITERATIONS

1392 ANSWERS

SEARCH TIME: 00.00.17

L21 1392 SEA SSS FUL L18 AND L16 NOT L17


=> => s l21

L22 28 L21

=> d l22 1-28 bib,ab,hitstr

L22 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1127812 CAPLUS
 DN 151:520158
 TI Design, synthesis, screening, and molecular modeling study of a new series
 of ROS1 receptor tyrosine kinase inhibitors
 AU El-Deeb, Ibrahim M.; Park, Byung Sun; Jung, Su Jin; Yoo, Kyung Ho; Oh,
 Chang-Hyun; Cho, Seung Joo; Han, Dong Keun; Lee, Jae Yeol; Lee, So Ha
 CS Life Sciences Research Division, Korea Institute of Science and
 Technology, Seoul, 130-650, S. Korea
 SO Bioorganic & Medicinal Chemistry Letters (2009), 19(19), 5622-5626
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB A series of rationally designed ROS1 tyrosine kinase inhibitors was
 synthesized and screened. Compound 12b has showed good potency with IC50
 value of 209 nM, which is comparable with that of the reference lead compound 1
 (I). Mol. modeling studies have been performed, i.e., a homol. model for
 ROS1 was built, and the screened inhibitors were docked into its major
 identified binding site. The docked poses along with the activity data
 have revealed a group of the essential features for activity. Overall,
 simplification of the lead compound 1 into compound 12b (II) has maintained the
 activity, while facilitated the synthetic advantages. A mol. interaction
 model for ROS1 kinase and inhibitors has been proposed.
 IT 1188271-28-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (design, synthesis, screening, and mol. modeling study of a new series
 of ROS1 receptor tyrosine kinase inhibitors)
 RN 1188271-28-4 CAPLUS
 CN 1H-Pyrazole-1-acetonitrile, 3-(3-hydroxy-5-methylphenyl)-4-[6-[(2S)-2-
 hydroxypropyl]amino]-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/582,704

L22 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:904811 CAPLUS
 DN 151:403239
 TI Design, synthesis and biological evaluation of new potent and highly
 selective ROS1-tyrosine kinase inhibitor
 AU Park, Byung Sun; El-Deeb, Ibrahim M.; Yoo, Kyung Ho; Oh, Chang-Hyun; Cho,
 Seung Joo; Han, Dong Keun; Lee, Hye-Seung; Lee, Jae Yeol; Lee, So Ha
 CS Life Sciences Research Division, Korea Institute of Science and
 Technology, Seoul, 130-650, S. Korea
 SO Bioorganic & Medicinal Chemistry Letters (2009) 19(16), 4720-4723
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB ROS1 protein is a receptor tyrosine kinase that has been reported mainly
 in meningiomas and astrocytomas, and until now, there is no selective
 inhibitor for this kinase. In this study, the synthesis of a highly
 potent and selective inhibitor for ROS1 kinase compound I is described.
 Compound I was tested initially at a single dose concentration of 10 μ M over
 45 different kinases. At this concentration, a 94% inhibition of the enzymic
 activity of ROS1 kinase was observed, while the inhibition in activity was
 below 30% in all of the other kinases. I was further tested in a 10-dose
 IC50 mode and showed an IC50 value of 199 nM for ROS1 kinase. I can be
 used as a promising lead for the development of new selective inhibitors
 for ROS1 kinase, and it may open the way for new selective therapeutics
 for astrocytomas.
 IT 1188271-28-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (design, preparation and biol. evaluation of a potent and highly selective
 ROS1-tyrosine kinase inhibitor pyridinyl(pyrimidinyl)pyrazole derivative as
 potential antitumor agent)
 RN 1188271-28-4 CAPLUS
 CN 1H-Pyrazole-1-acetonitrile, 3-(3-hydroxy-5-methylphenyl)-4-[6-[(2S)-2-
 hydroxypropyl]amino]-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)
 Absolute stereochemistry.



IT 1188271-33-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(design, preparation and biol. evaluation of a potent and highly selective ROS1-tyrosine kinase inhibitor pyridinyl(pyrimidinyl)pyrazole derivative as potential antitumor agent)

RN 1188271-33-1 CAPLUS

CN 1H-Pyrazole-1-acetonitrile, 4-[6-[[[(2S)-2-hydroxypropyl]amino]-2-(3-pyridinyl)-4-pyrimidinyl]-3-(3-methoxy-5-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/582,704

L22 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:643441 CAPLUS
 DN 151:78039
 TI Divergent Solution-Phase Synthesis of Diarylpyrimidine Libraries as
 Selective A3 Adenosine Receptor Antagonists
 AU Yaziji, Vicente; Coelho, Alberto; El Maatougui, Abdelaziz; Brea, Jose;
 Loza, M. Isabel; Garcia-Mera, Xerardo; Sotelo, Eddy
 CS Combinatorial Chemistry Unit (COMBIOMED) and Screening Unit (USEF),
 Institute of Industrial Pharmacy (IFI) and Departments of Pharmacology and
 Organic Chemistry, Faculty of Pharmacy, University of Santiago de
 Compostela, Santiago de Compostela, 15782, Spain
 SO Journal of Combinatorial Chemistry (2009), 11(4), 519-522
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 151:78039
 AB A practical and divergent solution-phase synthetic strategy has been
 optimized to prepare a highly diverse library of 2,4-diaryl- and
 2,6-diarylpyrimidines. Structural elaboration of the starting
 heterocyclic scaffolds was accomplished by exploiting the potential for
 diversity offered by the Suzuki-Miyaura cross-coupling reaction. These
 studies enabled the identification of structurally simple, highly potent,
 and selective A3 adenosine receptor antagonists.
 IT 856173-00-7P 1161849-95-1P 1161849-99-5P
 1161850-04-9P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP
 (Preparation)
 (parallel synthetic preparation and adenosine receptor antagonism of diaryl
 pyrimidine amine or amide derivs. via amidation of regioisomeric
 dichloropyrimidine amines and/or Suzuki coupling with boronic acids)
 RN 856173-00-7 CAPLUS
 CN 4-Pyrimidinamine, 2,6-di-2-furanyl- (CA INDEX NAME)




RN 1161849-95-1 CAPLUS
 CN Acetamide, N-(2,6-di-2-furanyl-4-pyrimidinyl)- (CA INDEX NAME)




RN 1161849-99-5 CAPLUS

CN Propanamide, N-(2,6-di-2-furanyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 1161850-04-9 CAPLUS

CN Butanamide, N-(2,6-di-2-furanyl-4-pyrimidinyl)- (CA INDEX NAME)




IT 1161850-05-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation) (parallel synthetic preparation and adenosine receptor antagonism of diaryl pyrimidine amine or amide derivs. via amidation of regioisomeric dichloropyrimidine amines and/or Suzuki coupling with boronic acids)


RN 1161850-05-0 CAPLUS

CN 4-Pyrimidinamine, 2,6-bis(1,3-benzodioxol-5-yl)- (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:420069 CAPLUS
 DN 151:505
 TI Discovery of substituted 4-anilino-2-arylpyrimidines as a new series of
 apoptosis inducers using a cell- and caspase-based high throughput
 screening assay. 2. Structure-activity relationships of the 2-aryl group
 AU Sirisoma, Nilantha; Pervin, Azra; Nguyen, Bao; Crogan-Grundy, Candace;
 Kasibhatla, Shailaja; Tseng, Ben; Drewe, John; Cai, Sui Xiong
 CS EpiCept Corporation, San Diego, CA, 92121 USA
 SO Bioorganic & Medicinal Chemistry Letters (2009), 19(8), 2305-2309
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 151:505
 AB As a continuation of our efforts to discover and develop the apoptosis
 inducing 4-anilino-2-(2-pyridyl)pyrimidines as potential anticancer
 agents, we explored replacing the 2-pyridyl group by other aryl groups.
 SAR studies showed that the 2-pyridyl group can be replaced by a
 3-pyridyl, 4-pyridyl and 2-pyrazinyl group, and that the SAR for the
 anilino group was similar to that of the 2-pyridyl series. However,
 replacement of the 2-pyridyl group by a Ph group, a 3,5-dichloro-4-pyridyl
 group, or a saturated ring led to inactive compds. Several potent compds.,
 including 2f, 3d, 3j and 4a, with EC50 values of 0.048-0.024 μ M in the
 apoptosis induction assay against T47D cells, were identified through the
 SAR studies. In a tubulin polymerization assay, compound 2f, which was active
 against all the three cell lines tested (T47D, HTC116 and SNU398),
 inhibited tubulin polymerization with an IC50 value of 0.5 μ M, while compound
 2a, which was active against T47D cells but not active against HTC116 and
 SNU398 cells, was not active in the tubulin assay at up to 50 μ M.
 IT 438248-45-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (discovery of substituted 4-anilino-2-arylpyrimidines as new series of
 apoptosis inducers. structure-activity relationships of 2-aryl group)
 RN 438248-45-4 CAPLUS
 CN 4-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-2,6-di-2-pyridinyl- (CA INDEX
 NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/582,704

L22 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:59824 CAPLUS
 DN 150:229197
 TI Similarity-Based Classifier Using Topomers to Provide a Knowledge Base for
 hERG Channel Inhibition
 AU Nisius, Britta; Goeller, Andreas H.
 CS Global Drug Discovery, Lead Generation and Optimization, Bayer HealthCare
 AG, Wuppertal, D-42096, Germany
 SO Journal of Chemical Information and Modeling (2009), 9(2), 247-256
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English
 AB In a proof of principle study we show that the similarity property
 principle can be applied to predict ADMET properties, exemplified on the
 case of hERG K⁺ channel inhibition. Early prediction of a drug
 candidate's hERG channel activity is becoming increasingly important in
 the drug discovery process because blockade of the hERG channel may lead
 to life-threatening cardiac arrhythmias. Using the Tripos Topomer Search
 technol. as compound similarity measure, we query mols. with unknown hERG
 activity for similar mols. in a set of compds. with known hERG activity.
 The hERG activity of the query mol. is then predicted based on the hERG
 activity of its Topomer Search neighbors and their distances to the query
 mol. The similarity property principle can be applied with promising
 performance to predict hERG inhibition as long as there is a high
 structural overlap between the chemical spaces of the query compds. and the
 reference data set. We show that this is achievable for database sizes of
 about 10000 structurally diverse mols. In this case topoHERG is a
 similarity-based hERG classifier, which also acts as a knowledge base for
 hERG channel inhibition.
 IT 912938-66-0 912939-70-9 912939-72-1
 912940-88-6 944704-43-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (similarity-based classifier using topomers to provide a knowledge base
 for hERG channel inhibition)
 RN 912938-66-0 CAPLUS
 CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-
 furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912939-70-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-

methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 912939-72-1 CAPLUS

CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)




RN 912940-88-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)- (CA INDEX NAME)



RN 944704-43-2 CAPLUS

CN Acetamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:48813 CAPLUS

DN 150:136099

TI N-[6-Amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A Receptor Antagonists with Improved Drug Like Properties and in Vivo Efficacy

AU Lanier, Marion C.; Moorjani, Manisha; Luo, Zhiyong; Chen, Yongsheng; Lin, Emily; Tellew, John E.; Zhang, Xiaohu; Williams, John P.; Gross, Raymond S.; Lechner, Sandra M.; Markison, Stacy; Joswig, Tanya; Kargo, William; Piercey, Jaime; Santos, Mark; Malany, Siobhan; Zhao, Marilyn; Petroski, Robert; Crespo, Maria I.; Diaz, Jose-Luis; Saunders, John; Wen, Jenny; O'Brien, Zhihong; Jalali, Kayvon; Madan, Ajay; Slee, Deborah H.

CS Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development and Preclinical Development, Neurocrine Biosciences, San Diego, CA, 92130, USA

SO Journal of Medicinal Chemistry (2009), 52(3), 709-717

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 150:136099

AB In the present article, we report on a strategy to improve the phys. properties of a series of small mol. human adenosine 2A (hA2A) antagonists. One of the aromatic rings typical of this series of antagonists is replaced with a series of aliphatic groups, with the aim of disrupting crystal packing of the mol. to lower the m.p. and in turn to improve the solubility. Herein, we describe the SAR of a new series of water-soluble 2,4,6-trisubstituted pyrimidines where R1 is an aromatic heterocycle, R2 is a short-chain alkyl amide, and the typical R3 aromatic heterocyclic substituent is replaced with an aliphatic amino substituent. This approach significantly enhanced aqueous solubility and lowered the log P of the system to provide mols.

without significant hERG or CYP liabilities and robust in vivo efficacy.


IT 1032047-51-0P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heteroaryl pyrimidinylacetamides as A2A receptor antagonists)

RN 1032047-51-0 CAPLUS


CN Acetamide, N-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1299465 CAPLUS
 DN 149:556566
 TI Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A Adenosine Receptor Antagonists for the Treatment of Parkinson's Disease
 AU Zhang, Xiaohu; Tellaw, John E.; Luo, Zhiyong; Moorjani, Manisha; Lin, Emily; Lanier, Marion C.; Chen, Yongsheng; Williams, John P.; Saunders, John; Lechner, Sandra M.; Markison, Stacy; Joswig, Tanya; Petroski, Robert; Piercey, Jaime; Kargo, William; Malany, Siobhan; Santos, Mark; Gross, Raymond S.; Wen, Jenny; Jalali, Kayvon; O'Brien, Zhihong; Stotz, Carol E.; Crespo, Maria I.; Diaz, Jose-Luis; Slee, Deborah H.
 CS Departments of Medicinal Chemistry, Pharmacology, Neuroscience, Chemical Development, Preclinical Development and Pharmaceutical Development, Neurocrine Biosciences, San Diego, CA 92130, USA
 SO Journal of Medicinal Chemistry (2008), 51(22), 7099-7110
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 149:556566
 AB 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)pyrimidines bearing substituted pyridyl groups as C-6 substituents were prepared as selective adenosine hA2A receptor antagonists for the treatment of Parkinson's disease. I (R = 5-MeO-3-pyridyl) (hA2AKi 2.3 nM, hA1Ki 190 nM) was orally active at 3 mg/kg in a rat HIC model but exposure was poor in nonrodent species, presumably due to poor aqueous solubility. Follow-on compound I (R = 6-(morpholin-4-yl)-2-pyridyl) (hA2AKi 0.83 nM, hA1Ki 130 nM) had improved solubility and was orally efficacious (3 mg/kg, HIC) but showed time-dependent cytochrome P 450 3A4 inhibition, possibly related to morpholine ring metabolism. I (R = 6-(4-methoxypiperidin-1-yl)-2-pyridyl) (hA2AKi 0.44 nM, hA1Ki 80 nM) was sparingly soluble but had good oral exposure in rodent and nonrodent species, had no cytochrome P 450 or human ether-a-go-go related gene channel issues, and was orally efficacious at 1 mg/kg in HIC and at 3 mg/kg for potentiation of L-dopa-induced contralateral rotations in 6-hydroxydopamine-lesioned rats.
 IT 1061747-79-2P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, physicochem. properties and biol. evaluation of (acetylamino)(dimethylpyrazol)(pyridyl)pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)
 RN 1061747-79-2 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




IT 1082056-57-2P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation, physicochem. properties and biol. evaluation of (acetylamino) (dimethylpyrazol) (pyridyl) pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)

RN 1082056-57-2 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 1082056-67-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation, physicochem. properties and biol. evaluation of (acetylamino) (dimethylpyrazol) (pyridyl) pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)


RN 1082056-67-4 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methoxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]-, acetate (4:1) (CA INDEX NAME)

CM 1

CRN 1061747-72-5

CMF C22 H27 N7 O2



CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 1082056-61-8P 1082056-62-9P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, physicochem. properties and biol. evaluation of (acetylamino) (dimethylpyrazol) (pyridyl)pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)


RN 1082056-61-8 CAPLUS

CN 4-Morpholineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1082056-62-9 CAPLUS

CN Propanamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




IT 1061747-82-7P 1061747-85-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, physicochem. properties and biol. evaluation of (acetylamino)(dimethylpyrazol)(pyridyl)pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)


RN 1061747-82-7 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methyl-1-piperazinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061747-85-0 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-hydroxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




IT 1082056-58-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, physicochem. properties and biol. evaluation of (acetylaminio)(dimethylpyrazol)(pyridyl)pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)

RN 1082056-58-3 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-hydroxy-3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




IT 1061747-76-9P 1061747-89-4P 1061747-95-2P
 1061748-02-4P 1061748-03-5P 1061748-33-1P
 1061748-41-1P 1061748-57-9P 1061748-68-2P
 1082056-53-8P 1082056-55-0P 1082056-60-7P
 1082056-63-0P 1082056-64-1P 1082056-66-3P
 1082056-68-5P 1082056-70-9P 1082056-71-0P
 1082056-72-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, physicochem. properties and biol. evaluation of (acetylamino) (dimethylpyrazol) (pyridyl) pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)

RN 1061747-76-9 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[(2-methoxyethyl)methylamino]-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061747-89-4 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-88-3

CMF C21 H25 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1061747-95-2 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(4-morpholinyl)-4-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-02-4 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-01-3

CMF C21 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-03-5 CAPLUS

CN Acetamide, N-[6-[6-(dimethylamino)-2-pyridinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-33-1 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-pyrrolidinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-41-1 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[5-(4-morpholinyl)-3-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061748-57-9 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[4-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-68-2 CAPLUS

CN Acetamide, N-[6-(6-amino-2-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-67-1

CMF C16 H17 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1082056-53-8 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(3-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1082056-52-7
 CMF C16 H16 N6 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1082056-55-0 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(4-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1082056-54-9
 CMF C16 H16 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1082056-60-7 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[5-(2-methoxyethoxy)-3-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1082056-59-4

CMF C19 H22 N6 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1082056-63-0 CAPLUS

CN Carbamic acid, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 1082056-64-1 CAPLUS
 CN Carbamic acid, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 1082056-66-3 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(6-(3-methoxy-1-azetidiny)-2-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1082056-65-2

CMF C20 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1082056-68-5 CAPLUS


CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1082056-70-9 CAPLUS


CN 4-Morpholineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1082056-71-0 CAPLUS

CN Propanamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1082056-72-1 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-hydroxy-3-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1082056-58-3

CMF C16 H16 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 1061748-14-8P 1061748-43-3P 1061750-08-0P

1061750-09-1P 1061750-13-7P 1082056-69-6P


1082056-73-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, physicochem. properties and biol. evaluation of (acetyl amino) (dimethylpyrazol) (pyridyl) pyrimidines and analogs as A2A adenosine receptor antagonists for the treatment of Parkinson's disease)


RN 1061748-14-8 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-morpholinyl)-2-pyridinyl]- (CA INDEX NAME)




RN 1061748-43-3 CAPLUS


CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[4-(4-morpholinyl)-2-pyridinyl]- (CA INDEX NAME)




RN 1061750-08-0 CAPLUS
 CN Acetamide, N-[6-(6-chloro-2-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061750-09-1 CAPLUS
 CN Acetamide, N-[6-(2-chloro-4-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061750-13-7 CAPLUS
 CN Acetamide, N-[6-(5-bromo-3-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1082056-69-6 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxy-3-pyridinyl)- (CA INDEX NAME)



RN 1082056-73-2 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-pyrrolidinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1062369-06-5
 CMF C18 H21 N7



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:1280206 CAPLUS
 DN 149:488716
 TI Novel inhibitors of glutaminyl cyclase and their therapeutic uses
 IN Buchholz, Mirko; Heiser, Ulrich; Sommer, Robert
 PA Probiobdrug A.-G., Germany
 SO U.S. Pat. Appl. Publ., 52pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20080260688	A1	20081023	US 2008-105832	20080418
WO 2008128984	A1	20081030	WO 2008-EP54714	20080418
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 2142536 A1 20100113 EP 2008-736363 20080418 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR PRAI US 2007-912942P P 20070420 WO 2008-EP54714 W 20080418				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 149:488716

AB Thirty-six novel compds. are provided that inhibit glutaminyl cyclase (EC 2.3.2.5). Thus, for example, N-(3-(1H-imidazol-1-yl)propyl)-6-methyl-2-phenylpyrimidin-4-amine inhibits glutaminyl cyclase with a Ki of 18 µM and IC50 of 47.8 µM. Such compds. or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, can be used to inhibit glutaminyl cyclase in vivo and for the treatment of conditions effected by modulation of glutaminyl cyclase activity. Also described are reactions for the synthesis of these compds.


IT 1070657-38-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitors of glutaminyl cyclase and their therapeutic uses)

RN 1070657-38-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3-furanyl)-N-[3-(1H-imidazol-1-yl)propyl]-2-(4-pyridinyl)- (CA INDEX NAME)



L22 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2008:1157507 CAPLUS
 DN 149:402382
 TI Preparation of pyrimidines as adenosine A2A receptor antagonists
 IN Chen, Yongsheng; Moorjani, Manisha; Slee, Deborah; Tellet, John; Zhang, Xiaohu
 PA Neurocrine Biosciences, Inc., USA
 SO PCT Int. Appl., 70pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008116185	A2	20080925	WO 2008-US57911	20080321
	WO 2008116185	A3	20090312		
	W:	AE, AG, AL, AM, AO, AP, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	EP 2132197	A2	20091216	EP 2008-732707	20080321
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
PRAI	US 2007-896198P	P	20070321		
OS	WO 2008-US57911	W	20080321		
AB	MARPAT 149:402382				
	Title compds. [I; R1 = (substituted) heterocyclyl, Ph, pyridyl; R2 = (substituted) isoquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl; R3 = H, R7, COR7, CO2R7; R7 = (substituted) alkyl], were prepared as adenosine A2A receptor antagonists (no data). Thus, 2-amino-3-(6-morpholin-4-ylpyridin-2-yl)acrylonitrile (preparation given), pyridine-2-carboxamide hydrochloride, and NaOEt were microwaved together in EtOH at 160-180° to give				
IT	2-(pyridin-2-yl)-6-(6-morpholin-4-ylpyridin-2-yl)pyrimidin-4-ylamine.				
	1061747-65-6P	1061747-69-0P	1061747-73-6P		
	1061747-75-8P	1061747-76-9P	1061747-78-1P		
	1061747-79-2P	1061747-82-7P	1061747-86-1P		
	1061747-89-4P	1061747-91-8P	1061747-93-0P		
	1061747-95-2P	1061747-99-6P	1061748-02-4P		
	1061748-03-5P	1061748-06-8P	1061748-08-0P		
	1061748-11-5P	1061748-15-9P	1061748-18-2P		
	1061748-19-3P	1061748-22-8P	1061748-24-0P		
	1061748-26-2P	1061748-30-8P	1061748-32-0P		
	1061748-33-1P	1061748-37-5P	1061748-40-0P		
	1061748-41-1P	1061748-44-4P	1061748-46-6P		
	1061748-49-9P	1061748-52-4P	1061748-55-7P		
	1061748-57-9P	1061748-60-4P	1061748-66-0P		
	1061748-68-2P	1061749-92-5P	1061749-94-7P		

1061749-95-8P 1061749-97-0P 1061749-99-2P

1061750-02-4P 1061750-05-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidines as adenosine A2A receptor antagonists)


RN 1061747-65-6 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(1-pyrrolidinyl)-4-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-64-5

CMF C20 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061747-69-0 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(1-pyrrolidinyl)-4-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-68-9

CMF C18 H21 N7



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061747-73-6 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methoxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-72-5

CMF C22 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061747-75-8 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methoxy-1-piperidinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-74-7

CMF C20 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1061747-76-9 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[(2-methoxyethyl)methylamino]-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061747-78-1 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[(2-methoxyethyl)methylamino]-2-pyridinyl]- (CA INDEX NAME)




RN 1061747-79-2 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061747-82-7 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methyl-1-piperazinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061747-86-1 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-hydroxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-85-0
 CMF C21 H25 N7 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1061747-89-4 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-88-3
 CMF C21 H25 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1061747-91-8 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1061747-93-0 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(ethylpropylamino)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-92-9
 CMF C21 H27 N7 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 1061747-95-2 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(4-morpholinyl)-4-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061747-99-6 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[ethyl(2-methoxyethyl)amino]-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061747-98-5
 CMF C21 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-02-4 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-piperidiny1)-2-pyridiny1]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-01-3

CMF C21 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1061748-03-5 CAPLUS

CN Acetamide, N-[6-[6-(dimethylamino)-2-pyridinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-06-8 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(2-methoxy-1-azetidinyl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-05-7

CMF C20 H23 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-08-0 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-07-9

CMF C21 H26 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1061748-11-5 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-pyrrolidinyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1061748-15-9 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-morpholinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-14-8

CMF C18 H21 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-18-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methyl-1-piperazinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-17-1

CMF C19 H24 N8



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1061748-19-3 CAPLUS

CN 4-Pyrimidinamine, 2-[(3,5-dimethyl-1H-pyrazol-1-yl)-6-[2-(4-morpholinyl)-4-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1061748-22-8 CAPLUS

CN 4-Piperidinol, 1-[6-[6-amino-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-21-7

CMF C19 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1061748-24-0 CAPLUS


CN 3-Pyrrolidinol, 1-[6-[6-amino-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-2-pyridinyl]-, (3R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-23-9

CMF C18 H21 N7 O

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1061748-26-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2-pyridinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1061748-30-8 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(2-methoxy-1-azetidinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-29-5
 CMF C18 H21 N7 O




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1061748-32-0 CAPLUS
 CN 4-Pyrimidinamine, 6-[6-(dimethylamino)-2-pyridinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 1061748-33-1 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(1-pyrrolidinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-37-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[5-(1-pyrrolidinyl)-3-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-36-4

CMF C18 H21 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-40-0 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[5-(1-pyrrolidinyl)-3-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061748-41-1 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[5-(4-morpholinyl)-3-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061748-44-4 CAPLUS

CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[4-(4-morpholinyl)-2-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-43-3

CMF C18 H21 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1061748-46-6 CAPLUS

CN 4-Pyrimidinamine, 6-[6-(4-morpholinyl)-2-pyridinyl]-2-(2-pyridinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-45-5

CMF C18 H18 N6 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1061748-49-9 CAPLUS

CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-[6-(4-morpholinyl)-2-pyridinyl]-
(CA INDEX NAME)


RN 1061748-52-4 CAPLUS

CN Acetamide, N-[6-[6-(4-morpholinyl)-2-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-51-3

CMF C20 H20 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1061748-55-7 CAPLUS
 CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-[6-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-54-6
 CMF C20 H21 N5 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 1061748-57-9 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[4-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061748-60-4 CAPLUS

CN Carbamic acid, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(4-morpholinyl)-2-pyridinyl]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)




RN 1061748-66-0 CAPLUS

CN Acetamide, N-[6-(4-amino-2-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-65-9

CMF C16 H17 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1061748-68-2 CAPLUS
 CN Acetamide, N-[6-(6-amino-2-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061748-67-1
 CMF C16 H17 N7 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 1061749-92-5 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-isoquinolinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061749-94-7 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(1,2,3,4-tetrahydro-5-isoquinolinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061749-95-8 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-ethyl-1,2,3,4-tetrahydro-5-isoquinolinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061749-97-0 CAPLUS


CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(1,2,3,4-tetrahydro-2-methyl-5-isoquinolinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061749-99-2 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(1,2,3,4-tetrahydro-7-isoquinolinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061749-98-1
 CMF C20 H22 N6 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1061750-02-4 CAPLUS
 CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1061750-01-3
 CMF C21 H24 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1061750-05-7 CAPLUS

CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-ethyl-1,2,3,4-tetrahydro-7-isoquinoliny)-4-pyrimidinyl]- (CA INDEX NAME)




IT 1061750-08-0P 1061750-09-1P 1061750-13-7P

1061750-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of pyrimidines as adenosine A2A receptor antagonists)


RN 1061750-08-0 CAPLUS

CN Acetamide, N-[6-(6-chloro-2-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061750-09-1 CAPLUS

CN Acetamide, N-[6-(2-chloro-4-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1061750-13-7 CAPLUS

CN Acetamide, N-[6-(5-bromo-3-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1061750-50-2 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 7-[6-(acetamino)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



L22 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:699897 CAPLUS
 DN 149:54010
 TI Substituted pyrimidines as adenosine receptor antagonists
 IN Lanier, Marion; Silee, Deborah; Luo, Zhiyong; Lin, Emily; Chen, Yongsheng;
 Moorjani, Manisha; Vong, Binh G.; Tellew, John
 PA Neurocrine Biosciences, Inc., USA; Laboratorios Almirall, S. A.
 SO PCT Int. Appl., 65pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008070661	A1	20080612	WO 2007-US86380	20071204
	W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 2121662	A1	20091125	EP 2007-865169	20071204
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2006-868517P	P	20061204		
	WO 2007-US86380	W	20071204		
OS	MARPAT 149:54010				

AB The invention is concerned about substituted pyrimidine compds. of formula I, including pharmaceutically acceptable salts, esters, solvates, and stereoisomers thereof [R1 = (substituted) heterocycle; R2 = substituted amino group, (substituted) heterocycle; R3 = H, (substituted) alkyl, (substituted) alkoxy, (substituted) alkylcarbonyl, amide group, ester group, N-containing heteroaryl]. Pharmaceutical compns. containing compound

I, as well as methods relating to the use thereof, are also disclosed.
 N-[2-(3,5-Dimethylpyrazol-1-yl)-6-(2-(R)-methoxymethyl)pyrrolidin-1-yl]pyrimidin-4-yl]acetamide was synthesized by the reaction of (R)-2-methoxymethylpyrrolidine with N-[6-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]acetamide which was prepared in several steps starting from 4-amino-2,6-dichloropyrimidine, hydrazine, and 2,4-pentanedione.
 IT 1032047-51-OP 1032047-52-1P 1032047-53-2P
 1032047-56-5P 1032047-66-7P 1032047-81-6P
 1032048-06-8P 1032048-20-6P 1032048-22-8P
 1032048-24-OP 1032048-30-8P 1032050-85-3P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(substituted pyrimidines as adenosine receptor antagonists)
 RN 1032047-51-0 CAPLUS
 CN Acetamide, N-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(3,5-dimethyl-1H-

pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032047-52-1 CAPLUS

CN Acetamide, N-[6-(2,3-dihydro-2-methyl-1H-indol-1-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032047-53-2 CAPLUS

CN Acetamide, N-[6-(2,3-dihydro-2-oxo-1H-indol-1-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032047-56-5 CAPLUS


CN Acetamide, N-[6-(1,3-dihydro-2H-isindol-2-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032047-66-7 CAPLUS
 CN Acetamide, N-[6-(3,6-dihydro-1(2H)-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032047-81-6 CAPLUS
 CN Acetamide, N-[6-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1032048-06-8 CAPLUS
 CN Acetamide, N-[6-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032048-20-6 CAPLUS
 CN Acetamide, N-[6-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032048-22-8 CAPLUS

CN Acetamide, N-[6-[2,3-dihydro-2-(methoxymethyl)-1H-indol-1-yl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032048-24-0 CAPLUS

CN Propanamide, N-[6-(2-methyl-1H-indol-1-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1032048-30-8 CAPLUS

CN Propanamide, N-[6-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1032050-85-3 CAPLUS

CN Butanamide, N-[6-(3,4-dihydro-2(1H)-isoquinolinyl)-2-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:338425 CAPLUS

DN 148:538203

TI Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

AU Zhang, Xiaohu; Rueter, Jaimie K.; Chen, Yongsheng; Moorjani, Manisha; Lanier, Marion C.; Lin, Emily; Gross, Raymond S.; Tellew, John E.; Williams, John P.; Lechner, Sandra M.; Markison, Stacy; Joswig, Tanya; Malany, Siobhan; Santos, Mark; Castro-Palomino, Julio C.; Crespo, Maria I.; Prat, Maria; Gual, Silvia; Diaz, Jose-Luis; Saunders, John; Slee, Deborah H.

CS Department of Medicinal Chemistry, Neurocrine Biosciences, San Diego, CA, 92130, USA

SO Bioorganic & Medicinal Chemistry Letters (2008), 18(6), 1778-1783

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 148:538203

AB A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A2A antagonists, e.g., I, is described. SAR studies led to II with excellent potency ($K_i = 0.4$ nM), selectivity ($A1/A2A > 100$), and efficacy (MED 10 mg/kg po) in the rat haloperidol-induced catalepsy model for Parkinson's disease.


IT	944703-84-8P	944703-85-9P	944703-86-0P
	944703-87-1P	944703-88-2P	944703-89-3P
	944703-90-6P	944703-92-8P	944703-94-0P
	944703-95-1P	944703-96-2P	944703-97-3P
	944703-98-4P	944703-99-5P	944704-00-1P
	944704-01-2P	1023289-99-7P	1023290-00-7P
	1023290-01-8P	1023290-02-9P	1023290-03-0P
	1023290-04-1P	1023290-05-2P	1023290-13-2P
	1023290-14-3P	1023290-17-6P	1023290-18-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and adenosine A2A receptor antagonists activity of pyrimidinylphenoxyacetamides via the addition of phenols to pyrimidinylacetamides or the addition of phenols to pyrimidinylacetamides followed by substitution with amines)


RN 944703-84-8 CAPLUS

CN Acetamide, 2-[3-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-85-9 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-[(ethylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 944703-86-0 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-87-1 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-88-2 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-89-3 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]-3-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-90-6 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-6-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-92-8 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-4-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 944703-94-0 CAPLUS


CN Acetamide, 2-[2-[(dimethylamino)methyl]-4-methylphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 944703-95-1 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-

pyrimidinyl]-2-[3-[(ethylmethylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 944703-96-2 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-(4-morpholinylmethyl)phenoxy]- (CA INDEX NAME)



RN 944703-97-3 CAPLUS


CN Acetamide, 2-[3-[2-(dimethylamino)ethyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 944703-98-4 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-(4-morpholinylmethyl)phenoxy]- (CA INDEX NAME)

pyrimidinyl)-2-[3-[2-(4-morpholinyl)ethyl]phenoxy]- (CA INDEX NAME)




RN 944703-99-5 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-fluoro-5-(1-pyrrolidinylmethyl)phenoxy]- (CA INDEX NAME)




RN 944704-00-1 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-fluoro-5-(4-morpholinylmethyl)phenoxy]- (CA INDEX NAME)




RN 944704-01-2 CAPLUS

CN Acetamide, 2-[3-[(dimethylamino)methyl]-5-fluorophenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023289-99-7 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-phenoxy- (CA INDEX NAME)




RN 1023290-00-7 CAPLUS

CN Acetamide, 2-(2-fluorophenoxy)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-01-8 CAPLUS

CN Acetamide, 2-(3-fluorophenoxy)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-02-9 CAPLUS

CN Acetamide, 2-(4-fluorophenoxy)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-03-0 CAPLUS

CN Acetamide, 2-(3-cyanophenoxy)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-04-1 CAPLUS

CN Acetamide, 2-(3-chlorophenoxy)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-14-3 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[2-(4-morpholinyl)ethyl]phenoxy- (CA INDEX NAME)



RN 1023290-17-6 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(4,6-dimethyl-2-pyrimidinyl)oxy]- (CA INDEX NAME)



RN 1023290-18-7 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(5-methyl-2-furanyl)-4-pyrimidinyl-2-[(4,6-dimethyl-2-pyrimidinyl)oxy]- (CA INDEX NAME)

pyrimidinyl]-2-[(2,6-dimethyl-4-pyridinyl)oxy]- (CA INDEX NAME)




IT 912940-73-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and adenosine A2A receptor antagonists activity of pyrimidinylphenoxyacetamides via the addition of phenols to pyrimidinylacetamides or the addition of phenols to pyrimidinylacetamides followed by substitution with amines)

RN 912940-73-9 CAPLUS

CN Acetamide, 2-chloro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 1023290-08-5P 1023290-09-6P 1023290-10-9P

1023290-11-0P 1023290-19-8P 1023290-20-1P

1023290-21-2P 1023290-22-3P 1023290-23-4P

1023290-24-5P 1023290-25-6P 1023290-26-7P


1023290-27-8P 1023290-28-9P 1023290-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and adenosine A2A receptor antagonists activity of pyrimidinylphenoxyacetamides via the addition of phenols to pyrimidinylacetamides or the addition of phenols to pyrimidinylacetamides followed by substitution with amines)


RN 1023290-08-5 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(3-fluorophenoxy)- (CA INDEX NAME)




RN 1023290-09-6 CAPLUS

CN Acetamide, 2-(3-cyanophenoxy)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-10-9 CAPLUS

CN Acetamide, 2-(3-fluorophenoxy)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-11-0 CAPLUS

CN Acetamide, 2-(3-cyanophenoxy)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1023290-19-8 CAPLUS

CN Benzoic acid, 3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]- (CA INDEX NAME)




RN 1023290-20-1 CAPLUS

CN Benzoic acid, 3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-5-fluoro- (CA INDEX NAME)




RN 1023290-21-2 CAPLUS

CN Benzeneacetic acid, 3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]- (CA INDEX NAME)




RN 1023290-22-3 CAPLUS

CN Benzoic acid, 2-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]- (CA INDEX NAME)




RN 1023290-23-4 CAPLUS

CN Benzoic acid, 2-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-5-methyl- (CA INDEX NAME)




RN 1023290-24-5 CAPLUS

CN Benzoic acid, 2-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-5-methoxy- (CA INDEX NAME)




RN 1023290-25-6 CAPLUS

CN Benzoic acid, 2-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-3-methoxy- (CA INDEX NAME)




RN 1023290-26-7 CAPLUS

CN Benzeneacetic acid, 2-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]- (CA INDEX NAME)




RN 1023290-27-8 CAPLUS

CN Benzoic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]- (CA INDEX NAME)




RN 1023290-28-9 CAPLUS

CN Benzoic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-3-methoxy- (CA INDEX NAME)



RN 1023290-29-0 CAPLUS

CN Benzoic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-2-methoxy- (CA INDEX NAME)



IT 856173-03-0P 912940-87-5P 912940-88-6P

944704-43-2P 1023290-07-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyrimidinylacetamides for use in the preparation of
pyrimidinylphenoxyacetamides)


RN 856173-03-0 CAPLUS

CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-87-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-pyridinyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-88-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
(CA INDEX NAME)


RN 944704-43-2 CAPLUS

CN Acetamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1023290-07-4 CAPLUS


CN Acetamide, 2-chloro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:263785 CAPLUS
 DN 148:393738
 TI 2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 2.
 Reduction of hERG Activity, Observed Species Selectivity, and
 Structure-Activity Relationships
 AU Slee, Deborah H.; Moorjani, Manisha; Zhang, Xiaohu; Lin, Emily; Lanier,
 Marion C.; Chen, Yongsheng; Rueter, Jaimie K.; Lechner, Sandra M.;
 Markison, Stacy; Malany, Siobhan; Joswig, Tanya; Santos, Mark; Gross,
 Raymond S.; Williams, John P.; Castro-Palomino, Julio C.; Crespo, Maria
 I.; Prat, Maria; Gual, Silvia; Diaz, Jose-Luis; Jalali, Kayvon; Sai, Yang;
 Zuo, Zhiyang; Yang, Chun; Wen, Jenny; O'Brien, Zhihong; Petroski, Robert;
 Saunders, John
 CS Departments of Medicinal Chemistry, Pharmacology and Lead Discovery,
 Neurocrine Biosciences, San Diego, CA 92130, USA
 SO Journal of Medicinal Chemistry (2008), 51(6), 1730-1739
 CODEN: JMCMAR; ISSN: 0022-2625
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 148:393738
 AB Previously we have described a series of novel A2A receptor antagonists
 with excellent water solubility. As described in the accompanying paper, the
 antagonists were first optimized to remove an unsubstituted furyl moiety,
 with the aim of avoiding the potential metabolic liabilities that can
 arise from the presence of an unsubstituted furan. This effort identified
 a series of potent and selective methylfuryl derivs. Herein, we describe
 the further optimization of this series to increase potency, maintain
 selectivity for the human A2A vs the human A1 receptor, and minimize
 activity against the hERG channel. In addition, the observed
 structure-activity
 relationships against both the human and the rat A2A receptor are
 reported.
 IT 912938-56-8P 912938-57-9P 912938-66-0P
 912938-67-1P 912938-70-6P 912938-71-7P
 912938-72-8P 912938-73-9P 912938-74-0P
 912938-77-3P 912938-84-2P 912938-85-3P
 912938-87-5P 912939-20-9P 912939-31-2P
 912939-32-3P 912939-49-2P 912939-72-1P
 912941-13-0P 912941-14-1P 912941-15-2P
 1016167-75-1P 1016167-80-8P 1016167-81-9P
 1016167-82-0P 1016167-83-1P 1016167-84-2P
 1016167-85-3P 1016167-86-4P 1016167-87-5P
 1016167-88-6P 1016167-89-7P 1016167-90-0P
 1016167-91-1P 1016167-92-2P 1016167-93-3P
 1016167-94-4P 1016167-95-5P 1016167-96-6P
 1016167-97-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (amino pyrimidinylacetamides as A2A receptor antagonists with reduced
 hERG activity)
 RN 912938-56-8 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-
 furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-57-9 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-66-0 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912938-67-1 CAPLUS

CN 4-Morpholineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-70-6 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro-4-methyl- (CA INDEX NAME)



RN 912938-71-7 CAPLUS


CN 1,4-Oxazepine-4(5H)-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]tetrahydro- (CA INDEX NAME)



RN 912938-72-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-73-9 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-74-0 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-77-3 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-ethyl]- (CA INDEX NAME)




RN 912938-84-2 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)



RN 912938-85-3 CAPLUS


CN 1-Piperazineacetamide, 4-acetyl-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-87-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-20-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(1-methylethoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-31-2 CAPLUS


CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-32-3 CAPLUS


CN 1-Piperidineacetamide, 4-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-49-2 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-72-1 CAPLUS


CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)



RN 912941-13-0 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912941-14-1 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912941-15-2 CAPLUS


CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1016167-75-1 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1016167-80-8 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro-4-methyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 1016167-81-9 CAPLUS
 CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:?), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


RN 1016167-82-0 CAPLUS
 CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:?), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 1016167-83-1 CAPLUS
 CN 1-Piperidineacetamide, 4-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:?)
 (CA INDEX NAME)




●x HCl

RN 1016167-84-2 CAPLUS
 CN 4-Morpholineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 912938-67-1
 CMF C20 H24 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1016167-85-3 CAPLUS

CN 1,4-Oxazepine-4(5H)-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furyl)-4-pyrimidinyl]tetrahydro-, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)

CM 1

CRN 912938-71-7

CMF C21 H26 N6 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 1016167-86-4 CAPLUS
CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methoxy-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 912938-84-2
CMF C22 H28 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1016167-87-5 CAPLUS
CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 1016167-88-6 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 912938-74-0
 CMF C20 H24 N6 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 1016167-89-7 CAPLUS
 CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:?), (3S)-
 (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 1016167-90-0 CAPLUS
 CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)-, 2,2,2-trifluoroacetate
 (1:?) (CA INDEX NAME)

CM 1

CRN 912938-72-8

CMF C22 H29 N7 O2

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 1016167-91-1 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(1-methylethoxy)-, hydrochloride (1:?), (3S)- (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 1016167-92-2 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, hydrochloride (1:?), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 1016167-93-3 CAPLUS
 CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 912938-87-5
 CMF C24 H33 N7 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1016167-94-4 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:2), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 1016167-95-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:2), (3S)- (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 1016167-96-6 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 1016167-97-7 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:3), (3S)- (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

IT 912940-88-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amino pyrimidinylacetamides as A2A receptor antagonists with reduced
 hERG activity)
 RN 912940-88-6 CAPLUS
 CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
 (CA INDEX NAME)




IT 912939-26-5P 912939-70-9P 944704-43-2P
 1016167-74-0P 1016167-76-2P 1016167-77-3P
 1016167-78-4P 1016167-79-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (amino pyrimidinylacetamides as A2A receptor antagonists with reduced
 hERG activity)
 RN 912939-26-5 CAPLUS
 CN Carbamic acid, N-[[1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-
 furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-4-piperidinyl]methyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 912939-70-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 944704-43-2 CAPLUS

CN Acetamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1016167-74-0 CAPLUS


CN 2-Propenamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1016167-76-2 CAPLUS

CN Carbamic acid, N-[[[(3R)-1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-3-piperidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1016167-77-3 CAPLUS

CN Carbamic acid, N-[[[(3S)-1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-3-piperidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1016167-78-4 CAPLUS

CN Carbamic acid, N-[[[(3R)-1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-3-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 1016167-79-5 CAPLUS

CN Carbamic acid, N-[[[(3S)-1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-3-pyrrolidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:263781 CAPLUS

DN 148:369288

TI 2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 1. Structure-Activity Relationships and Optimization of Heterocyclic Substituents

AU Slee, Deborah H.; Chen, Yongsheng; Zhang, Xiaohu; Moorjani, Manisha; Lanier, Marion C.; Lin, Emily; Rueter, Jaimie K.; Williams, John P.; Lechner, Sandra M.; Markison, Stacy; Malany, Siobhan; Santos, Mark; Gross, Raymond S.; Jalali, Kayvon; Sai, Yang; Zuo, Zhiyang; Yang, Chun; Castro-Palomino, Julio C.; Crespo, Maria I.; Prat, Maria; Gual, Silvia; Diaz, Jose-Luis; Saunders, John

CS Departments of Medicinal Chemistry, Pharmacology and Lead Discovery, Neurocrine Biosciences, San Diego, CA 92130, USA

SO Journal of Medicinal Chemistry (2008), 51(6), 1719-1729

CODEN: JMCMAR; ISSN: 0022-2621

PB American Chemical Society

DT Journal

LA English

OS CASREACT 148:369288

AB Previously we have described a novel series of potent and selective A2A receptor antagonists (e.g., 1) with excellent aqueous solubility. While these compds. are efficacious A2A antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted furyl moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.

IT 912935-89-8P 912935-94-5P 912937-94-1P

912938-14-8P 912938-52-4P 912938-66-0P

912939-82-3P 912939-95-8P 912940-01-3P

912940-10-4P 912940-20-6P 912940-34-2P

1014720-76-3P 1014720-77-4P 1014720-78-5P

1014720-79-6P 1014720-96-7P 1014720-97-8P

1014720-98-9P 1014720-99-0P 1014721-00-6P

1014721-01-7P 1014721-02-8P 1014721-03-9P

1014721-04-0P 1014721-05-1P 1014721-07-3P


1014721-08-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino pyrimidinacetamides as A2A receptor antagonists)


RN 912935-89-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912935-94-5 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-94-1 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-14-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912938-52-4 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-66-0 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912939-82-3 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-95-8 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-01-3 CAPLUS

CN 1-Piperazineacetamide, N-(2,6-di-1H-pyrazol-1-yl)-4-pyrimidinyl-4-methyl- (CA INDEX NAME)




RN 912940-10-4 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-20-6 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-34-2 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 1014720-76-3 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(5-methyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1014720-77-4 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1014720-78-5 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-oxazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 1014720-79-6 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(4-methyl-5-oxazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 1014720-96-7 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methyl-, hydrochloride (1:2) (CA INDEX NAME)



RN 1014720-97-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-methyl-, hydrochloride (1:2) (CA INDEX NAME)




RN 1014720-98-9 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912935-94-5

CMF C19 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014720-99-0 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912937-94-1

CMF C20 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-00-6 CAPLUS

CN 1-Piperazineacetamide, N-(2,6-di-1H-pyrazol-1-yl-4-pyrimidinyl)-4-methyl-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912940-01-3

CMF C17 H21 N9 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-01-7 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-thiazolyl)-
4-pyrimidinyl]-4-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1014720-77-4

CMF C19 H24 N8 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-02-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-oxazolyl)-4-pyrimidinyl]-4-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1014720-78-5

CMF C19 H24 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-03-9 CAPLUS

CN 1-Piperazineacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(4-methyl-5-oxazolyl)-4-pyrimidinyl]-4-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1014720-79-6

CMF C20 H26 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-04-0 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912940-10-4
 CMF C17 H20 N8 O S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1014721-05-1 CAPLUS
 CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912939-82-3
 CMF C19 H22 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-07-3 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912939-95-8

CMF C21 H26 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1014721-08-4 CAPLUS
 CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 912940-34-2

CMF C19 H24 N8 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 856171-18-1P	856171-19-2P	856171-38-5P
856171-70-5P	856172-97-9P	856173-03-0P
856173-06-3P	912940-80-8P	912940-88-6P
1014720-74-1P	1014720-83-2P	1014720-84-3P
1014720-85-4P	1014720-88-7P	1014720-90-1P
1014720-93-4P	1014720-94-5P	1014721-06-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(amino pyrimidinacetamides as A2A receptor antagonists)

RN 856171-18-1 CAPLUS


CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-19-2 CAPLUS
 CN Acetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-38-5 CAPLUS
 CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)- (CA INDEX NAME)



RN 856171-70-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856172-97-9 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 856173-03-0 CAPLUS

CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 856173-06-3 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-80-8 CAPLUS

CN 4-Pyrimidinamine, 2,6-di-1H-pyrazol-1-yl- (CA INDEX NAME)




RN 912940-88-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
(CA INDEX NAME)




RN 1014720-74-1 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1014720-83-2 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1014720-84-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)- (CA INDEX NAME)




RN 1014720-85-4 CAPLUS

CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(5-methyl-1H-pyrazol-1-yl)-
(CA INDEX NAME)


RN 1014720-88-7 CAPLUS

CN 4-Pyrimidinamine, 6-(2-pyridinyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 1014720-90-1 CAPLUS


CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-thiazolyl)- (CA
INDEX NAME)




RN 1014720-93-4 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-oxazolyl)- (CA INDEX NAME)



RN 1014720-94-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(4-methyl-5-oxazolyl)- (CA INDEX NAME)




RN 1014721-06-2 CAPLUS
 CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




OSC.G	8	THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT	38	THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:232042 CAPLUS
 DN 148:449569
 TI 2,6-Diaryl-4-phenacylamino-pyrimidines as potent and selective adenosine
 A2A antagonists with reduced hERG liability
 AU Moorjani, Manisha; Zhang, Xiaohu; Chen, Yongsheng; Lin, Emily; Rueter,
 Jaimie K.; Gross, Raymond S.; Lanier, Marion C.; Tellet, John E.;
 Williams, John P.; Lechner, Sandra M.; Malany, Siobhan; Santos, Mark;
 Ekhlassi, Paddi; Castro-Palomino, Julio C.; Crespo, Maria I.; Prat, Maria;
 Gual, Silvia; Diaz, Jose-Luis; Saunders, John; Slee, Deborah H.
 CS Department of Medicinal Chemistry, Neurocrine Biosciences, San Diego, CA,
 92130, USA
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1269-1273
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 148:449569
 AB The design and synthesis of a series of pyrimidine based adenosine A2A
 antagonists are described. The strategy and outcome of expanding the
 exploration of the structure-activity relationship to attenuate hERG and
 improve selectivity over A1 are discussed. Compound I exhibited excellent
 potency, selectivity over A1 and reduced hERG liability.
 IT 1015484-02-2P 1015484-03-3P 1015484-04-4P
 1015484-05-5P 1015484-06-6P 1015484-07-7P
 1015484-08-8P 1015484-09-9P 1015484-10-2P
 1015484-11-3P 1015484-12-4P 1015484-13-5P
 1015484-14-6P 1015484-15-7P 1015484-16-8P
 1015484-17-9P 1015484-18-0P 1015484-19-1P
 1015484-20-4P 1015484-21-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation and structure-activity relationships of
 2,6-diaryl-4-(phenacylamino)pyrimidines as selective adenosine A2A
 antagonists)
 RN 1015484-02-2 CAPLUS
 CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-
 furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 1015484-03-3 CAPLUS
 CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-

furanyl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 1015484-04-4 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3,5-dimethoxy- (CA INDEX NAME)




RN 1015484-05-5 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3,5-difluoro- (CA INDEX NAME)




RN 1015484-06-6 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3,4-difluoro- (CA INDEX NAME)




RN 1015484-07-7 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-4-methoxy- (CA INDEX NAME)




RN 1015484-08-8 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methoxy-3-methyl- (CA INDEX NAME)




RN 1015484-09-9 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-[(methylsulfonyl)amino]- (CA INDEX NAME)



RN 1015484-10-2 CAPLUS


CN Benzeneacetamide, 4-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1015484-11-3 CAPLUS


CN Benzeneacetamide, 4-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)

1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1015484-12-4 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 1015484-13-5 CAPLUS

CN Benzeneacetamide, 4-methoxy-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1015484-14-6 CAPLUS

CN Benzeneacetamide, 4-methoxy-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1015484-15-7 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 1015484-16-8 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 1015484-17-9 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3,5-dimethoxy- (CA INDEX NAME)




RN 1015484-18-0 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-ethoxy-3-methoxy- (CA INDEX NAME)




RN 1015484-19-1 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3,5-dimethyl- (CA INDEX NAME)




RN 1015484-20-4 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)




RN 1015484-21-5 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 856171-70-5P 856173-03-0P 912940-87-5P
 912940-88-6P 1014720-83-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and structure-activity relationships of
 2,6-diaryl-4-(phenacylamino)pyrimidines as selective adenosine A2A
 antagonists)
 RN 856171-70-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX
 NAME)



RN 856173-03-0 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-87-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-pyridinyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-88-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
(CA INDEX NAME)



RN 1014720-83-2 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)- (CA
INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:69887 CAPLUS
 DN 148:168734
 TI Preparation of pyrimidine derivatives as ALK-5 inhibitors
 IN Leblanc, Catherine; Pipet, Maude Nadine Pierrette; Fairhurst, Robin Alec;
 Adcock, Claire; Pulz, Robert Alexander; Shaw, Duncan; Stiefl, Nikolaus
 Johannes
 PA Novartis AG, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 86pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	FILE	APPLICATION NO.	DATE
PI	WO 2008006583	A1	20080117	WO 2007-EP6192	2007/0712
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	EP 1878733	A1	20080116	EP 2006-117227	2006/0714
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	AU 2007271964	A1	20080117	AU 2007-271964	2007/0712
	CA 2657227	A1	20080117	CA 2007-2657227	2007/0712
	EP 2044056	A1	20090408	EP 2007-786024	2007/0712
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
	JP 2009543765	T	20091210	JP 2009-518795	2007/0712
	US 20090209539	A1	20090820	US 2008-308232	20081209
	IN 2008DN10293	A	20090320	IN 2008-DN10293	20081212
	MX 2009000310	A	20090126	MX 2009-310	20090108
	KR 2009018213	A	20090219	KR 2009-700642	20090113
	CN 101490038	A	20090722	CN 2007-80026705	20090114
PRAI	EP 2006-117227	A	20060714		
	EP 2006-119564	A	20060825		
	WO 2007-EP6192	W	20070712		

OS MARPAT 148:168734

AB Title compds. represented by the formula I [wherein T1 = (un)substituted heterocyclyl; T2 = (un)substituted heterocyclyl; Ra, Rb = independently H, (un)substituted (cyclo)alkyl or aryl; and free salts or solvates thereof] were prepared as activin-like kinase 5 (ALK-5) inhibitors. For example, reaction of 4-chloro-6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidine with (1H-indol-4-yl)methylamine gave II. I have IC50 values below 2 μ M for the kinase activity of ALK-5. Thus, I and their pharmaceutical compns. are useful for the treatment of inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle

diseases and systemic skeletal disorders.

IT 887451-44-7P, [2-(1H-Indol-3-yl)ethyl][2-(pyridin-3-yl)-6-(pyridin-2-yl)pyrimidin-4-yl]amine 887456-30-6P, (Benzyl)[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-43-4P, [(1H-Indol-4-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-44-5P, [2-(1H-Indol-4-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-45-6P, [2-(1H-Indol-3-yl)ethyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-46-7P, 4-[2-[[2-(6-Methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001913-47-8P, 4-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001913-48-9P, [2-(1H-Indol-4-yl)ethyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-49-0P, [(1H-Indazol-4-yl)methyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-50-3P, [(1H-Indol-4-yl)methyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-51-4P, 3-[2-[[2-(6-Methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-ol 1001913-52-5P, [2-(2-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-53-6P, [2-(7-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-54-7P, [2-(2,3-Dihydrobenzofuran-7-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-55-8P, [2-(5-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-56-9P, [2-(6-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-58-1P, [2-(5-Fluoro-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-59-2P, [2-(6-Fluoro-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-60-5P, [2-(Pyridin-2-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-61-6P, [2-(1-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-62-7P, [2-(5-Chloro-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-63-8P, [2-(Pyridin-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-64-9P, [2-(2-Methyl-1-phenyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-65-0P, [(1H-Indol-3-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-66-1P, (3-Phenoxybenzyl)[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-67-2P, 2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]-1-(o-tolyl)ethanol 1001913-68-3P, 2-Methyl-3-[2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indole-5-carbonitrile 1001913-69-4P, 1-(Piperazin-1-yl)-3-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]propan-1-one 1001913-70-7P, [(1H-Indol-2-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-71-8P, 3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-

indol-5-yl 1001913-72-9P,
[2-(6-Chloro-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-73-0P,
[2-(6-Methoxy-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-74-1P,
[(2,3-Dimethyl-1H-indol-5-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-75-2P,
[(1H-Indol-6-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-76-3P,
[(1H-Indol-4-yl)methyl][2-(3-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-77-4P,
[2-(Indol-1-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-79-6P,
[2-(5-Methyl-4H-[1,2,4]triazol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-80-9P,
[2-(Pyrazin-2-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-81-0P,
(2-Phenylsulfonyl-ethyl)[2-(pyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-82-1P,
(S)-1-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]pyrrolidin-3-ol 1001913-83-2P,
(R)-1-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]pyrrolidin-3-ol 1001913-84-3P,
1-[5-Methoxy-3-[2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]indol-1-yl]ethanone 1001913-85-4P,
[2-(7-Fluoro-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-86-5P,
[[2-(Morpholin-4-yl)pyridin-4-yl]methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-87-6P,
[(5-Cyclopropyl-1H-pyrazol-4-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-88-7P,
[2-(4-Chlorophenylsulfonyl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-89-8P,
1-(Pyridin-2-yl)-2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethanol 1001913-90-1P,
[2-(1H-Indol-3-yl)ethyl][2-(3-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001913-91-2P,
3-[2-[[2-(6-Methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001913-92-3P,
2-Methyl-3-[2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-ol 1001913-93-4P,
[2-(Benzoimidazol-1-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-94-5P,
[2-(1H-Indol-3-yl)propyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-95-6P,
3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-7-ol 1001913-96-7P,
[2-(4-Methyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001913-97-8P,
3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-4-ol 1001913-98-9P,
[3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-yl]methanol 1001913-99-0P,
3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indole-5-carboxylic acid 1001914-00-6P,
[3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-yl]amine 1001914-01-7P,

3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-6-ol 1001914-02-8P,
 4-[1-Hydroxy-2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001914-03-9P,
 2-Propyl-4-[2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001914-04-0P,
 4-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-06-2P, 2-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]phenol 1001914-07-3P,
 3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]propyl]phenyl]methanol 1001914-08-4P,
 3-[1H-Pyrazol-3-yl]phenyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-09-5P,
 [2-(Morpholin-2-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-10-8P,
 [(5-Methylisoxazol-3-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-11-9P,
 N-[3-[2-[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-yl]methanesulfonamide 1001914-12-0P,
 3-[1-Methyl-2-[[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]ethyl]-1H-indol-5-ol 1001914-13-1P,
 [2-(1-Methylsulfonyl-1H-indol-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-14-2P,
 [(2-Methyl-1H-indol-5-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-15-3P,
 [2-(4-Methoxyphenyl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-16-4P,
 3-[[[6-(Pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-17-5P, [(1H-Indol-5-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-19-7P,
 [(1-Methyl-1H-indol-4-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-20-0P,
 (4-Methoxybenzyl)[6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-21-1P, [2-(Benzofuran-3-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-22-2P,
 [(1H-Indazol-4-yl)methyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-23-3P,
 [2-(1H-Indol-6-yl)ethyl][6-(pyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-24-4P,
 [2-(4-Methoxyphenyl)ethyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001914-25-5P,
 [2-(1H-Indol-6-yl)ethyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001914-26-6P,
 [2-(6-Methyl-1H-indol-3-yl)ethyl][2-(6-methylpyridin-2-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]amine 1001914-28-8P 1001914-29-9P
 , [(1H-Indol-4-yl)methyl][6-(5-methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]amine 1001914-30-2P,
 [2-(1H-Indol-3-yl)ethyl][6-(5-methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]amine 1001914-31-3P,
 [2-(1H-Indol-4-yl)ethyl][6-(5-methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]amine 1001914-32-4P,
 [6-(3,5-Dimethylisoxazol-4-yl)-2-(6-methylpyridin-2-yl)pyrimidin-4-yl][2-(1H-indol-3-yl)ethyl]amine 1001914-33-5P,
 [2-(1H-Indol-3-yl)ethyl][6-(5-methoxypyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-34-6P,
 [2-(1H-Indol-3-yl)ethyl][6-(5-phenylpyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-36-8P,

5-[6-[[2-(1H-Indol-3-yl)ethyl]amino]-2-(pyridin-2-yl)pyrimidin-4-yl]nicotinonitrile 1001914-37-9P,
 5-[6-[[1(1H-Indol-4-yl)methyl]amino]-2-(pyridin-2-yl)pyrimidin-4-yl]nicotinonitrile 1001914-38-0P,
 1(1H-Indol-4-yl)methyl 12-(pyridin-2-yl)-6-[5-(1H-tetrazol-5-yl)pyridin-3-yl]pyrimidin-4-yl]amine 1001914-39-1P,
 5-[6-[[2-(1H-Indol-3-yl)ethyl]amino]-2-(pyridin-2-yl)pyrimidin-4-yl]nicotinic acid ethyl ester 1001914-40-4P,
 [6-(3,5-Dimethylisoxazol-4-yl)-2-(pyridin-2-yl)pyrimidin-4-yl][2-(1H-indol-3-yl)ethyl]amine 1001914-41-5P,
 [4-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]phenyl](4-methylpiperazin-1-yl)methanone 1001914-42-6P,
 [6-[5-(4-Fluorophenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][2-(1H-indol-3-yl)ethyl]amine 1001914-43-7P,
 [[6-[5-(3-Methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-44-8P,
 N-[3-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]phenyl]methanesulfonamide 1001914-45-9P,
 3-[[[6-[5-(3-Methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-46-0P,
 1(1H-Indol-4-yl)methyl 16-[5-(3-methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-47-1P,
 (Benzyl)[6-[5-(3-methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-49-3P,
 (Cyclopropyl)[6-[5-(3-methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-50-6P,
 (Ethyl)[6-[5-(3-methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-51-7P,
 (Methyl)[6-[5-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-53-9P,
 (Methyl)[6-[5-[3-(morpholin-4-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-54-0P,
 [4-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]phenyl]morpholin-4-yl-methanone 1001914-55-1P,
 (Methyl)[2-(pyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-yl]pyrimidin-4-yl]amine 1001914-56-2P,
 [[6-[5-(1H-Indol-4-yl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-57-3P,
 [[6-[5-(3-Ethoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-58-4P,
 [[6-[5-(3-Methylsulfonylphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-59-5P,
 3-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]benzenesulfonamide 1001914-60-8P,
 [[6-[5-(4-Fluorophenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-61-9P,
 [2-(1H-Indol-3-yl)ethyl][6-(5-methylpyridin-3-yl)-2-(pyridin-2-yl)pyrimidin-4-yl]amine 1001914-62-0P,
 [[6-[5-(4-Methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-63-1P,
 [[6-[5-(2-Methoxyphenyl)pyridin-3-yl]-2-(pyridin-2-yl)pyrimidin-4-yl][methyl]amine 1001914-64-2P,
 (Methyl)[2-(pyridin-2-yl)-6-[5-[4-[(pyrrolidin-1-yl)methyl]phenyl]pyridin-3-yl]pyrimidin-4-yl]amine 1001914-65-3P,
 [4-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]phenyl]pyrrolidin-1-yl-methanone 1001914-66-4P,
 (Methyl)[2-(pyridin-2-yl)-6-[5-[3-[(pyrrolidin-1-yl)methyl]phenyl]pyridin-

3-yl]pyrimidin-4-yl]amine 1001914-67-5P,
 [3-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]pyrrolidin-1-yl-methanone 1001914-68-6P,
 [3-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]morpholin-4-yl-methanone 1001914-69-7P,
 (Methyl)[6-[5-[3-(morpholin-4-yl)methyl]phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-71-1P,
 (Methyl)[6-[5-[4-(morpholin-4-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-72-2P,
 (Methyl)[2-(pyridin-2-yl)-6-[5-[4-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amine 1001914-73-3P,
 [[6-[5-[4-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl][methyl]amine 1001914-74-4P,
 [[6-[5-[3-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl][methyl]amine 1001914-75-5P,
 3-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]-N-
 (tetrahydropyran-4-yl)benzamide 1001914-76-6P,
 4-[5-[6-Methylamino-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]-N-
 (tetrahydropyran-4-yl)benzamide 1001914-77-7P,
 3-[[[6-[5-[3-(Morpholin-4-yl)methyl]phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-78-8P,
 3-[[[2-(Pyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amino]methyl]phenol 1001914-79-9P,
 3-[[[6-[5-[3-(Morpholin-4-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-80-2P,
 3-[[[2-(Pyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)methyl]phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amino]methyl]phenol 1001914-81-3P,
 [4-[5-[6-[3-(3-Hydroxybenzyl)amino]-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]morpholin-4-ylmethanone 1001914-82-4P,
 3-[[[6-[5-[4-(Morpholin-4-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-83-5P,
 3-[[[6-[5-[4-(4-Methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-84-6P,
 [3-[5-[6-[3-(3-Hydroxybenzyl)amino]-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl](4-methylpiperazin-1-yl)methanone 1001914-85-7P,
 3-[[[6-[5-[3-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-86-8P,
 3-[[[6-[5-[4-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-87-9P,
 [3-[5-[6-(Benzyl)amino]-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]morpholin-4-yl-methanone 1001914-88-0P,
 (Benzyl)[6-[5-[4-(2-dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-89-1P,
 [4-[5-[6-[3-(Benzyl)amino]-2-(pyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl](4-methylpiperazin-1-yl)methanone 1001914-91-5P,
 (Benzyl)[6-[5-[3-(2-dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-92-6P,
 (Benzyl)[6-[5-[3-(morpholin-4-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-93-7P,
 (Benzyl)[2-(pyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amine 1001914-94-8P,
 (Benzyl)[6-[5-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-95-9P,
 (Benzyl)[6-[5-[4-[4-(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-
 (pyridin-2-yl)pyrimidin-4-yl]amine 1001914-96-0P,
 (Methyl)[6-[5-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amine 1001914-97-1P,

(Methyl) [6-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-
 (pyridin-2-yl)pyrimidin-4-yl]amine 1001914-98-2P,
 3-[[[6-[5-[4-[(4-Methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-
 (pyridin-2-yl)pyrimidin-4-yl]amino]methyl]phenol 1001914-99-3P
 , 3-[[[6-[5-[4-(Piperidin-1-yl)phenyl]pyridin-3-yl]-2-(pyridin-2-
 yl)pyrimidin-4-yl]amino]methyl]phenol 1001915-00-9P,
 [[6-[5-(4-Fluorophenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl][methyl]amine 1001915-01-0P,
 [[6-[5-(3-Methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl][methyl]amine 1001915-02-1P,
 3-[[[6-[5-(3-Methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl]amino]methyl]phenol 1001915-03-2P,
 3-[[[6-[5-(4-Fluorophenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl]amino]methyl]phenol 1001915-04-3P,
 [[6-[5-(4-Methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl][methyl]amine 1001915-05-4P,
 [[6-[5-(2-Methoxyphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-
 yl][methyl]amine 1001915-06-5P,
 (Methyl) [2-(6-methylpyridin-2-yl)-6-[5-[4-[(pyrrolidin-1-
 yl)methyl]phenyl]pyridin-3-yl]pyrimidin-4-yl]amine 1001915-07-6P
 , [4-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]pyrrolidin-1-ylmethanone 1001915-09-8P,
 (Methyl) [2-(6-methylpyridin-2-yl)-6-[5-[3-[(pyrrolidin-1-
 yl)methyl]phenyl]pyridin-3-yl]pyrimidin-4-yl]amine 1001915-10-1P
 , [3-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]pyrrolidin-1-ylmethanone 1001915-11-2P,
 (Methyl) [2-(6-methylpyridin-2-yl)-6-[5-[3-[(morpholin-4-
 yl)methyl]phenyl]pyridin-3-yl]pyrimidin-4-yl]amine 1001915-12-3P
 , [3-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl]morpholin-4-ylmethanone 1001915-13-4P,
 [[6-[5-[4-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-
 yl)pyrimidin-4-yl][methyl]amine 1001915-14-5P,
 [[6-[5-[3-(2-Dimethylaminoethoxy)phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-
 yl)pyrimidin-4-yl][methyl]amine 1001915-15-6P,
 3-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]-N-
 (tetrahydropyran-4-yl)benzamide 1001915-16-7P,
 4-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-yl]-N-
 (tetrahydropyran-4-yl)benzamide 1001915-17-8P,
 3-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]benzenesulfonamide 1001915-18-9P,
 [[6-[5-(3-Methylsulfonylphenyl)pyridin-3-yl]-2-(6-methylpyridin-2-
 yl)pyrimidin-4-yl][methyl]amine 1001915-19-0P,
 (Benzyl) [2-(6-methylpyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amine 1001915-20-3P,
 3-[[[2-(6-Methylpyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amino]methyl]phenol 1001915-21-4P,
 (Benzyl) [6-[5-[3-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(6-
 methylpyridin-2-yl)pyrimidin-4-yl]amine 1001915-22-5P,
 (Methyl) [2-(6-methylpyridin-2-yl)-6-[5-[3-(pyrrolidin-1-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amine 1001915-23-6P,
 (Methyl) [2-(6-methylpyridin-2-yl)-6-[5-[3-(morpholin-4-yl)phenyl]pyridin-3-
 yl]pyrimidin-4-yl]amine 1001915-24-7P
 , (Methyl) [6-[5-[4-(4-methylpiperazin-1-yl)phenyl]pyridin-3-yl]-2-(6-
 methylpyridin-2-yl)pyrimidin-4-yl]amine 1001915-25-8P,
 [4-[5-[6-Methylamino-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]pyridin-3-
 yl]phenyl] (4-methylpiperazin-1-yl)methanone 1001915-26-9P,
 (Methyl) [6-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-(6-


methylpyridin-2-yl)pyrimidin-4-yl]amine 1001915-27-0P,
(Methyl) [6-[5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]pyridin-3-yl]-2-(6-methylpyridin-2-yl)pyrimidin-4-yl]amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidine derivs. as ALK-5 inhibitors useful in mono- and
combination treatment of diseases)


RN 887451-44-7 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(2-pyridinyl)-2-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 887456-30-6 CAPLUS

CN 4-Pyrimidinamine, N-(phenylmethyl)-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA
INDEX NAME)




RN 1001913-43-4 CAPLUS

CN 1H-Indole-4-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 1001913-44-5 CAPLUS

CN 1H-Indole-4-ethanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 1001913-45-6 CAPLUS

CN 1H-Indole-3-ethanamine, N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-46-7 CAPLUS

CN Phenol, 4-[2-[[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-47-8 CAPLUS

CN Phenol, 4-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)



RN 1001913-48-9 CAPLUS


CN 1H-Indole-4-ethanamine, N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1001913-49-0 CAPLUS


CN 1H-Indazole-4-methanamine, N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-

pyrimidinyl]- (CA INDEX NAME)




RN 1001913-50-3 CAPLUS

CN 1H-Indole-4-methanamine, N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-51-4 CAPLUS

CN 1H-Indol-5-ol, 3-[2-[[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-52-5 CAPLUS

CN 1H-Indole-3-ethanamine, 2-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-53-6 CAPLUS

CN 1H-Indole-3-ethanamine, 7-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-54-7 CAPLUS

CN 4-Pyrimidinamine, N-[2-(2,3-dihydro-7-benzofuranyl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001913-55-8 CAPLUS

CN 1H-Indole-3-ethanamine, 5-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-56-9 CAPLUS

CN 1H-Indole-3-ethanamine, 6-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-58-1 CAPLUS

CN 1H-Indole-3-ethanamine, 5-fluoro-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-59-2 CAPLUS

CN 1H-Indole-3-ethanamine, 6-fluoro-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-60-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-pyridinyl)-6-(3-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 1001913-61-6 CAPLUS

CN 1H-Indole-3-ethanamine, 1-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-62-7 CAPLUS

CN 1H-Indole-3-ethanamine, 5-chloro-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-63-8 CAPLUS

CN 4-Pyrimidinamine, 2-(2-pyridinyl)-6-(3-pyridinyl)-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 1001913-64-9 CAPLUS


CN 1H-Indole-3-ethanamine, 2-methyl-1-phenyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1001913-65-0 CAPLUS


CN 1H-Indole-3-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 1001913-66-1 CAPLUS

CN 4-Pyrimidinamine, N-[(3-phenoxyphenyl)methyl]-2-(2-pyridinyl)-6-(3-pyridinyl)-
(CA INDEX NAME)


RN 1001913-67-2 CAPLUS

CN Benzenemethanol, 2-methyl-α-[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]methyl]-
(CA INDEX NAME)




RN 1001913-68-3 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-methyl-3-[2-([2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino)ethyl]- (CA INDEX NAME)




RN 1001913-69-4 CAPLUS

CN 1-Propanone, 1-(1-piperazinyl)-3-([2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino)- (CA INDEX NAME)




RN 1001913-70-7 CAPLUS

CN 1H-Indole-2-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-71-8 CAPLUS

CN 1H-Indol-5-ol, 3-[2-([2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino)ethyl]- (CA INDEX NAME)




RN 1001913-72-9 CAPLUS

CN 1H-Indole-3-ethanamine, 6-chloro-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-73-0 CAPLUS

CN 1H-Indole-3-ethanamine, 6-methoxy-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-74-1 CAPLUS

CN 1H-Indole-5-methanamine, 2,3-dimethyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-75-2 CAPLUS

CN 1H-Indole-6-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-76-3 CAPLUS


CN 1H-Indole-4-methanamine, N-[2-(3-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1001913-77-4 CAPLUS


CN 1H-Indole-1-ethanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 1001913-79-6 CAPLUS

CN 4-Pyrimidinamine, N-[2-(3-methyl-1H-1,2,4-triazol-5-yl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)-
(CA INDEX NAME)


RN 1001913-80-9 CAPLUS

CN 4-Pyrimidinamine, N-[2-(2-pyrazinyl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)-
(CA INDEX NAME)



RN 1001913-81-0 CAPLUS


CN 4-Pyrimidinamine, N-[2-(phenylsulfonyl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)



RN 1001913-82-1 CAPLUS

CN 3-Pyrrolidinol, 1-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001913-83-2 CAPLUS


CN 3-Pyrrolidinol, 1-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001913-84-3 CAPLUS

CN Ethanone, 1-[5-methoxy-3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]-1H-indol-1-yl]- (CA INDEX NAME)




RN 1001913-85-4 CAPLUS

CN 1H-Indole-3-ethanamine, 7-fluoro-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-86-5 CAPLUS

CN 4-Pyrimidinamine, N-[[2-(4-morpholinyl)-4-pyridinyl]methyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001913-87-6 CAPLUS

CN 4-Pyrimidinamine, N-[(5-cyclopropyl-1H-pyrazol-4-yl)methyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001913-88-7 CAPLUS

CN 4-Pyrimidinamine, N-[2-[(4-chlorophenyl)sulfonyl]ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001913-89-8 CAPLUS

CN 2-Pyridinemethanol, alpha-[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinylamino]methyl]- (CA INDEX NAME)




RN 1001913-90-1 CAPLUS

CN 1H-Indole-3-ethanamine, N-[2-(3-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-91-2 CAPLUS

CN Phenol, 3-[2-[[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-92-3 CAPLUS

CN 1H-Indol-5-ol, 2-methyl-3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-93-4 CAPLUS

CN 1H-Benzimidazole-1-ethanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-94-5 CAPLUS

CN 1H-Indole-3-ethanamine, β-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-95-6 CAPLUS

CN 1H-Indol-7-ol, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-96-7 CAPLUS

CN 1H-Indole-3-ethanamine, 4-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001913-97-8 CAPLUS

CN 1H-Indole-4-ol, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-98-9 CAPLUS

CN 1H-Indole-5-methanol, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001913-99-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001914-00-6 CAPLUS

CN 1H-Indole-3-ethanamine, 5-amino-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-01-7 CAPLUS

CN 1H-Indol-6-ol, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001914-02-8 CAPLUS

CN Benzenemethanol, 4-hydroxy- α -[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)


RN 1001914-03-9 CAPLUS

CN Phenol, 2-propyl-4-[2-[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001914-04-0 CAPLUS

CN Phenol, 4-[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-06-2 CAPLUS

CN Phenol, 2-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]-
(CA INDEX NAME)


RN 1001914-07-3 CAPLUS

CN Benzenemethanol, 3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]propyl]- (CA INDEX NAME)




RN 1001914-08-4 CAPLUS

CN 4-Pyrimidinamine, N-[3-(1H-pyrazol-3-yl)phenyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001914-09-5 CAPLUS

CN 2-Morpholineethanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 1001914-10-8 CAPLUS

CN 4-Pyrimidinamine, N-[(5-methyl-3-isoxazolyl)methyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001914-11-9 CAPLUS

CN Methanesulfonamide, N-[3-[2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]-1H-indol-5-yl]- (CA INDEX NAME)




RN 1001914-12-0 CAPLUS

CN 1H-Indol-5-ol, 3-[1-methyl-2-[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]ethyl]- (CA INDEX NAME)




RN 1001914-13-1 CAPLUS

CN 1H-Indole-3-ethanamine, 1-(methylsulfonyl)-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-14-2 CAPLUS

CN 1H-Indole-5-methanamine, 2-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-15-3 CAPLUS


CN 4-Pyrimidinamine, N-[2-(4-methoxyphenyl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)



RN 1001914-16-4 CAPLUS


CN Phenol, 3-[[[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]amino]methyl]-
(CA INDEX NAME)

RN 1001914-17-5 CAPLUS

CN 1H-Indole-5-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 1001914-19-7 CAPLUS

CN 1H-Indole-4-methanamine, 1-methyl-N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 1001914-20-0 CAPLUS

CN 4-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001914-21-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-(3-benzofuranyl)ethyl]-2-(2-pyridinyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 1001914-22-2 CAPLUS


CN 1H-Indazole-4-methanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1001914-23-3 CAPLUS


CN 1H-Indole-6-ethanamine, N-[2-(2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 1001914-24-4 CAPLUS

CN 4-Pyrimidinamine, N-[2-(4-methoxyphenyl)ethyl]-2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-
(CA INDEX NAME)


RN 1001914-25-5 CAPLUS

CN 1H-Indole-6-ethanamine, N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 1001914-26-6 CAPLUS

CN 1H-Indole-3-ethanamine, 6-methyl-N-[2-(6-methyl-2-pyridinyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-28-8 CAPLUS

CN 1H-Indole-3-ethanamine, N-[2-(2-pyridinyl)[4,5'-bipyrimidin]-6-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1001914-27-7

CMF C23 H19 N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1001914-29-9 CAPLUS

CN 1H-Indole-4-methanamine, N-[6-(5-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-30-2 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(5-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-31-3 CAPLUS

CN 1H-Indole-4-ethanamine, N-[6-(5-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-32-4 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(3,5-dimethyl-4-isoxazolyl)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-33-5 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(5-methoxy-3-pyridinyl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-34-6 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(5-phenyl-3-pyridinyl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-36-8 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[6-[[2-(1H-indol-3-yl)ethyl]amino]-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-37-9 CAPLUS

CN 3-Pyridinecarbonitrile, 5-[6-[(1H-indol-4-yl)methyl]amino]-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-38-0 CAPLUS

CN 1H-Indole-4-methanamine, N-[2-(2-pyridinyl)-6-[5-(2H-tetrazol-5-yl)-3-pyridinyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-39-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[6-[[2-(1H-indol-3-yl)ethyl]amino]-2-(2-pyridinyl)-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 1001914-40-4 CAPLUS


CN 1H-Indole-3-ethanamine, N-[6-(3,5-dimethyl-4-isoxazolyl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 1001914-41-5 CAPLUS


CN Methanone, [4-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-

pyridinyl]phenyl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 1001914-42-6 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-[5-(4-fluorophenyl)-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-43-7 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(3-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-44-8 CAPLUS

CN Methanesulfonamide, N-[3-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 1001914-45-9 CAPLUS

CN Phenol, 3-[[[6-[5-(3-methoxyphenyl)-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-46-0 CAPLUS

CN 1H-Indole-4-methanamine, N-[6-[5-(3-methoxyphenyl)-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-47-1 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(3-methoxyphenyl)-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-49-3 CAPLUS

CN 4-Pyrimidinamine, N-cyclopropyl-6-[5-(3-methoxyphenyl)-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-50-6 CAPLUS

CN 4-Pyrimidinamine, N-ethyl-6-[5-(3-methoxyphenyl)-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-51-7 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-(4-morpholinylmethyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-53-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[3-(4-morpholinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-54-0 CAPLUS

CN Methanone, [4-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 1001914-55-1 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(2-pyridinyl)-6-[5-[3-(1-pyrrolidinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001914-56-2 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(1H-indol-4-yl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-57-3 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(3-ethoxyphenyl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-58-4 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[3-(methylsulfonyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-59-5 CAPLUS

CN Benzenesulfonamide, 3-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001914-60-8 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(4-fluorophenyl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-61-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-[6-(5-methyl-3-pyridinyl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1001914-62-0 CAPLUS


CN 4-Pyrimidinamine, 6-[5-(4-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1001914-63-1 CAPLUS
 CN 4-Pyrimidinamine, 6-[5-(2-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-64-2 CAPLUS
 CN 4-Pyrimidinamine, N-methyl-2-(2-pyridinyl)-6-[5-[4-(1-pyrrolidinylmethyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001914-65-3 CAPLUS
 CN Methanone, [4-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]-2-pyridinyl]- (CA INDEX NAME)

pyridinyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 1001914-66-4 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(2-pyridinyl)-6-[5-[3-(1-pyrrolidinylmethyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001914-67-5 CAPLUS

CN Methanone, [3-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 1001914-68-6 CAPLUS

CN Methanone, [3-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 1001914-69-7 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[3-(4-morpholinylmethyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-71-1 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-(4-morpholinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-72-2 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(2-pyridinyl)-6-[5-[4-(1-pyrrolidinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)



RN 1001914-73-3 CAPLUS


CN 4-Pyrimidinamine, 6-[5-[4-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1001914-74-4 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[3-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-N-methyl-2-(2-pyridinyl)- (CA INDEX NAME)


methyl-2-(2-pyridinyl)- (CA INDEX NAME)



Me₂N-CH₂-CH₂-O-


RN 1001914-75-5 CAPLUS

CN Benzamide, 3-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1001914-76-6 CAPLUS

CN Benzamide, 4-[5-[6-(methylamino)-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1001914-77-7 CAPLUS

CN Phenol, 3-[[[6-[5-[3-(4-morpholinylmethyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-78-8 CAPLUS

CN Phenol, 3-[[[2-(2-pyridinyl)-6-[5-[3-(1-pyrrolidinyl)phenyl]-3-pyridinyl]-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-79-9 CAPLUS

CN Phenol, 3-[[[6-[5-[3-(4-morpholinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-80-2 CAPLUS

CN Phenol, 3-[[[2-(2-pyridinyl)-6-[5-[3-(1-pyrrolidinylmethyl)phenyl]-3-pyridinyl]-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1001914-81-3 CAPLUS


CN Methanone, [4-[5-[6-[(3-hydroxyphenyl)methyl]amino]-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl-4-morpholinyl- (CA INDEX NAME)



RN 1001914-82-4 CAPLUS


CN Phenol, 3-[[[6-[5-[4-(4-morpholinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)

CN Phenol, 3-[[[6-[5-[3-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-86-8 CAPLUS

CN Phenol, 3-[[[6-[5-[4-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-87-9 CAPLUS

CN Methanone, 4-morpholinyl[3-[5-[6-[(phenylmethyl)amino]-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 1001914-88-0 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[4-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-89-1 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[4-[5-[6-[(phenylmethyl)amino]-2-(2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]- (CA INDEX NAME)




RN 1001914-91-5 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[3-(2-(dimethylamino)ethoxy)phenyl]-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1001914-92-6 CAPLUS


CN 4-Pyrimidinamine, 6-[5-[3-(4-(morpholinyl)phenyl)-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)



RN 1001914-93-7 CAPLUS


CN 4-Pyrimidinamine, N-(phenylmethyl)-2-(2-pyridinyl)-6-[5-[3-(1-

pyrrolidinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001914-94-8 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[4-(4-methyl-1-piperazinyl)phenyl]-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-95-9 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-3-pyridinyl]-N-(phenylmethyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-96-0 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-(4-methyl-1-piperazinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-97-1 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-3-pyridinyl]-2-(2-pyridinyl)- (CA INDEX NAME)




RN 1001914-98-2 CAPLUS

CN Phenol, 3-[[[6-[5-[4-((4-methyl-1-piperazinyl)methyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001914-99-3 CAPLUS

CN Phenol, 3-[[[6-[5-[4-(1-piperidinyl)phenyl]-3-pyridinyl]-2-(2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001915-00-9 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(4-fluorophenyl)-3-pyridinyl]-N-methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 1001915-01-0 CAPLUS


CN 4-Pyrimidinamine, 6-[5-(3-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 1001915-02-1 CAPLUS


CN Phenol, 3-[[[6-[5-(3-methoxyphenyl)-3-pyridinyl]-2-(6-methyl-2-pyridinyl)-

4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001915-03-2 CAPLUS

CN Phenol, 3-[[[6-[5-(4-fluorophenyl)-3-pyridinyl]-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001915-04-3 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(4-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1001915-05-4 CAPLUS

CN 4-Pyrimidinamine, 6-[5-(2-methoxyphenyl)-3-pyridinyl]-N-methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1001915-06-5 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-(4-(1-pyrrolidinylmethyl)phenyl)-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-07-6 CAPLUS

CN Methanone, [4-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 1001915-09-8 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-[3-(1-pyrrolidinylmethyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-10-1 CAPLUS

CN Methanone, [3-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 1001915-11-2 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-[3-(4-morpholinylmethyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-12-3 CAPLUS

CN Methanone, [3-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 1001915-13-4 CAPLUS


CN 4-Pyrimidinamine, 6-[5-[4-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-N-methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 1001915-14-5 CAPLUS


CN 4-Pyrimidinamine, 6-[5-[3-[2-(dimethylamino)ethoxy]phenyl]-3-pyridinyl]-N-

methyl-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1001915-15-6 CAPLUS

CN Benzamide, 3-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1001915-16-7 CAPLUS

CN Benzamide, 4-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 1001915-17-8 CAPLUS

CN Benzenesulfonamide, 3-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-18-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-[3-(methylsulfonyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-19-0 CAPLUS

CN 4-Pyrimidinamine, 2-(6-methyl-2-pyridinyl)-N-(phenylmethyl)-6-[5-[3-(1-pyrrolidinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-20-3 CAPLUS

CN Phenol, 3-[[[2-(6-methyl-2-pyridinyl)-6-[5-[3-(1-pyrrolidinyl)phenyl]-3-pyridinyl]-4-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1001915-21-4 CAPLUS

CN 4-Pyrimidinamine, 6-[5-[3-(4-methyl-1-piperazinyl)phenyl]-3-pyridinyl]-2-(6-methyl-2-pyridinyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 1001915-22-5 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-[3-(1-methyl-4-piperidinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-23-6 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-(6-methyl-2-pyridinyl)-6-[5-[3-(4-morpholinyl)phenyl]-3-pyridinyl]- (CA INDEX NAME)




RN 1001915-24-7 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-(4-methyl-1-piperazinyl)phenyl]-3-pyridinyl]-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1001915-25-8 CAPLUS

CN Methanone, [4-[5-[6-(methylamino)-2-(6-methyl-2-pyridinyl)-4-pyrimidinyl]-3-pyridinyl]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 1001915-26-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-3-pyridinyl]-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 1001915-27-0 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-[5-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-3-pyridinyl]-2-(6-methyl-2-pyridinyl)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L22 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:53468 CAPLUS
 DN 148:229143
 TI Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
 Acetamides as A2A Receptor Antagonists with In Vivo Efficacy
 AU Slee, Deborah H.; Zhang, Xiaohu; Moorjani, Manisha; Lin, Emily; Lanier,
 Marlon C.; Chen, Yongsheng; Rueter, Jaimie K.; Lechner, Sandra M.;
 Markison, Stacy; Malany, Siobhan; Joswig, Tanya; Santos, Mark; Gross,
 Raymond S.; Williams, John P.; Castro-Palomino, Julio C.; Crespo, Maria
 I.; Prat, Maria; Gual, Silvia; Diaz, Jose-Luis; Wen, Jenny; O'Brien,
 Zhihong; Saunders, John
 CS Departments of Medicinal Chemistry, Pharmacology and Lead Discovery,
 Neuroscience, Chemical Development and Preclinical Development, Neurocrine
 Biosciences, San Diego, CA, 92136, USA
 SO Journal of Medicinal Chemistry (2008) 51(3), 400-406
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 148:229143
 AB Potent adenosine hA2A receptor antagonists are often accompanied by poor
 aqueous solubility, which presents issues for drug development. Herein we
 describe the early exploration of the structure-activity relationships of a lead
 pyrimidin-4-yl acetamide series to provide potent and selective
 2-amino-N-pyrimidin-4-yl acetamides as hA2A receptor antagonists with
 excellent aqueous solubility. In addition, this series of compds. has
 demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's
 disease, despite having reduced potency for the rat A2A receptor vs. the
 human A2A receptor.
 IT 856171-18-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
 Acetamides as A2A Receptor Antagonists with In Vivo Efficacy)
 RN 856171-18-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)



IT 856171-19-2P 856173-75-6P 912935-88-7P
 912938-14-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
 Acetamides as A2A Receptor Antagonists with In Vivo Efficacy)


RN 856171-19-2 CAPLUS

CN Acetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-75-6 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-88-7 CAPLUS

CN 4-Morpholineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-14-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




IT 912935-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
Acetamides as A2A Receptor Antagonists with In Vivo Efficacy)

RN 912935-89-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
4-methyl- (CA INDEX NAME)


IT 856171-38-5P 856172-97-9P 912940-72-8P

1006381-06-1P 1006381-07-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
Acetamides as A2A Receptor Antagonists with In Vivo Efficacy)


RN 856171-38-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)- (CA
INDEX NAME)




RN 856172-97-9 CAPLUS


CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-72-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 1006381-06-1 CAPLUS

CN Acetamide, 2-chloro-N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 1006381-07-2 CAPLUS
 CN Acetamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 912940-20-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Identification of Novel, Water-Soluble, 2-Amino-N-pyrimidin-4-yl
 Acetamides as A2A Receptor Antagonists with In Vivo Efficacy)
 RN 912940-20-6 CAPLUS
 CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:817639 CAPLUS

DN 147:211909

TI Phenoxy-substituted pyrimidines as adenosine receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Slee, Deborah; Zhang, Xiaohu; Rueter, Jaimie K.; Lin, Emily; Crespo Crespo, Maria Isabel; Castro Palomino Laria, Julio Cesar

PA Neurocrine Biosciences, Inc., USA; Laboratorios Almirall, S.A.

SO PCT Int. Appl., 49pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007084914	A2	20070726	WO 2007-US60632	20070117
	WO 2007084914	A3	20071004		
	W:	AE, AG, AL, AM, AT, AU, BE, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	EP 1976851	A2	20081008	EP 2007-718002	20070117
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRAI	US 2006-759692P	P	20060117		
	WO 2007-US60632	W	20070117		

OS MARPAT 147:211909

AB Comps. of formula I, including pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof thereof, and a method for preparing comps. of formula I, are disclosed. Pharmaceutical comps. containing

a compound of structure I, as well as methods relating to the use thereof, are also disclosed. Comps. of formula I wherein R1 and R2 are independently (un)substituted (hetero)aryl; R3 and R4 are independently H, (un)substituted alkyl, and (un)substituted alkoxy; R5 is H, (un)substituted HO-C1-6 alkyl, (un)substituted C1-6 alkoxy-C1-6 alkyl, (un)substituted morpholinyl-C1-6 alkyl, etc.; X is bond, NH and O; m and N are independently 1, 2, and 3; and their pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention comps. were evaluated for their adenosine receptor antagonistic activity (some data given).

IT	944703-84-8P	944703-85-9P	944703-86-0P
	944703-87-1P	944703-88-2P	944703-89-3P
	944703-90-6P	944703-91-7P	944703-92-8P
	944703-93-9P	944703-94-0P	944703-95-1P
	944703-96-2P	944703-97-3P	944703-98-4P
	944703-99-5P	944704-00-1P	944704-01-2P


944704-02-3P	944704-03-4P	944704-04-5P
944704-05-6P	944704-06-7P	944704-07-8P
944704-08-9P	944704-09-0P	944704-10-3P
944704-11-4P	944704-12-5P	944704-13-6P
944704-14-7P	944704-15-8P	944704-16-9P
944704-17-0P	944704-18-1P	944704-19-2P
944704-20-5P	944704-21-6P	944704-22-7P
944704-23-8P	944704-24-9P	944704-25-0P
944704-26-1P	944704-27-2P	944704-28-3P
944704-29-4P	944704-30-7P	944704-31-8P
944704-32-9P	944704-33-0P	944704-34-1P
944704-35-2P	944704-36-3P	944704-37-4P
944704-38-5P	944704-39-6P	944704-40-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenoxy-substituted pyrimidines as adenosine receptor antagonists)


RN 944703-84-8 CAPLUS

CN Acetamide, 2-[3-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-85-9 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-[(ethylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 944703-86-0 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-87-1 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-88-2 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-89-3 CAPLUS

CN Acetamide, 2-[4-[(dimethylamino)methyl]-3-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-90-6 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-6-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-91-7 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-5-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-92-8 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-4-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-93-9 CAPLUS

CN Acetamide, 2-[3-chloro-4-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-94-0 CAPLUS

CN Acetamide, 2-[2-[(dimethylamino)methyl]-4-methylphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-95-1 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-[(ethylmethylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 944703-96-2 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-(4-morpholinylmethyl)phenoxy]- (CA INDEX NAME)




RN 944703-97-3 CAPLUS

CN Acetamide, 2-[3-[2-(dimethylamino)ethyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944703-98-4 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-[2-(4-morpholinyl)ethyl]phenoxy]- (CA INDEX NAME)




RN 944703-99-5 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-fluoro-5-(1-pyrrolidinylmethyl)phenoxy]- (CA INDEX NAME)




RN 944704-00-1 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-fluoro-5-(4-morpholinylmethyl)phenoxy]- (CA INDEX NAME)



RN 944704-01-2 CAPLUS


CN Acetamide, 2-[3-[(dimethylamino)methyl]-5-fluorophenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 944704-02-3 CAPLUS


CN Propanamide, 2-[3-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-

pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, hydrochloride (1:1)
(CA INDEX NAME)




● HCl

RN 944704-03-4 CAPLUS
CN Acetamide, 2-[3-[(dimethylamino)methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-04-5 CAPLUS
CN Acetamide, 2-[3-[(ethylamino)methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-05-6 CAPLUS

CN Acetamide, 2-[3-[[[(1-methylethyl)amino]methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-06-7 CAPLUS

CN Acetamide, 2-[3-[[[(cyclopropylamino)methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-07-8 CAPLUS

CN Acetamide, 2-[3-[(cyclobutylamino)methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-08-9 CAPLUS

CN Acetamide, 2-[3-[[2-(methoxyethyl)amino]methyl]phenoxy]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-09-0 CAPLUS

CN Acetamide, 2-[5-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-10-3 CAPLUS

CN Propanamide, 2-[3-[(dimethylamino)methyl]phenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-11-4 CAPLUS

CN Propanamide, 2-[3-[(dimethylamino)methyl]-5-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-12-5 CAPLUS

CN Propanamide, 2-[5-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-13-6 CAPLUS

CN Propanamide, 2-[3-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-14-7 CAPLUS

CN Propanamide, 2-[3-[(dimethylamino)methyl]-4-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-15-8 CAPLUS

CN Propanamide, 2-[2-[(dimethylamino)methyl]-4-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-16-9 CAPLUS

CN Propanamide, 2-[2-[(dimethylamino)methyl]-3-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-17-0 CAPLUS

CN Propanamide, 2-[2-[(dimethylamino)methyl]-5-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-18-1 CAPLUS

CN Propanamide, 2-[2-[(dimethylamino)methyl]-6-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-19-2 CAPLUS

CN Propanamide, 2-[4-[(dimethylamino)methyl]-3-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-20-5 CAPLUS

CN Propanamide, 2-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-21-6 CAPLUS

CN Urea, N-[2-[2-[(dimethylamino)methyl]-6-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-22-7 CAPLUS

CN Urea, N-[2-[2-[(dimethylamino)methyl]-5-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-23-8 CAPLUS

CN Urea, N-[2-[2-[(dimethylamino)methyl]-4-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-24-9 CAPLUS

CN Urea, N-[2-[2-[(dimethylamino)methyl]-3-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-25-0 CAPLUS

CN Urea, N-[2-[3-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-26-1 CAPLUS

CN Urea, N-[2-[3-[(dimethylamino)methyl]-4-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-27-2 CAPLUS


CN Urea, N-[2-[3-[(dimethylamino)methyl]-5-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 944704-28-3 CAPLUS


CN Urea, N-[2-[5-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA
INDEX NAME)

RN 944704-29-4 CAPLUS

CN Urea, N-[2-[4-[(dimethylamino)methyl]-3-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA
INDEX NAME)


RN 944704-30-7 CAPLUS

CN Urea, N-[2-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl]-N'-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA
INDEX NAME)




RN 944704-31-8 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[2-[(dimethylamino)methyl]-6-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-32-9 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[2-[(dimethylamino)methyl]-5-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-33-0 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[2-[(dimethylamino)methyl]-4-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-34-1 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[2-[(dimethylamino)methyl]-3-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-35-2 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[5-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-36-3 CAPLUS

CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[3-[(dimethylamino)methyl]-5-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




RN 944704-37-4 CAPLUS


CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[3-[(dimethylamino)methyl]-4-methoxyphenoxy]ethyl ester
(CA INDEX NAME)



RN 944704-38-5 CAPLUS


CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[3-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl ester
(CA INDEX NAME)

RN 944704-39-6 CAPLUS


CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]ethyl ester
(CA INDEX NAME)

RN 944704-40-9 CAPLUS


CN Carbamic acid, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-[4-[(dimethylamino)methyl]-3-methoxyphenoxy]ethyl ester
(CA INDEX NAME)




IT 856173-03-0P 912940-73-9P 912940-88-6P
 944704-43-2P 944704-44-3P 944704-45-4P
 944704-47-6P 944704-48-7P 944704-49-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of phenoxy-substituted pyrimidines as adenosine
 receptor antagonists)
 RN 856173-03-0 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)



RN 912940-73-9 CAPLUS
 CN Acetamide, 2-chloro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-
 pyrimidinyl]- (CA INDEX NAME)




RN 912940-88-6 CAPLUS
 CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
 (CA INDEX NAME)




RN 944704-43-2 CAPLUS

CN Acetamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-44-3 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(3-formylphenoxy)- (CA INDEX NAME)




RN 944704-45-4 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[3-(2-hydroxyethyl)phenoxy]- (CA INDEX NAME)




RN 944704-47-6 CAPLUS

CN Carbamic acid, N-[3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethoxy]-5-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 944704-48-7 CAPLUS

CN Propanamide, 2-chloro-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 944704-49-8 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(3-formylphenoxy)- (CA INDEX NAME)



L22 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:477996 CAPLUS
 DN 147:109060
 TI Small molecule inhibitors of E. coli primase, a novel bacterial target
 AU Agarwal, Atul; Louise-May, Shirley; Thanassi, Jane A.; Podos, Steven D.;
 Cheng, Jijun; Thoma, Christy; Liu, Cuixian; Wiles, Jason A.; Nelson, David
 M.; Phadke, Avinash S.; Bradbury, Barton J.; Deshpande, Milind S.; Pucci,
 Michael J.
 CS Achillion Pharmaceuticals, New Haven, CT 06511, USA
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2807-2810
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB Bacterial primase is essential for DNA replication in Gram-pos. and
 Gram-neg. bacteria. It is also structurally distinct from eukaryotic
 primases, and therefore an attractive, but under-explored, target for
 therapeutic intervention. We applied virtual screening to discover
 primase inhibitors, and subsequently several com. available analogs of
 these initial hits showed potent primase inhibition and in vitro
 antibacterial activity. This work provides a 3D pharmacophore for primase
 ligands, SAR trends, and leads that can be further optimized.
 IT 887461-82-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (small mol. inhibitors of novel bacterial target, E. coli primase)
 RN 887461-82-7 CAPLUS
 CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-[2-(2-pyridinyl)-6-(4-pyridinyl)-4-
 pyrimidinyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1093757 CAPLUS
 DN 145:438634
 TI Preparation of acylaminopyrimidines as adenosine receptor antagonists
 IN Slee, Deborah; Lanier, Marion; Vong, Binh G.; Chen, Yongsheng; Zhang, Xiaohui; Lin, Emily; Moorjani, Manisha; Castro Palomino Laria, Julio Cesar
 PA Neurocrine Biosciences, Inc., USA; Almirall Prodesfarma, S.A.
 SO PCT Int. Appl., 1/2 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006110884	A2	20061019	WO 2006-US13940	20060411
	WO 2006110884	A3	20061123		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP	1888565	A2	20080220	EP 2006-750082	20060411
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US	20080275064	A1	20081106	US 2008-911187	20080617
PRAI	US 2005-670482P	P	20050411		
	WO 2006-US13940	W	20060411		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 145:438634; MARPAT 145:438634

AB Title compds. [I; R1, R2 = (substituted) aryl, heteroaryl; R3 = (CR4R5)nR6, (CR4R5)nNR7R8, O(CR4R5)nR6, (CR4R5)nOR8; R4, R5 = H, OH, SH, NO2, cyano, amino, halo, (substituted) alkyl, alkoxy, alkylthio, cycloalkyl, alkylamino; R6 = (substituted) heterocyclyl; R7 = H, (substituted) alkyl; R8 = (CR4R5)nR6; NR7R8 = (substituted) heterocyclyl; n = 0-4], were prepared. Thus, 1-tert-butoxycarbonylpiperidin-4-ylacetic acid was stirred 30 min. with (COCl)₂ and cat. DMF in THF to give a first mixture; 2-(5-methyl-2-furyl)-6-(thiazol-2-yl)pyrimidin-4-amine (preparation given) in THF was treated with NaH and this second mixture was added dropwise to the first mixture followed by stirring for 1 h to give coupling product, which was treated with CF₃CO₂H in CH₂Cl₂ to give N-[2-(5-methylfuran-2-yl)-6-thiazol-2-ylpyrimidin-4-yl]-2-(1-methylpiperidin-4-yl)acetamide. In adenosine A_{2A} receptor binding assays, I may have IC₅₀'s of <10 μM.

IT	912935-87-6P	912935-88-7P	912935-89-8P
	912935-90-1P	912935-91-2P	912935-92-3P
	912935-93-4P	912935-94-5P	912935-95-6P
	912935-96-7P	912935-97-8P	912935-98-9P
	912935-99-0P	912936-00-6P	912936-01-7P
	912936-02-8P	912936-03-9P	912936-04-0P

912936-05-1P	912936-06-2P	912936-07-3P
912936-08-4P	912936-09-5P	912936-11-9P
912936-12-0P	912936-13-1P	912936-14-2P
912936-15-3P	912936-16-4P	912936-17-5P
912936-18-6P	912936-19-7P	912936-20-0P
912936-21-1P	912936-22-2P	912936-23-3P
912936-24-4P	912936-25-5P	912936-26-6P
912936-27-7P	912936-28-8P	912936-29-9P
912936-30-2P	912936-31-3P	912936-32-4P
912936-33-5P	912936-34-6P	912936-35-7P
912936-36-8P	912936-37-9P	912936-38-0P
912936-39-1P	912936-40-4P	912936-41-5P
912936-42-6P	912936-43-7P	912936-44-8P
912936-45-9P	912936-46-0P	912936-47-1P
912936-48-2P	912936-49-3P	912936-50-6P
912936-51-7P	912936-52-8P	912936-53-9P
912936-54-0P	912936-55-1P	912936-56-2P
912936-57-3P	912936-58-4P	912936-59-5P
912936-60-8P	912936-61-9P	912936-62-0P
912936-63-1P	912936-64-2P	912936-65-3P
912936-66-4P	912936-67-5P	912936-68-6P
912936-69-7P	912936-70-0P	912936-71-1P
912936-72-2P	912936-73-3P	912936-74-4P
912936-75-5P	912936-76-6P	912936-77-7P
912936-78-8P	912936-79-9P	912936-80-2P
912936-81-3P	912936-82-4P	912936-83-5P
912936-84-6P	912936-85-7P	912936-86-8P
912936-87-9P	912936-88-0P	912936-89-1P
912936-90-4P	912936-91-5P	912936-92-6P
912936-93-7P	912936-94-8P	912936-95-9P
912936-96-0P	912936-97-1P	912936-98-2P
912937-00-9P	912937-01-0P	912937-02-1P
912937-03-2P	912937-20-3P	912937-31-6P
912937-32-7P	912937-33-8P	912937-34-9P
912937-35-0P	912937-36-1P	912937-37-2P
912937-38-3P	912937-40-7P	912937-41-8P
912937-42-9P	912937-43-0P	912937-44-1P
912937-45-2P	912937-46-3P	912937-47-4P
912937-48-5P	912937-49-6P	912937-50-9P
912937-51-0P	912937-52-1P	912937-53-2P
912937-54-3P	912937-55-4P	912937-56-5P
912937-57-6P	912937-58-7P	912937-59-8P
912937-60-1P	912937-61-2P	912937-62-3P
912937-63-4P	912937-64-5P	912937-65-6P
912937-66-7P	912937-67-8P	912937-68-9P
912937-69-0P	912937-70-3P	912937-71-4P
912937-72-5P	912937-73-6P	912937-74-7P
912937-75-8P	912937-76-9P	912937-77-0P
912937-78-1P	912937-79-2P	912937-80-5P
912937-81-6P	912937-82-7P	912937-83-8P
912937-84-9P	912937-85-0P	912937-86-1P
912937-87-2P	912937-88-3P	912937-89-4P
912937-90-7P	912937-91-8P	912937-92-9P
912937-93-0P	912937-94-1P	912937-95-2P
912937-96-3P	912937-97-4P	912937-98-5P
912937-99-6P	912938-00-2P	912938-01-3P
912938-02-4P	912938-03-5P	912938-04-6P


912938-05-7P	912938-06-8P	912938-07-9P
912938-08-0P	912938-09-1P	912938-10-4P
912938-11-5P	912938-12-6P	912938-13-7P
912938-14-8P	912938-15-9P	912938-16-0P
912938-17-1P	912938-18-2P	912938-19-3P
912938-20-6P	912938-21-7P	912938-22-8P
912938-23-9P	912938-24-0P	912938-25-1P
912938-26-2P	912938-27-3P	912938-29-5P
912938-31-9P	912938-32-0P	912938-33-1P
912938-34-2P	912938-35-3P	912938-36-4P
912938-37-5P	912938-38-6P	912938-39-7P
912938-40-0P	912938-41-1P	912938-42-2P
912938-43-3P	912938-44-4P	912938-45-5P
912938-46-6P	912938-47-7P	912938-48-8P
912938-49-9P	912938-50-2P	912938-51-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of acylaminopyrimidines as adenosine receptor antagonists)


RN 912935-87-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 912935-88-7 CAPLUS

CN 4-Morpholineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 912935-89-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912935-90-1 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-91-2 CAPLUS

CN 4-Morpholineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-92-3 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-93-4 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-94-5 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-95-6 CAPLUS

CN 1-Piperazineacetamide, 2,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-96-7 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-97-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-phenyl- (CA INDEX NAME)




RN 912935-98-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912935-99-0 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-phenyl- (CA INDEX NAME)




RN 912936-00-6 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-phenyl- (CA INDEX NAME)




RN 912936-01-7 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 912936-02-8 CAPLUS

CN 1-Piperidineacetamide, 2-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-03-9 CAPLUS

CN 1H-Pyrrole-1-acetamide, 2,5-dihydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-04-0 CAPLUS

CN 1H-Pyrrole-1-acetamide, 2,5-dihydro-2,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-05-1 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(5-ethyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2,5-dimethyl- (CA INDEX NAME)




RN 912936-06-2 CAPLUS

CN 1-Piperazineacetamide, 3,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-07-3 CAPLUS

CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-08-4 CAPLUS

CN 1-Piperidineacetamide, 3-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-09-5 CAPLUS

CN 1H-Azepine-1-acetamide, hexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-11-9 CAPLUS

CN 1-Piperidineacetamide, 3,3-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-12-0 CAPLUS

CN 1-Piperidineacetamide, 3,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-13-1 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-phenyl- (CA INDEX NAME)




RN 912936-14-2 CAPLUS

CN 1-Piperidineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-15-3 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 912936-16-4 CAPLUS

CN [1,4'-Bipiperidine]-1'-acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-17-5 CAPLUS

CN 2(1H)-Isoquinolineacetamide, 3,4-dihydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-18-6 CAPLUS


CN 2(1H)-Isoquinolineacetamide, octahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-19-7 CAPLUS


CN 1-Pyrrolidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-20-0 CAPLUS

CN 1-Piperazineacetamide, 4-(3,4-dimethylphenyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-21-1 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 912936-22-2 CAPLUS

CN 1-Piperazineacetamide, 4-(3-chlorophenyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-23-3 CAPLUS

CN 4-Morpholineacetamide, 2,6-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-24-4 CAPLUS

CN 1-Piperazineacetamide, 3-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(3-methylphenyl)- (CA INDEX NAME)




RN 912936-25-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-26-6 CAPLUS

CN 1-Piperazineacetamide, 4-(3-methoxyphenyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-27-7 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 912936-28-8 CAPLUS

CN 1,4-Oxazepine-4(5H)-acetamide, tetrahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-29-9 CAPLUS

CN 1-Piperidineacetamide, 4,4-difluoro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-30-2 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-31-3 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[1-(phenylmethyl)-3-pyrrolidinyl]methyl]amino]- (CA INDEX NAME)




RN 912936-32-4 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-acetylhexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-33-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(phenylmethyl)- (CA INDEX NAME)




RN 912936-34-6 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-35-7 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 912936-36-8 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-37-9 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912936-38-0 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-39-1 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[2-(1-pyrrolidiny)ethyl]amino]- (CA INDEX NAME)




RN 912936-40-4 CAPLUS

CN 1-Piperidineacetamide, 3-(aminocarbonyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-41-5 CAPLUS


CN 1-Piperidineacetamide, 4-(aminocarbonyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-42-6 CAPLUS


CN 1-Piperazineacetamide, 3-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-43-7 CAPLUS

CN 1,4-Piperazinediacetamide, N1-(1-methylethyl)-N4-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-44-8 CAPLUS

CN 1-Piperidineacetamide, 4-amino-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-45-9 CAPLUS


CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-46-0 CAPLUS
 CN 1-Piperidineacetamide, 4-(diethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-47-1 CAPLUS
 CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-48-2 CAPLUS

CN 1-Piperidineacetamide, 4-[(1-methylethyl)amino]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-49-3 CAPLUS

CN 1-Piperidineacetamide, 4-(cyclopentylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-50-6 CAPLUS

CN 1-Piperidineacetamide, 4-(dipropylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-51-7 CAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-52-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[(1-methylethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-53-9 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(cyclopentylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-54-0 CAPLUS


CN 1-Piperidineacetamide, 4-(acetylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-55-1 CAPLUS


CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-

pyrimidinyl]-4-[(1-oxopropyl)amino]- (CA INDEX NAME)




RN 912936-56-2 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(acetylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-57-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-[(1-oxopropyl)amino]- (CA INDEX NAME)




RN 912936-58-4 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4- (CA INDEX NAME)




RN 912936-59-5 CAPLUS

CN Pyrrolo[1,2-a]pyrazine-2(1H)-acetamide, hexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-60-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-(1-piperidinyl)- (CA INDEX NAME)




RN 912936-61-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-(4-morpholinyl)- (CA INDEX NAME)




RN 912936-62-0 CAPLUS

CN 1-Piperazineacetamide, 2-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-oxo- (CA INDEX NAME)




RN 912936-63-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, ethyl ester (CA INDEX NAME)



RN 912936-64-2 CAPLUS


CN 1-Piperidineacetamide, 3-[[[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]amino]carbonyl]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-65-3 CAPLUS

CN 1-Pyrrolidineacetamide, 3-[(2-hydroxyethyl)amino]carbonyl]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912936-66-4 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(ethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-67-5 CAPLUS

CN 1-Piperazineacetamide, 4-ethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-68-6 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[2-(1-piperidinyl)ethyl]amino]- (CA INDEX NAME)




RN 912936-69-7 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[methyl(1-methyl-4-piperidinyl)amino]- (CA INDEX NAME)




RN 912936-70-0 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)




RN 912936-71-1 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-(3-pyrrolidinylamino)- (CA INDEX NAME)




RN 912936-72-2 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[3-(1-pyrrolidinyl)propyl]amino]- (CA INDEX NAME)




RN 912936-73-3 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)




RN 912936-74-4 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 912936-75-5 CAPLUS

CN 1-Piperidineacetamide, 4-hydroxy-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-76-6 CAPLUS


CN 1-Piperidineacetamide, 3-hydroxy-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-77-7 CAPLUS

CN 1-Pyrrolidineacetamide, 3-hydroxy-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912936-78-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(acetamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912936-79-9 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(acetylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-80-2 CAPLUS

CN 1-Pyrrolidineacetamide, 3-hydroxy-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-81-3 CAPLUS

CN 1-Piperazineacetamide, 4-(1-methylethyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-82-4 CAPLUS

CN 1-Piperazineacetamide, 4-cyclopentyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-83-5 CAPLUS

CN 1-Piperazineacetamide, 4-cyclohexyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-84-6 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(1-oxopropyl)- (CA INDEX NAME)




RN 912936-85-7 CAPLUS

CN 1-Piperazineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 912936-86-8 CAPLUS

CN 1-Piperidineacetamide, 4-(aminomethyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-87-9 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[(3-pyrrolidinylmethyl)amino]- (CA INDEX NAME)




RN 912936-88-0 CAPLUS

CN 1-Piperidineacetamide, 3-(aminomethyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-89-1 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[(1-methyl-3-pyrrolidinyl)methyl]amino]- (CA INDEX NAME)




RN 912936-90-4 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(aminomethyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-91-5 CAPLUS

CN 1-Piperidineacetamide, 4-methoxy-N-[2-(5-methyl-2-furyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-92-6 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[2-(5-methyl-2-furyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-93-7 CAPLUS

CN 1-Piperidineacetamide, 4-[(dimethylamino)methyl]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-94-8 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[methyl[(1-methyl-3-pyrrolidiny)methyl]amino]- (CA INDEX NAME)



RN 912936-95-9 CAPLUS


CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912936-96-0 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912936-97-1 CAPLUS

CN 1-Piperazinepropanamide, 4-acetyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912936-98-2 CAPLUS

CN 1-Piperazinepropanamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-00-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 912937-01-0 CAPLUS

CN Acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 912937-02-1 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(4-methoxy-3-pyridinyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912937-03-2 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(6-methoxy-3-pyridinyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912937-20-3 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methoxy-3-pyridinyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912937-31-6 CAPLUS

CN 4-Morpholineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-32-7 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-33-8 CAPLUS

CN 1,4-Piperazinediacetamide, N1-(1-methylethyl)-N4-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-34-9 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]-4-phenyl- (CA INDEX NAME)




RN 912937-35-0 CAPLUS

CN [1,4'-Bipiperidine]-1'-acetamide, N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-36-1 CAPLUS

CN 2(1H)-Isoquinolineacetamide, 3,4-dihydro-N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-37-2 CAPLUS

CN 1-Piperazineacetamide, 4-(3-methoxyphenyl)-N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-38-3 CAPLUS


CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-40-7 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912937-41-8 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912937-42-9 CAPLUS

CN 1-Piperazineacetamide, 2,5-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-43-0 CAPLUS

CN 1-Piperazineacetamide, 3,5-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-44-1 CAPLUS

CN 1-Piperazineacetamide, 4-phenyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-45-2 CAPLUS

CN 1-Piperazineacetamide, 2-(2-methoxyphenyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-46-3 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-47-4 CAPLUS

CN 1-Piperazineacetamide, 4-(phenylmethyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-48-5 CAPLUS

CN 4-Morpholineacetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-49-6 CAPLUS

CN 4-Morpholineacetamide, 2,6-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-50-9 CAPLUS

CN 1-Piperidineacetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 912937-51-0 CAPLUS

CN 1-Piperidineacetamide, 2-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 912937-52-1 CAPLUS

CN 1-Piperidineacetamide, 3-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 912937-53-2 CAPLUS

CN 1-Piperidineacetamide, 3,3-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-54-3 CAPLUS

CN 1-Piperidineacetamide, 3,5-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-55-4 CAPLUS

CN 1-Piperidineacetamide, 4-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-56-5 CAPLUS

CN 1-Piperidineacetamide, 4-(phenylmethyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-57-6 CAPLUS


CN [1,4'-Bipiperidine]-1'-acetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-58-7 CAPLUS


CN 1-Pyrrolidineacetamide, 2-(methoxymethyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912937-59-8 CAPLUS


CN 2-(1H)-Isoquinolineacetamide, octahydro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-60-1 CAPLUS


CN 1-Pyrrolidineacetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- 2-(1-pyrrolidinylmethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912937-61-2 CAPLUS

CN 1-Piperazineacetamide, 4-(3,4-dimethylphenyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-65-6 CAPLUS

CN 1-Piperazineacetamide, 4-(4-methoxyphenyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-66-7 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-67-8 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, hexahydro-4-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-68-9 CAPLUS


CN 1-Piperidineacetamide, 2-[[[(2S)-1-methyl-2-pyrrolidinyl]methyl]-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 912937-69-0 CAPLUS


CN 1-Piperidineacetamide, 2-[2-(1-piperidinyl)ethyl]-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-70-3 CAPLUS


CN 1-Piperazineacetamide, 2-methyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912937-71-4 CAPLUS

CN 1H-Pyrrole-1-acetamide, 2,5-dihydro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-72-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-acetylhexahydro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-73-6 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-74-7 CAPLUS

CN 1-Piperidineacetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 912937-75-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-79-2 CAPLUS

CN 1-Pyrrolidineacetamide, 2,5-dimethyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-80-5 CAPLUS

CN 1-Piperidineacetamide, 2-phenyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-81-6 CAPLUS

CN 1-Piperidineacetamide, 2-phenyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-82-7 CAPLUS

CN 1,4-Oxazepine-4(5H)-acetamide, tetrahydro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-83-8 CAPLUS

CN 1-Piperidineacetamide, 4,4-difluoro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-84-9 CAPLUS

CN 1-Piperidineacetamide, 4-phenyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-85-0 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 912937-86-1 CAPLUS

CN 1,4-Piperazinediacetamide, N1-(1-methylethyl)-N4-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-87-2 CAPLUS

CN 1-Piperidineacetamide, 3-(aminocarbonyl)-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-88-3 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-89-4 CAPLUS

CN Acetamide, 2-[methyl[2-(1-pyrrolidinyl)ethyl]amino]-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-90-7 CAPLUS

CN 1-Piperazinepropanamide, 4-acetyl-N-[2-(2-pyridinyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-94-1 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-95-2 CAPLUS

CN 4-Morpholineacetamide, N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-96-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-97-4 CAPLUS

CN Acetamide, 2-[methyl(1-methyl-4-piperidinyl)amino]-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912937-98-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912937-99-6 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, hexahydro-4-methyl-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-00-2 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 4-ethylhexahydro-N-[6-(2-pyridinyl)-2-(2-

thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-01-3 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-4-propyl-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-02-4 CAPLUS

CN 1-Piperidineacetamide, 4-amino-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-03-5 CAPLUS

CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-04-6 CAPLUS

CN 1-Piperidineacetamide, 4-(diethylamino)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-05-7 CAPLUS

CN 1-Piperidineacetamide, 4-(dipropylamino)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-06-8 CAPLUS

CN 1-Piperidineacetamide, 4-(acetylamino)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-07-9 CAPLUS


CN 1-Piperidineacetamide, 4-[(1-oxopropyl)amino]-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-08-0 CAPLUS


CN 1-Piperidineacetamide, N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]-4-

(1-pyrrolidinyl)- (CA INDEX NAME)




RN 912938-09-1 CAPLUS

CN 1-Piperidineacetamide, 4-(4-morpholinyl)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-10-4 CAPLUS

CN [1,4'-Bipiperidine]-1'-acetamide, N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-11-5 CAPLUS

CN 1-Piperidineacetamide, 4-[(2-oxo-1-imidazolidinyl)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-12-6 CAPLUS

CN 1-Piperidineacetamide, 4-[(1-iminoethyl)amino]-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-13-7 CAPLUS

CN 1-Piperidineacetamide, 4-(1-azetidiny)-N-[6-(2-pyridinyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-14-8 CAPLUS

CN 1-Piperazineacetamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912938-15-9 CAPLUS

CN 1-Piperidineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-16-0 CAPLUS

CN 1-Piperidineacetamide, 2-(1-pyrrolidinylmethyl)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-17-1 CAPLUS

CN 1-Piperidineacetamide, 2-[2-(1-piperidinyl)ethyl]-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-18-2 CAPLUS

CN 1-Piperidineacetamide, 3-methyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-19-3 CAPLUS

CN 1-Piperidineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 912938-20-6 CAPLUS

CN 1-Piperidineacetamide, 3-(aminocarbonyl)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-21-7 CAPLUS

CN [1,4'-Bipiperidine]-1'-acetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-22-8 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-23-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-acetylhexahydro-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-24-0 CAPLUS

CN 1-Piperidineacetamide, 4-(1-pyrrolidinyl)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-25-1 CAPLUS

CN 1-Piperazineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-26-2 CAPLUS

CN 1-Piperazineacetamide, 2,5-dimethyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-27-3 CAPLUS

CN 1-Piperazineacetamide, 3,5-dimethyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-29-5 CAPLUS

CN 1-Piperazineacetamide, 4-phenyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-31-9 CAPLUS

CN 1,4-Piperazinediacetamide, N1-(1-methylethyl)-N4-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-32-0 CAPLUS

CN 4-Morpholineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-33-1 CAPLUS

CN 4-Morpholineacetamide, 2,6-dimethyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-34-2 CAPLUS

CN 4-Thiomorpholineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-35-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-36-4 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-37-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-38-6 CAPLUS

CN Acetamide, 2-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-39-7 CAPLUS

CN 1-Piperidineacetamide, 3,5-dimethyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-40-0 CAPLUS

CN 1-Piperidineacetamide, 4,4-difluoro-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-41-1 CAPLUS

CN 1-Piperidineacetamide, 4-phenyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-42-2 CAPLUS

CN 1H-Azepine-1-acetamide, hexahydro-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-43-3 CAPLUS

CN 1-Piperidineacetamide, 4-(aminocarbonyl)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-44-4 CAPLUS


CN 1-Piperazineacetamide, 4-(3-methoxyphenyl)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-45-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-46-6 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912938-47-7 CAPLUS


CN Acetamide, 2-[[[(1-ethyl-2-pyrrolidinyl)methyl]amino]-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-48-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(ethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-49-9 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(ethylamino)-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-50-2 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-51-3 CAPLUS

CN 1-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)



IT	912938-52-4P	912938-53-5P	912938-54-6P
	912938-55-7P	912938-56-8P	912938-57-9P
	912938-58-0P	912938-59-1P	912938-60-4P
	912938-61-5P	912938-62-6P	912938-63-7P
	912938-64-8P	912938-65-9P	912938-66-0P
	912938-67-1P	912938-68-2P	912938-69-3P
	912938-70-6P	912938-71-7P	912938-72-8P
	912938-73-9P	912938-74-0P	912938-75-1P
	912938-76-2P	912938-77-3P	912938-78-4P
	912938-79-5P	912938-80-8P	912938-81-9P

912938-82-0P	912938-83-1P	912938-84-2P
912938-85-3P	912938-86-4P	912938-87-5P
912938-88-6P	912938-89-7P	912938-90-0P
912938-91-1P	912938-92-2P	912938-93-3P
912938-94-4P	912938-95-5P	912938-96-6P
912938-97-7P	912938-98-8P	912938-99-9P
912939-00-5P	912939-01-6P	912939-02-7P
912939-03-8P	912939-04-9P	912939-05-0P
912939-06-1P	912939-07-2P	912939-08-3P
912939-09-4P	912939-10-7P	912939-11-8P
912939-12-9P	912939-13-0P	912939-14-1P
912939-15-2P	912939-16-3P	912939-17-4P
912939-18-5P	912939-19-6P	912939-20-9P
912939-21-0P	912939-22-1P	912939-23-2P
912939-24-3P	912939-25-4P	912939-26-5P
912939-27-6P	912939-28-7P	912939-29-8P
912939-30-1P	912939-31-2P	912939-32-3P
912939-33-4P	912939-34-5P	912939-36-7P
912939-37-8P	912939-38-9P	912939-39-0P
912939-40-3P	912939-41-4P	912939-42-5P
912939-43-6P	912939-44-7P	912939-45-8P
912939-47-0P	912939-48-1P	912939-49-2P
912939-50-5P	912939-51-6P	912939-52-7P
912939-53-8P	912939-54-9P	912939-55-0P
912939-56-1P	912939-57-2P	912939-58-3P
912939-59-4P	912939-60-7P	912939-61-8P
912939-62-9P	912939-63-0P	912939-64-1P
912939-65-2P	912939-66-3P	912939-67-4P
912939-68-5P	912939-69-6P	912939-70-9P
912939-71-0P	912939-72-1P	912939-73-2P
912939-74-3P	912939-75-4P	912939-76-5P
912939-77-6P	912939-78-7P	912939-79-8P
912939-80-1P	912939-81-2P	912939-82-3P
912939-83-4P	912939-84-5P	912939-85-6P
912939-86-7P	912939-87-8P	912939-88-9P
912939-89-0P	912939-90-3P	912939-91-4P
912939-92-5P	912939-93-6P	912939-94-7P
912939-95-8P	912939-96-9P	912939-97-0P
912939-98-1P	912939-99-2P	912940-00-2P
912940-01-3P	912940-02-4P	912940-03-5P
912940-04-6P	912940-05-7P	912940-06-8P
912940-07-9P	912940-08-0P	912940-09-1P
912940-10-4P	912940-11-5P	912940-12-6P
912940-13-7P	912940-14-8P	912940-15-9P
912940-16-0P	912940-17-1P	912940-18-2P
912940-19-3P	912940-20-6P	912940-21-7P
912940-22-8P	912940-23-9P	912940-24-0P
912940-25-1P	912940-26-2P	912940-27-3P
912940-28-4P	912940-29-5P	912940-30-8P
912940-31-9P	912940-32-0P	912940-33-1P
912940-34-2P	912940-35-3P	912940-36-4P
912940-37-5P	912940-39-7P	912940-41-1P
912940-42-2P	912940-43-3P	912940-44-4P
912940-45-5P	912940-46-6P	912940-47-7P
912940-48-8P	912940-49-9P	912940-50-2P
912940-52-4P	912940-53-5P	912940-54-6P
912940-55-7P	912940-56-8P	912940-57-9P


912940-58-0P	912940-59-1P	912940-60-4P
912940-61-5P	912940-62-6P	912940-63-7P
912940-64-8P	912940-65-9P	912940-66-0P
912940-67-1P	912940-68-2P	912940-69-3P
912940-70-6P	912940-71-7P	1026745-98-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of acylaminopyrimidines as adenosine receptor antagonists)


RN 912938-52-4 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-53-5 CAPLUS


CN 1-Piperazineacetamide, 4-acetyl-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-54-6 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(ethylamino)-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912938-55-7 CAPLUS


CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3,5-dimethyl- (CA INDEX NAME)



RN 912938-56-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-57-9 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-58-0 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-59-1 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(3-pyrrolidinylamino)- (CA INDEX NAME)




RN 912938-60-4 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(2-(1-pyrrolidinyl)ethyl)amino]- (CA INDEX NAME)




RN 912938-61-5 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[3-(1-pyrrolidinyl)propyl]amino]- (CA INDEX NAME)




RN 912938-62-6 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[3-(1-methyl-2-pyrrolidinyl)ethyl]amino]- (CA INDEX NAME)




RN 912938-63-7 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[2-(1-piperidiny)ethyl]amino]- (CA INDEX NAME)




RN 912938-64-8 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)




RN 912938-65-9 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[3-(4-morpholinyl)propyl]amino]- (CA INDEX NAME)




RN 912938-66-0 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912938-67-1 CAPLUS

CN 4-Morpholineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-68-2 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro- (CA INDEX NAME)




RN 912938-69-3 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-70-6 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro-4-methyl- (CA INDEX NAME)



RN 912938-71-7 CAPLUS


CN 1,4-Oxazepine-4(5H)-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]tetrahydro- (CA INDEX NAME)



RN 912938-72-8 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-73-9 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-74-0 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-75-1 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4,4-difluoro- (CA INDEX NAME)




RN 912938-76-2 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(2-thiazolyl)- (CA INDEX NAME)



RN 912938-77-3 CAPLUS


CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-ethyl- (CA INDEX NAME)



RN 912938-78-4 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(acetylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-79-5 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(acetylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-80-8 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-81-9 CAPLUS

CN 4-Morpholineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2,6-dimethyl- (CA INDEX NAME)




RN 912938-82-0 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-hydroxy- (CA INDEX NAME)




RN 912938-83-1 CAPLUS

CN [1,4'-Bipiperidine]-1'-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912938-84-2 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)



RN 912938-85-3 CAPLUS


CN 1-Piperazineacetamide, 4-acetyl-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912938-86-4 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-87-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-88-6 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylmethylamino)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-89-7 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylmethylamino)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-90-0 CAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-91-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-92-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(4-morpholinyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-93-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(1-piperidinyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-94-4 CAPLUS

CN [1,3'-Bipyrrolidine]-1'-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
, (3'R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912938-95-5 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(4-morpholinyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-96-6 CAPLUS
 CN [1,3'-Bipyrrolidine]-1'-acetamide,
 N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
 , (3'S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912938-97-7 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(1-piperidinyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912938-98-8 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)



RN 912938-99-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-00-5 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-hydroxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-01-6 CAPLUS

CN [1,3'-Bipyrrolidine]-1'-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3R,3'R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-02-7 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[(2-methoxyethyl)methylamino]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-03-8 CAPLUS

CN [1,3'-Bipyrrolidine]-1'-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3S,3'S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-04-9 CAPLUS


CN [1,3'-Bipyrrolidine]-1'-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
3-fluoro-, (3R,3'S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-05-0 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(2,5-dihydro-1H-pyrrol-1-yl)-N-[6-(3,5-dimethyl-
1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-06-1 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[(2-methoxyethyl)methylamino], (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-07-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-08-3 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-09-4 CAPLUS


CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3R)- (CA INDEX NAME)



RN 912939-10-7 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[(2-methoxyethyl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-11-8 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(trifluoromethyl)- (CA INDEX NAME)




RN 912939-12-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyrazine-7(8H)-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
5,6-dihydro-3-(trifluoromethyl)- (CA INDEX NAME)




RN 912939-13-0 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(2-oxo-1-pyrrolidinyl)- (CA INDEX NAME)




RN 912939-14-1 CAPLUS

CN 1-Piperidineacetamide, 4-(acetylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-15-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, phenyl ester (CA INDEX NAME)



RN 912939-16-3 CAPLUS


CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-[(phenylmethyl)amino]carbonyl]- (CA INDEX NAME)



RN 912939-17-4 CAPLUS


CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-

furanyl)-4-pyrimidinyl]-4-(3-methylbenzoyl)- (CA INDEX NAME)



RN 912939-18-5 CAPLUS


CN 1-Piperazineacetamide, 4-[(dimethylamino)carbonyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-19-6 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[ethyl(2-methoxyethyl)amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-22-1 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-9-carboxylic acid,
3-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-
pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 912939-23-2 CAPLUS


CN 3,9-Diazabicyclo[4.2.1]nonane-3-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
9-methyl- (CA INDEX NAME)



RN 912939-24-3 CAPLUS


CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-

furanyl)-4-pyrimidinyl]-4-[[(2-methoxyethyl)methylamino]methyl]- (CA INDEX NAME)




RN 912939-25-4 CAPLUS

CN 3,9-Diazabicyclo[4.2.1]nonane-3-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
9-(2-methoxyethyl)- (CA INDEX NAME)




RN 912939-26-5 CAPLUS

CN Carbamic acid, N-[[1-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-4-piperidinyl]methyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 912939-27-6 CAPLUS

CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-[(2-methoxyethyl)methylamino]- (CA INDEX NAME)



RN 912939-28-7 CAPLUS


CN 4-Morpholineacetamide, 2-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-29-8 CAPLUS

CN 1-Piperidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-30-1 CAPLUS

CN 1-Piperidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-31-2 CAPLUS


CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-32-3 CAPLUS

CN 1-Piperidineacetamide, 4-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-33-4 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(1-methyl-4-piperidinyl)amino]- (CA INDEX NAME)



RN 912939-34-5 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(3R)-3-pyrrolidinylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-36-7 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[(2R)-tetrahydro-2-furanyl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-37-8 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(tetrahydro-2H-pyran-4-yl)methyl]amino]- (CA INDEX NAME)



RN 912939-38-9 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(2S)-tetrahydro-2-furanyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 912939-39-0 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-(4-piperidinylamino)- (CA INDEX NAME)



RN 912939-40-3 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(3S)-3-piperidinylamino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-41-4 CAPLUS

CN Acetamide, 2-(3-azetidinylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-42-5 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[[2-(4-morpholinyl)ethyl]amino]- (CA INDEX NAME)



RN 912939-43-6 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(3R)-3-piperidinylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-44-7 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(2R)-2-pyrrolidinylmethyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-45-8 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(3S)-3-pyrrolidinylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-47-0 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(3R)-3-pyrrolidinylmethylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-48-1 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-49-2 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-50-5 CAPLUS

CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912939-51-6 CAPLUS

CN 4-Morpholinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-52-7 CAPLUS

CN 4-Morpholinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2,6-dimethyl- (CA INDEX NAME)




RN 912939-53-8 CAPLUS

CN 1-Piperidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 912939-54-9 CAPLUS

CN 1H-1,4-Diazepine-1-propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro- (CA INDEX NAME)



RN 912939-55-0 CAPLUS


CN 1H-1,4-Diazepine-1-propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro-4-methyl- (CA INDEX NAME)



RN 912939-56-1 CAPLUS

CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-57-2 CAPLUS


CN 1-Pyrrolidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-(ethylamino)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-58-3 CAPLUS

CN 1,4-Oxazepine-4(5H)-propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]tetrahydro- (CA INDEX NAME)




RN 912939-59-4 CAPLUS

CN [1,4'-Bipiperidine]-1'-propanamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 912939-60-7 CAPLUS

CN 1-Piperidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 912939-61-8 CAPLUS

CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(2-thiazolyl)- (CA INDEX NAME)




RN 912939-62-9 CAPLUS

CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-ethyl- (CA INDEX NAME)



RN 912939-63-0 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(diethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-64-1 CAPLUS


CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3,5-dimethyl-, (3R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 912939-65-2 CAPLUS

CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-66-3 CAPLUS

CN 4-Morpholinebutanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-67-4 CAPLUS


CN 1-Pyrrolidinebutanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-68-5 CAPLUS

CN 1-Pyrrolidinebutanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-69-6 CAPLUS


CN 1-Pyrrolidinebutanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-fluoro-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-70-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 912939-71-0 CAPLUS

CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-72-1 CAPLUS

CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)




RN 912939-73-2 CAPLUS

CN 4-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)- (CA INDEX NAME)




RN 912939-74-3 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 912939-75-4 CAPLUS


CN 1-Piperazineacetamide, 4-methyl-N-[2-(2-oxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912939-76-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-77-6 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912939-78-7 CAPLUS

CN 4-Morpholineacetamide, 2,6-dimethyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-79-8 CAPLUS

CN 1-Piperidineacetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 912939-80-1 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-81-2 CAPLUS

CN 1-Piperazineacetamide, 3,5-dimethyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-82-3 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-83-4 CAPLUS

CN 4-Morpholineacetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-84-5 CAPLUS

CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-85-6 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912939-86-7 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3,5-dimethyl- (CA INDEX NAME)



RN 912939-87-8 CAPLUS


CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 912939-88-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3-(ethylmethylamino)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-89-0 CAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-90-3 CAPLUS

CN 1-Pyrrolidineacetamide, 3-amino-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 912939-91-4 CAPLUS

CN 1-Thiopyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3-[(2,2,2-trifluoroacetyl)amino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-92-5 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyrazine-7(8H)-acetamide,
N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-5,6-
dihydro-3-(trifluoromethyl)- (CA INDEX NAME)

RN 912939-93-6 CAPLUS

CN 4-Morpholineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-
4-pyrimidinyl]- (CA INDEX NAME)


RN 912939-94-7 CAPLUS

CN 1,4-Oxazepine-4(5H)-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-
pyridinyl)-4-pyrimidinyl]tetrahydro- (CA INDEX NAME)




RN 912939-95-8 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 912939-96-9 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]hexahydro-4-methyl- (CA INDEX NAME)



RN 912939-97-0 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-98-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912939-99-2 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-00-2 CAPLUS


CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912940-01-3 CAPLUS


CN 1-Piperazineacetamide, N-(2,6-di-1H-pyrazol-1-yl)-4-methyl- (CA INDEX NAME)



RN 912940-02-4 CAPLUS


CN 1-Piperidineacetamide, N-(2,6-di-1H-pyrazol-1-yl)-4-(1-methylpiperidin-4-yl)- (CA INDEX NAME)

pyrrolidinyl)- (CA INDEX NAME)




RN 912940-03-5 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-(2,6-di-1H-pyrazol-1-yl-4-pyrimidinyl)- (CA INDEX NAME)




RN 912940-04-6 CAPLUS

CN 1-Piperazineacetamide, N-[2,6-bis(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-05-7 CAPLUS


CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-oxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-06-8 CAPLUS
 CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(5-oxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-07-9 CAPLUS
 CN 1-Piperazineacetamide, 4-methyl-N-[2-(4-methyl-5-oxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-08-0 CAPLUS
 CN 1-Piperazineacetamide, N-[2-(3-isoxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-09-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[2-(3-isoxazolyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-10-4 CAPLUS

CN 1-Piperazineacetamide, 4-methyl-N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-11-5 CAPLUS


CN 1-Piperidineacetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 912940-12-6 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-13-7 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(ethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-

thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-14-8 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(ethylamino)-N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-15-9 CAPLUS

CN 1-Piperazinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 912940-16-0 CAPLUS


CN 1-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 912940-17-1 CAPLUS

CN 1-Pyrrolidineacetamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-18-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-3-(ethylamino)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-19-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyrazine-7(8H)-acetamide,

N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-5,6-dihydro-3-(trifluoromethyl)- (CA INDEX NAME)




RN 912940-20-6 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-21-7 CAPLUS

CN 1-Piperazineacetamide, α ,4-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-22-8 CAPLUS
 CN 1-Piperazineacetamide, 4-methyl-N-[2-(5-methyl-2-furanyl)-6-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-23-9 CAPLUS
 CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912940-24-0 CAPLUS
 CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-25-1 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-26-2 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-27-3 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-28-4 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-29-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-30-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-31-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]carbonyl]-, phenylmethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-32-0 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-33-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-34-2 CAPLUS

CN 1-Piperazineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 912940-35-3 CAPLUS


CN 1-Piperidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 912940-36-4 CAPLUS

CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-37-5 CAPLUS


CN 1-Pyrrolidinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-3-(ethylamino)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-39-7 CAPLUS

CN 1,4-Oxazepine-4(5H)-propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]tetrahydro- (CA INDEX NAME)




RN 912940-41-1 CAPLUS

CN 2-Morpholinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-42-2 CAPLUS

CN 2-Morpholinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-43-3 CAPLUS

CN 2-Morpholinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 912940-44-4 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-45-5 CAPLUS

CN 4-Morpholinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-46-6 CAPLUS

CN 1-Piperazinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)




RN 912940-47-7 CAPLUS

CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-(2-(4-morpholinyl)ethyl)- (CA INDEX NAME)



RN 912940-48-8 CAPLUS


CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-(3-(1-piperidiny)propyl)- (CA INDEX NAME)



RN 912940-49-9 CAPLUS

CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-50-2 CAPLUS

CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-52-4 CAPLUS

CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-53-5 CAPLUS

CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-54-6 CAPLUS

CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912940-55-7 CAPLUS


CN 3-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912940-56-8 CAPLUS


CN 4-Piperidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-methyl- (CA INDEX NAME)



RN 912940-57-9 CAPLUS


CN 3-Piperidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-58-0 CAPLUS

CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-(3-(1-pyrrolidinyl)propyl)- (CA INDEX NAME)




RN 912940-59-1 CAPLUS

CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 912940-60-4 CAPLUS

CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 912940-61-5 CAPLUS


CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-[2-(1-methyl-2-piperidinyl)ethyl]- (CA INDEX NAME)



RN 912940-62-6 CAPLUS


CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-

pyrimidinyl]-N'-[2-(2-piperidiny1)ethyl]- (CA INDEX NAME)




RN 912940-63-7 CAPLUS

CN Urea, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-N'-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 912940-64-8 CAPLUS


CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(2-methoxyethyl)amino]- (CA INDEX NAME)



RN 912940-65-9 CAPLUS


CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-2-[(2-methoxyethyl)amino]-

pyrimidinyl]-, 2-(hexahydro-1H-azepin-1-yl)ethyl ester (9CI) (CA INDEX NAME)




RN 912940-66-0 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 912940-67-1 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 3-(2-oxo-1-pyrrolidinyl)propyl ester (9CI) (CA INDEX NAME)




RN 912940-68-2 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 912940-69-3 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-(1-piperidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 912940-70-6 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 912940-71-7 CAPLUS


CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 1026745-98-1 CAPLUS

CN 1-Pyrrolidineacetamide, 2-(methoxymethyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT	912940-90-0P	912940-91-1P	912940-92-2P
	912940-93-3P	912940-94-4P	912940-95-5P
	912940-96-6P	912940-97-7P	912940-98-8P
	912940-99-9P	912941-00-5P	912941-01-6P
	912941-02-7P	912941-03-8P	912941-07-2P
	912941-08-3P	912941-09-4P	912941-10-7P
	912941-11-8P	912941-12-9P	912941-13-0P
	912941-14-1P	912941-15-2P	912941-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminopyrimidines as adenosine receptor antagonists)


RN 912940-90-0 CAPLUS

CN 1-Pyrrolidineacetamide, 2,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-91-1 CAPLUS

CN 1-Piperazinepropanamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-92-2 CAPLUS


CN 4-Morpholinepropanamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-93-3 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-94-4 CAPLUS

CN 1H-1,4-Diazepine-1-propanamide, 4-acetylhexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-95-5 CAPLUS

CN 1,4-Oxazepine-4(5H)-propanamide, tetrahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-96-6 CAPLUS


CN 1H-1,4-Diazepine-1-propanamide, hexahydro-4-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-97-7 CAPLUS


CN 1-Pyrrolidinepropanamide, 3-(ethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912940-98-8 CAPLUS

CN 1-Piperazinepropanamide, 3,5-dimethyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-99-9 CAPLUS

CN 1H-1,4-Diazepine-1-propanamide, hexahydro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912941-00-5 CAPLUS

CN 4-Piperidineacetamide, 1-methyl-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912941-01-6 CAPLUS


CN 4-Piperidineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912941-02-7 CAPLUS


CN 1-Pyrrolidineacetamide, 3-(2,5-dihydro-1H-pyrrol-1-yl)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912941-03-8 CAPLUS


CN 1H-1,4-Diazepine-1-propanamide, 4-acetyl-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]hexahydro- (CA INDEX NAME)



RN 912941-07-2 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-[(2,4,6-trifluorophenyl)methyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912941-08-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-1-(2-methoxyethyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912941-09-4 CAPLUS

CN Carbamic acid, [6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, 2-(1-methyl-2-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 912941-10-7 CAPLUS


CN 1-Piperazineacetamide, 4-acetyl-N-[6-(2-thiazolyl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912941-11-8 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-3-[(2,2,2-trifluoroacetyl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 912941-12-9 CAPLUS


CN 4-Morpholineacetamide, 2-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912941-13-0 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912941-14-1 CAPLUS

CN 1-Piperidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 912941-15-2 CAPLUS


CN 1-Pyrrolidineacetamide, 3-[(dimethylamino)methyl]-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 912941-16-3 CAPLUS


CN 1-Pyrrolidineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-pyridinyl)-4-pyrimidinyl]-3-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)




IT 856173-06-3 912940-87-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of acylaminopyrimidines as adenosine receptor antagonists)
 RN 856173-06-3 CAPLUS
 CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)- (CA INDEX NAME)



RN 912940-87-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-pyridinyl)-6-(2-thiazolyl)- (CA INDEX NAME)




IT 856171-18-1P 856171-38-5P 856173-03-0P
 912940-72-8P 912940-73-9P 912940-79-5P
 912940-80-8P 912940-81-9P 912940-82-0P
 912940-83-1P 912940-84-2P 912940-85-3P
 912940-88-6P 912941-06-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of acylaminopyrimidines as adenosine receptor antagonists)
 RN 856171-18-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-38-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)- (CA INDEX NAME)




RN 856173-03-0 CAPLUS

CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 912940-72-8 CAPLUS

CN Acetamide, 2-chloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-73-9 CAPLUS

CN Acetamide, 2-chloro-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 912940-79-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-oxazolyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 912940-80-8 CAPLUS

CN 4-Pyrimidinamine, 2,6-di-1H-pyrazol-1-yl- (CA INDEX NAME)




RN 912940-81-9 CAPLUS

CN 4-Pyrimidinamine, 2,6-bis(2-thiazolyl)- (CA INDEX NAME)




RN 912940-82-0 CAPLUS

CN 4-Pyrimidinamine, 2-(5-oxazolyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 912940-83-1 CAPLUS

CN 4-Pyrimidinamine, 2-(4-methyl-5-oxazolyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 912940-84-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3-isoxazolyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 912940-85-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 912940-88-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-
(CA INDEX NAME)




RN 912941-06-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methyl-2-furanyl)-4-pyrimidinyl]amino]carbonyl]-, 1,1-dimethylethyl ester,
(3S)- (CA INDEX NAME)

Absolute stereochemistry.

L22 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1001140 CAPLUS
 DN 146:2893
 TI Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3
 AU Chen, Jack J.; Thakur, Kumar D.; Clark, Michael P.; Laughlin, Steven K.;
 George, Kelly M.; Bookland, Roger G.; Davis, Jan R.; Cabrera, Edward J.;
 Easwaran, Vijay; De, Biswanath; George Zhang, Y.
 CS Health Care Research Center, Procter and Gamble Pharmaceuticals, Mason,
 OH, 45040, USA
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5633-5638
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 146:2893
 AB A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors
 are described. Many of these inhibitors showed low nanomolar activity
 against JAK3.
 IT 915152-39-5 915152-43-1 915152-46-4
 915152-47-5 915152-48-6 915152-49-7
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation and structure activity relations of pyrimidine-based inhibitors
 of Janus tyrosine kinase 3)
 RN 915152-39-5 CAPLUS
 CN 4-Pyrimidinamine, 6-(3-furanyl)-2-(3H-imidazo[4,5-c]pyridin-3-yl)-N-[(1S)-
 1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 915152-43-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(3H-imidazo[4,5-c]pyridin-3-yl)-6-(1-methyl-1H-pyrazol-
 4-yl)-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.


RN 915152-48-6 CAPLUS
 CN 1H-Benzimidazole-6-carbonitrile, 1-[4-[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-(3-furanyl)-2-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 915152-49-7 CAPLUS
 CN 1H-Benzimidazole-6-carbonitrile, 1-[4-(3-furanyl)-6-[(1S)-2-methoxy-1-methylethyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:343626 CAPLUS
 DN 144:382034
 TI Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of a VRL antagonist
 IN Cai, Dongwei; Jones, A. Brian
 PA Merck Sharp & Dohme Limited, UK; Merck & Co., Inc.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006038041	A1	20060413	WO 2005-GB50172	20051004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TD, TM				

PRAI US 2004-617134P P 20041008

Claims entitled to the priority date of 10/5/04

OS MARPAT 144:382034

AB The invention provides compds. Y-J-NH-Z [Y = (un)substituted (iso)quinoline; J = is (un)substituted pyridine, (un)substituted pyridazine, (un)substituted pyrazine, etc.; J is substituted at positions meta to each other by NH and Y; Z = (un)substituted Ph, (un)substituted pyridyl] as the besylate salt; pharmaceutical compns. comprising these compds.; their use in methods of therapy; use for manufacturing medicaments;

and

methods of use to treat diseases requiring administration of a VRL antagonist, e.g. pain, cough, GERD and depression. Besylate salt preparation is described.

IT 882686-29-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VRL antagonist)


RN 882686-29-5 CAPLUS

CN 4-Pyrimidinamine, 6-(7-quinolinyl)-2-(2H-tetrazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-97-6

CME C21 H13 F3 N8



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:1154381 CAPLUS

DN 143:422362

TI Preparation of polycyclic pyrimidines as potassium ion channel modulators

IN Wang, Xiadong; Spear, Kerry Leigh; Fulp, Alan Bradley; Seconi, Darrick; Suzuki, Takeshi; Ishii, Takahiro; Moritomo, Ayako; Kubota, Hideki; Kazami, Jun-Ichi

PA Icaegen, Inc., USA; Astellas Pharma Inc.; et al.

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

102 (e)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005099711	A1	20051027	WO 2005-US12696	20050413
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, <u>US</u> , UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005232745	A1	20051027	AU 2005-232745	20050413
	CA 2561895	A1	20051027	CA 2005-2561895	20050413
	US 20050267089	A1	20051201	US 2005-105938	20050413
	US 7560464	B2	20090714		
	EP 1742634	A1	20070117	EP 2005-749983	20050413
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2007532669	T	20071115	JP 2007-508533	20050413
	JP 2008247916	A	<u>20081016</u>	JP 2008-113282	20080424
PRAI	US 2004-561990P	P	<u>20040413</u>		
	JP 2007-508533	A3	20050413		
	WO 2005-US12696	W	20050413		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:422362; MARPAT 143:422362

AB Title compds. I [A and B independently = (un)substituted 5 or 6-membered heterocycloalkyl or heteroaryl; W1 = unsatd. carbon or tertiary N; W2 and Z2 independently = -CH=, NH, -N=, S, O; Z1 = unsatd. C, tertiary or quaternary N; X = bond, CH2, or NR4; Y = bond, -CH=NNH, -NHCH2-, or NR5; m and p independently = 1-4; n = 1-2; R1, R2, and R3 independently = H, OH, NO2, halo, etc.; R4 and R5 independently = H, (un)substituted alkyl, heteroalkyl, etc.], are prepared and disclosed as modulators of potassium ion channels. Thus, e.g., II was prepared by nucleophilic substitution of the chloropyrimidine with the pyridinylamine derivative. In assays to determine potassium channel modulation, I possessed IC50 values ranging from 0.0 μ M to >30 μ M. The modulators of the invention are of use in both therapeutic and diagnostic methods. A pharmaceutical composition comprising a pharmaceutically acceptable carrier is claimed.

IT 868366-53-4P 868366-54-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of polycyclic pyrimidines as potassium ion channel modulators)


RN 868366-53-4 CAPLUS

CN 4-Pyrimidinamine, N,2,6-tri-2-pyridinyl- (CA INDEX NAME)



RN 868366-54-5 CAPLUS

CN 4-Pyrimidinamine, 2,6-di-2-pyridinyl-N-[5-(trifluoromethyl)-2-pyridinyl]-
(CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:570888 CAPLUS
 DN 143:97389
 TI Preparation of 2,6-bis(heteroaryl)-4-aminopyrimidines as adenosine
 receptor antagonists
 IN Crespo Crespo, Maria Isabel; Prat, Quinones Maria; Gual Roig, Silvia;
 Castro Palomino Laria, Julio Cesar; Slege, Deborah H.
 PA Almirall Prodesfarma S. A., Spain
 SO PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005058883	A1	20050630	WO 2004-US41970	20041214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2234433	A1	20050616	ES 2003-2951	20031215
ES 2234433	B1	20061101		
AU 2004299461	A1	20050630	AU 2004-299461	20041214
CA 2551944	A1	20050630	CA 2004-2551944	20041214
EP 1697351	A1	20060906	EP 2004-814183	20041214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1953975	A	20070425	CN 2004-80041454	20041214
BR 2004017478	A	20070508	BR 2004-17478	20041214
JP 2007514003	T	20070531	JP 2006-545817	20041214
ZA 2006004823	A	20071031	ZA 2006-4823	20041214
IN 2006DN03238	A	20070824	IN 2006-DN3238	20060606
NO 2006002713	A	20060801	NO 2006-2713	20060612
MX 2006006776	A	20070323	MX 2006-6776	20060614
KR 2007020397	A	20070221	KR 2006-714378	20060714
US 20080058356	A1	20080306	US 2007-582704	20070601
PRAI ES 2003-2951	A	20031215		
WO 2004-EP11086	A	20041005		
WO 2004-US41970	W	20041214		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:97389; MARPAT 143:97389


AB 4-Aminopyrimidine derivs. I [wherein R1, R2 = (un)substituted heteroaryl; R3 = H or carbonyl; with some exclusions, or pharmaceutically acceptable salts thereof] were prepared as antagonists of adenosine receptors, especially, adenosine A2A receptors. For example, II was synthesized from 2-furancarboxamide hydrochloride (preparation given) via (1) cyclization with di-Et malonate (78% yield), (2) chlorination of the resultant pyrimidine-4,6-diol with POC13 to 4,6-dichloride (87% yield), (3) substitution of one chloride with ammonium hydroxide (76% yield) and (4)

substitution of the remaining chloride with pyrazole (55% yield). I and their pharmaceutical compns. are useful for the treatment of disorders of the central nervous which are known to be improved by the use of antagonists of the A2A adenosine receptors, more specifically movement disorders such as Parkinson's disease.


IT 856171-18-1P, 2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
 856171-38-5P, 6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-amine 856171-54-5P,
 2-(2-Furyl)-6-(4-methyl-1H-pyrazol-1-yl)pyrimidin-4-amine
 856171-56-7P, 2-(2-Furyl)-6-(3-methyl-1H-pyrazol-1-yl)pyrimidin-4-amine 856171-58-9P,
 2-(2-Furyl)-6-[3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-4-amine
 856171-60-3P, 2-(2-Furyl)-6-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-4-amine 856171-62-5P,
 2-(2-Furyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-amine
 856171-66-9P, 2-(5-Bromo-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856171-68-1P, 2-(5-Chloro-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856171-70-5P,
 2-(5-Methyl-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
 856171-72-7P, N-[2-(2-Furyl)-6-(pyridin-3-yl)pyrimidin-4-yl]propanamide 856171-74-9P,
 6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine 856171-85-2P,
 6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine 856171-89-6P, 2-(2-Thienyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-amine 856171-94-3P, 6-(2-Furyl)-2-(1H-pyrazol-1-yl)pyrimidin-4-amine 856171-98-7P, 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(2-furyl)pyrimidin-4-amine 856172-00-4P,
 6-(2-Furyl)-2-(1H-1,2,4-triazol-1-yl)pyrimidin-4-amine
 856172-02-6P, 2-(1H-Pyrazol-1-yl)-6-(pyridin-2-yl)pyrimidin-4-amine 856172-04-8P, 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-2-yl)pyrimidin-4-amine 856172-07-1P,
 2-(1H-Pyrazol-1-yl)-6-(pyridin-3-yl)pyrimidin-4-amine
 856172-09-3P, 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-3-yl)pyrimidin-4-amine 856172-12-8P,
 2-(1H-Pyrazol-1-yl)-6-(pyridin-4-yl)pyrimidin-4-amine
 856172-14-0P, 6-(2-Furyl)-2-(pyridin-2-yl)pyrimidin-4-amine
 856172-16-2P, 2-(3-Methylpyridin-2-yl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856172-18-4P,
 6-(1H-Pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-amine
 856172-21-9P, 6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-amine 856172-25-3P,
 2-(Pyridin-3-yl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-amine
 856172-30-0P, [6-(2-Furyl)-2-(pyridin-4-yl)pyrimidin-4-yl]amine
 856172-32-2P, 6-(2-Furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-amine
 856172-92-4P, 2-(2-Furyl)-6-(2H-1,2,3-triazol-2-yl)pyrimidin-4-amine 856172-93-5P, 2-(2-Furyl)-6-(1H-1,2,3-triazol-1-yl)pyrimidin-4-amine 856172-97-9P,
 2-(2-Furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-00-7P,
 2,6-Di-2-furylpyrimidin-4-amine 856173-03-0P,
 2-(5-Methyl-2-furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of aminopyrimidines as adenosine receptor antagonists)
 RN 856171-18-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-38-5 CAPLUS
 CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)- (CA INDEX NAME)




RN 856171-54-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(4-methyl-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-56-7 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(3-methyl-1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-58-9 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-6-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-
(CA INDEX NAME)


RN 856171-60-3 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-6-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-
1-yl]- (CA INDEX NAME)


RN 856171-62-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-1,2,4-triazol-1-yl)- (CA INDEX
NAME)


RN 856171-66-9 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-bromo-2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-68-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-chloro-2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856171-70-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-72-7 CAPLUS
 CN Propanamide, N-[2-(2-furanyl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-74-9 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(2-thienyl)- (CA INDEX NAME)




RN 856171-85-2 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)- (CA INDEX NAME)




RN 856171-89-6 CAPLUS

CN 4-Pyrimidinamine, 2-(2-thienyl)-6-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 856171-94-3 CAPLUS


CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856171-98-7 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-furanyl)- (CA INDEX NAME)




RN 856172-00-4 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 856172-02-6 CAPLUS
 CN 4-Pyrimidinamine, 2-(1H-pyrazol-1-yl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 856172-04-8 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 856172-07-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(1H-pyrazol-1-yl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 856172-09-3 CAPLUS
 CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(3-pyridinyl)- (CA INDEX NAME)



RN 856172-12-8 CAPLUS
 CN 4-Pyrimidinamine, 2-(1H-pyrazol-1-yl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 856172-14-0 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(2-pyridinyl)- (CA INDEX NAME)




RN 856172-16-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3-methyl-2-pyridinyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856172-18-4 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 856172-21-9 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(3-pyridinyl)- (CA INDEX NAME)




RN 856172-25-3 CAPLUS


CN 4-Pyrimidinamine, 2-(3-pyridinyl)-6-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 856172-30-0 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 856172-32-2 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(2-thiazolyl)- (CA INDEX NAME)




RN 856172-92-4 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(2H-1,2,3-triazol-2-yl)- (CA INDEX NAME)




RN 856172-93-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-1,2,3-triazol-1-yl)- (CA INDEX NAME)




RN 856172-97-9 CAPLUS
CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)



RN 856173-00-7 CAPLUS
CN 4-Pyrimidinamine, 2,6-di-2-furanyl- (CA INDEX NAME)



RN 856173-03-0 CAPLUS
CN 4-Pyrimidinamine, 2-(5-methyl-2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)



IT 856171-19-2P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]acetamide 856171-20-5P,
N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide
856171-21-6P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-
methylpropanamide 856171-22-7P,
N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2,2-dimethylpropanamide

856171-23-8P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]cyclopropanecarboxamide 856171-24-9P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]cyclobutanecarboxamide
 856171-25-0P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]cyclohexanecarboxamide 856171-26-1P,
 3-Cyclopentyl-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide
 856171-27-2P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(4-methoxyphenyl)acetamide 856171-28-3P,
 2-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]acetamide 856171-29-4P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-3-phenylpropanamide
 856171-30-7P 856171-31-8P,
 3,3,3-Trifluoro-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-32-9P,
 3-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-33-0P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-methyl-3-phenylpropanamide 856171-34-1P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-3-phenoxypropanamide
 856171-35-2P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-3-(pyridin-3-yl)propanamide 856171-36-3P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(pyridin-3-yl)acetamide 856171-37-4P,
 (2E)-3-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-propenamide 856171-39-6P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]acetamide
 856171-40-9P, N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]propanamide 856171-41-0P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-2-methylpropanamide 856171-42-1P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-2,2-dimethylpropanamide 856171-43-2P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]cyclopropanecarboxamide 856171-44-3P,
 3-Cyclopentyl-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]propanamide 856171-45-4P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-2-(4-methoxyphenyl)acetamide 856171-46-5P,
 2-(3,4-Dimethoxyphenyl)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]acetamide 856171-47-6P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-3-phenylpropanamide 856171-48-7P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-3,3,3-trifluoropropanamide 856171-49-8P,
 3-(3,4-Dimethoxyphenyl)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]propanamide 856171-50-1P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-3-phenoxypropanamide 856171-52-3P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-2-(pyridin-3-yl)acetamide 856171-53-4P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-3-(pyridin-3-yl)propanamide 856171-55-6P,
 N-[2-(2-Furyl)-6-(4-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide
 856171-57-8P, N-[2-(2-Furyl)-6-(3-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-59-0P,
 N-[2-(2-Furyl)-6-[3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-4-yl]propanamide 856171-61-4P,

N-[2-(2-Furyl)-6-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-4-yl]propanamide 856171-63-6P,
 N-[2-(2-Furyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]acetamide 856171-64-7P, N-[2-(2-Furyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856171-65-8P,
 3,3,3-Trifluoro-N-[2-(2-furyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856171-67-0P,
 N-[2-(5-Bromo-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-69-2P, N-[2-(5-Chloro-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-71-6P,
 N-[2-(5-Methyl-2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-73-8P 856171-75-0P,
 N-[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]acetamide 856171-76-1P, N-[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-77-2P,
 3-Cyclopentyl-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-78-3P,
 3-Phenyl-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-79-4P, 3,3,3-Trifluoro-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-80-7P,
 3-(3,4-Dimethoxyphenyl)-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-81-8P,
 3-Phenoxy-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-82-9P, N-[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]-2-(pyridin-3-yl)acetamide 856171-83-0P,
 N-[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]-3-(pyridin-3-yl)propanamide 856171-84-1P,
 (2E)-3-(3,4-Dimethoxyphenyl)-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]-2-propenamide 856171-86-3P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]acetamide 856171-87-4P, N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]propanamide 856171-88-5P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]-3,3,3-trifluoropropanamide 856171-90-9P,
 N-[2-(2-Thienyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]acetamide 856171-91-0P, N-[2-(2-Thienyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856171-92-1P,
 3,3,3-Trifluoro-N-[2-(2-thienyl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856171-93-2P,
 N-[2-(3-Methyl-2-thienyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-95-4P, N-[6-(2-Furyl)-2-(1H-pyrazol-1-yl)pyrimidin-4-yl]acetamide 856171-96-5P,
 N-[6-(2-Furyl)-2-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-97-6P, 3,3,3-Trifluoro-N-[6-(2-furyl)-2-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide 856171-99-8P,
 N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(2-furyl)pyrimidin-4-yl]-2-(4-methoxyphenyl)acetamide 856172-01-5P,
 N-[6-(2-Furyl)-2-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856172-03-7P, N-[2-(1H-Pyrazol-1-yl)-6-(pyridin-2-yl)pyrimidin-4-yl]propanamide 856172-05-9P,
 N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-2-yl)pyrimidin-4-yl]propanamide 856172-06-0P,
 N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-2-yl)pyrimidin-4-yl]-2-(4-methoxyphenyl)acetamide 856172-08-2P,
 N-[2-(1H-Pyrazol-1-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]propanamide 856172-10-6P, N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]propanamide 856172-11-7P,

N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(pyridin-3-yl)pyrimidin-4-yl]-2-(4-methoxyphenyl)acetamide 856172-13-9P,
 N-[2-(1H-Pyrazol-1-yl)-6-(pyridin-4-yl)pyrimidin-4-yl]acetamide
 856172-15-1P, N-[6-(2-Furyl)-2-(pyridin-2-yl)pyrimidin-4-yl]propanamide 856172-17-3P,
 N-[2-(3-Methylpyridin-2-yl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]propanamide
 856172-19-5P, N-[6-(1H-Pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl]acetamide 856172-20-8P,
 N-[6-(1H-Pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl]propanamide
 856172-22-0P, N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl]acetamide 856172-23-1P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl]propanamide 856172-24-2P,
 N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-3-yl)pyrimidin-4-yl]-3,3,3-trifluoropropanamide 856172-26-4P,
 3,3,3-Trifluoro-N-[2-(pyridin-3-yl)-6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl]propanamide 856172-27-5P,
 N-[6-(2-Furyl)-2-(pyridin-3-yl)pyrimidin-4-yl]propanamide
 856172-28-6P, N-[6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-4-yl)pyrimidin-4-yl]propanamide 856172-29-7P,
 6-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-(pyridin-4-yl)pyrimidin-4-amine
 856172-31-1P, N-[6-(2-Furyl)-2-(pyridin-4-yl)pyrimidin-4-yl]propanamide 856172-33-3P,
 N-[6-(2-Furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-yl]propanamide
 856172-34-4P, 2-(4-Fluorophenyl)-N-[6-(2-Furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-yl]acetamide 856172-35-5P,
 N-(Cyclopropylmethyl)-2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
 856172-36-6P, (2R)-2-[[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]amino]propan-1-ol 856172-37-7P,
 3-[[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]amino]propan-1-ol
 856172-38-8P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]ethane-1,2-diamine 856172-39-9P,
 2-(2-Furyl)-N-[2-(4-methoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856172-40-2P, N-[2-(3,4-Dimethoxyphenyl)ethyl]-2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856172-41-3P,
 2-(2-Furyl)-6-(1H-pyrazol-1-yl)-N-[2-(pyridin-2-yl)ethyl]pyrimidin-4-amine
 856172-42-4P, 2-(2-Furyl)-6-(1H-pyrazol-1-yl)-N-[2-(pyridin-3-yl)ethyl]pyrimidin-4-amine 856172-43-5P,
 2-(2-Furyl)-N-(3-phenylpropyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
 856172-44-6P, 2-(2-Furyl)-N-[3-(1H-imidazol-1-yl)propyl]-6-(1H-pyrazol-1-yl)pyrimidin-4-amine 856172-45-7P,
 N-(Cyclopropylmethyl)-6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine
 856172-46-8P, (2R)-2-[[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]amino]propan-1-ol 856172-47-9P,
 3-[[6-(1H-Pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]amino]propan-1-ol
 856172-48-0P, N-(2-Aminoethyl)-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]amine 856172-49-1P,
 N-[2-(4-Methoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine 856172-50-4P, N-[2-(3,4-Dimethoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine 856172-51-5P,
 6-(1H-Pyrazol-1-yl)-N-[2-(pyridin-3-yl)ethyl]-2-(2-thienyl)pyrimidin-4-amine 856172-52-6P, 6-(1H-Pyrazol-1-yl)-N-[2-(pyridin-2-yl)ethyl]-2-(2-thienyl)pyrimidin-4-amine 856172-53-7P,
 N-(3-Phenylpropyl)-6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine
 856172-54-8P, N-[3-(1H-Imidazol-1-yl)propyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-amine 856172-55-9P, Ethyl
 [6-(1H-pyrazol-1-yl)-2-(2-thienyl)pyrimidin-4-yl]carbamate

856172-56-0P 856172-57-1P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-N'-propylurea
 856172-58-2P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-N'-
 isopropylurea 856172-59-3P,
 N-Cyclopentyl-N'-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]urea
 856172-60-6P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-N'-
 (4-methoxyphenyl)urea 856172-61-7P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-N'-(2-phenylethyl)urea
 856172-62-8P, N-Benzyl-N'-[2-(2-furyl)-6-(1H-pyrazol-1-
 yl)pyrimidin-4-yl]urea 856172-63-9P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-3-methylbutanamide
 856172-64-0P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-
 3,3-dimethylbutanamide 856172-65-1P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]cyclopentanecarboxamide
 856172-66-2P 856172-67-3P,
 2-Phenyl-N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]acetamide
 856172-68-4P, 2-(4-Fluorophenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-
 yl)pyrimidin-4-yl]acetamide 856172-69-5P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(3-
 methoxyphenyl)acetamide 856172-70-8P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(2-
 methoxyphenyl)acetamide 856172-71-9P,
 2-(3,4-Dichlorophenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]acetamide 856172-72-0P 856172-73-1P,
 2-(3,4-Dihydroxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]acetamide 856172-74-2P,
 2-(2,5-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]acetamide 856172-75-3P,
 2-(4-Chloro-3-methylphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]acetamide 856172-76-4P,
 2-(3,5-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]acetamide 856172-77-5P,
 2-[3-(Benzyloxy)-4-methoxyphenyl]-N-[2-(2-furyl)-6-(1H-pyrazol-1-
 yl)pyrimidin-4-yl]acetamide 856172-78-6P,
 2-[4-(Cyclobutylloxy)-3-methoxyphenyl]-N-[2-(2-furyl)-6-(1H-pyrazol-1-
 yl)pyrimidin-4-yl]acetamide 856172-79-7P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(4-difluoromethoxy-3-
 methoxyphenyl)acetamide 856172-80-0P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-(3,4,5-
 trimethoxyphenyl)acetamide 856172-81-1P,
 2-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]propanamide 856172-82-2P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzamide
 856172-83-3P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-
 3,4-dimethoxybenzamide 856172-84-4P,
 2,6-Difluoro-N-[2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]benzamide
 856172-85-5P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-2-
 furancarboxamide 856172-86-6P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]thiophene-2-carboxamide
 856172-87-7P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-
 yl]nicotinamide 856172-88-8P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]isonicotinamide
 856172-89-9P, N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]-1-
 naphthalenecarboxamide 856172-90-2P,
 N-[2-(2-Furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]quinoline-2-carboxamide
 856172-91-3P, (2E)-3-(3,4-Dimethoxyphenyl)-N-[6-(3,5-dimethyl-1H-
 pyrazol-1-yl)-2-(2-furyl)pyrimidin-4-yl]-2-propenamide


856172-94-6P, N-[2-(2-Furyl)-6-(2H-1,2,3-triazol-2-yl)pyrimidin-4-yl]propanamide 856172-95-7P,
 2-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(2H-1,2,3-triazol-2-yl)pyrimidin-4-yl]acetamide 856172-96-8P,
 N-[2-(2-Furyl)-6-(1H-1,2,3-triazol-1-yl)pyrimidin-4-yl]propanamide 856172-98-0P, N-[2-(2-Furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-yl]propanamide 856172-99-1P,
 3-(3,4-Dimethoxyphenyl)-N-[2-(2-furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-yl]propanamide 856173-01-8P,
 N-(2,6-Di-2-furylpyrimidin-4-yl)-2-(3,4-dimethoxyphenyl)acetamide 856173-02-9P, 6-(1,3-Benzothiazol-2-yl)-2-(2-furyl)pyrimidin-4-amine 856173-04-1P, 6-(1,3-Thiazol-2-yl)-2-(2-thienyl)pyrimidin-4-amine 856173-05-2P,
 2-(3,4-Dimethoxyphenyl)-N-[6-(2-furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-yl]acetamide 856173-06-3P,
 6-(1H-Pyrazol-1-yl)-2-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-07-4P, 2-(3,4-Dimethoxyphenyl)-N-[6-(1H-pyrazol-1-yl)-2-(1,3-thiazol-2-yl)pyrimidin-4-yl]acetamide 856173-08-5P,
 2-(2-Furyl)-N-methyl-6-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-09-6P, N-(Cyclopropylmethyl)-2-(2-furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-10-9P,
 N-[2-(3,4-Dimethoxyphenyl)ethyl]-2-(2-furyl)-6-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-11-0P, N-(Cyclopropylmethyl)-6-(2-furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-12-1P,
 N-[2-(3,4-Dimethoxyphenyl)ethyl]-6-(2-furyl)-2-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-13-2P, 6-(2-Furyl)-N-[2-(pyridin-3-yl)ethyl]-2-(1,3-thiazol-2-yl)pyrimidin-4-amine 856173-14-3P
 856173-15-4P, Ethyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-16-5P, Cyclopentylmethyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-17-6P, Benzyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-18-7P, 3,4-Dimethoxybenzyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-19-8P, Pyridin-3-ylmethyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-20-1P, 4-Methoxyphenyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-21-2P, 3,4-Dimethoxyphenyl [2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl]carbamate 856173-74-5P, N-[2-(Furan-2-yl)-6-(pyrazol-1-yl)pyrimidin-4-yl]-2-methylaminoacetamide 856173-75-6P,
 2-Dimethylamino-N-[2-(furan-2-yl)-6-(pyrazol-1-yl)pyrimidin-4-yl]acetamide 856173-76-7P, 2-Methylamino-N-[2-(5-methylfuran-2-yl)-6-(thiazol-2-yl)pyrimidin-4-yl]acetamide 856173-77-8P
 856173-79-0P 856173-80-3P 856173-81-4P,
 N-[2-(5-Methylfuran-2-yl)-6-(thiazol-2-yl)pyrimidin-4-yl]-3-(pyridin-3-yl)propionamide 856173-82-5P,
 N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(2-furyl)pyrimidin-4-yl]propanamide 856173-83-6P, 2-Diethylamino-N-[2-(5-methylfuran-2-yl)-6-(thiazol-2-yl)pyrimidin-4-yl]acetamide 1000004-63-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as adenosine receptor antagonists)

RN 856171-19-2 CAPLUS


CN Acetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX

NAME)




RN 856171-20-5 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-21-6 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 856171-22-7 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2,2-dimethyl- (CA INDEX NAME)




RN 856171-26-1 CAPLUS

CN Cyclopentanepropanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856171-27-2 CAPLUS


CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 856171-28-3 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-

dimethoxy- (CA INDEX NAME)




RN 856171-29-4 CAPLUS

CN Benzenepropanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 856171-30-7 CAPLUS


CN Cyclopropanecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2-phenyl-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 856171-31-8 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-32-9 CAPLUS


CN Benzenepropanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)



RN 856171-33-0 CAPLUS


CN Benzenepropanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
α-methyl- (CA INDEX NAME)

RN 856171-34-1 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-phenoxy-
(CA INDEX NAME)


RN 856171-35-2 CAPLUS

CN 3-Pyridinepropanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 856171-36-3 CAPLUS


CN 3-Pyridineacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-37-4 CAPLUS

CN 2-Propenamide, 3-(3,4-dimethoxyphenyl)-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.




RN 856171-39-6 CAPLUS
 CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856171-40-9 CAPLUS
 CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-41-0 CAPLUS
 CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 856171-42-1 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-2,2-dimethyl- (CA INDEX NAME)




RN 856171-43-2 CAPLUS

CN Cyclopropanecarboxamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-44-3 CAPLUS

CN Cyclopentanepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-45-4 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 856171-46-5 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 856171-47-6 CAPLUS

CN Benzeneacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-48-7 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-3,3,3-trifluoro- (CA INDEX NAME)




RN 856171-49-8 CAPLUS

CN Benzenepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 856171-50-1 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-3-phenoxy- (CA INDEX NAME)




RN 856171-52-3 CAPLUS

CN 3-Pyridineacetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-53-4 CAPLUS

CN 3-Pyridinepropanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-55-6 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(4-methyl-1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-57-8 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(3-methyl-1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-59-0 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-[3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-61-4 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-63-6 CAPLUS

CN Acetamide, N-[2-(2-furanyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-64-7 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-65-8 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[2-(2-furanyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-67-0 CAPLUS

CN Propanamide, N-[2-(5-bromo-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-69-2 CAPLUS

CN Propanamide, N-[2-(5-chloro-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-71-6 CAPLUS


CN Propanamide, N-[2-(5-methyl-2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-73-8 CAPLUS
 CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 856171-75-0 CAPLUS
 CN Acetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-76-1 CAPLUS
 CN Propanamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856171-77-2 CAPLUS
 CN Cyclopentanepropanamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-78-3 CAPLUS

CN Benzenepropanamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 856171-79-4 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-80-7 CAPLUS

CN Benzenepropanamide, 3,4-dimethoxy-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-81-8 CAPLUS

CN Propanamide, 3-phenoxy-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 856171-82-9 CAPLUS

CN 3-Pyridineacetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 856171-83-0 CAPLUS


CN 3-Pyridinepropanamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-
(CA INDEX NAME)



RN 856171-84-1 CAPLUS


CN 2-Propenamide, 3-(3,4-dimethoxyphenyl)-N-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 856171-86-3 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-87-4 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-88-5 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-3,3,3-trifluoro- (CA INDEX NAME)




RN 856171-90-9 CAPLUS

CN Acetamide, N-[2-(2-thienyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-91-0 CAPLUS

CN Propanamide, N-[2-(2-thienyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-92-1 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[2-(2-thienyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-93-2 CAPLUS

CN Propanamide, N-[2-(3-methyl-2-thienyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856171-95-4 CAPLUS

CN Acetamide, N-[6-(2-furanyl)-2-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-96-5 CAPLUS

CN Propanamide, N-[6-(2-furanyl)-2-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-97-6 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[6-(2-furanyl)-2-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856171-99-8 CAPLUS

CN Benzeneacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-furanyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 856172-01-5 CAPLUS


CN Propanamide, N-[6-(2-furanyl)-2-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-03-7 CAPLUS
 CN Propanamide, N-[2-(1H-pyrazol-1-yl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-05-9 CAPLUS
 CN Propanamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-06-0 CAPLUS
 CN Benzeneacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-pyridinyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 856172-08-2 CAPLUS
 CN Propanamide, N-[2-(1H-pyrazol-1-yl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-10-6 CAPLUS
 CN Propanamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-11-7 CAPLUS
 CN Benzeneacetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(3-pyridinyl)-4-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 856172-13-9 CAPLUS
 CN Acetamide, N-[2-(1H-pyrazol-1-yl)-6-(4-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-15-1 CAPLUS

CN Propanamide, N-[6-(2-furanyl)-2-(2-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-17-3 CAPLUS

CN Propanamide, N-[2-(3-methyl-2-pyridinyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-19-5 CAPLUS


CN Acetamide, N-[6-(1H-pyrazol-1-yl)-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-20-8 CAPLUS


CN Propanamide, N-[6-(1H-pyrazol-1-yl)-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)

INDEX NAME)




RN 856172-22-0 CAPLUS

CN Acetamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-23-1 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-24-2 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(3-pyridinyl)-4-pyrimidinyl]-3,3,3-trifluoro- (CA INDEX NAME)




RN 856172-26-4 CAPLUS

CN Propanamide, 3,3,3-trifluoro-N-[2-(3-pyridinyl)-6-(1H-1,2,4-triazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-27-5 CAPLUS

CN Propanamide, N-[6-(2-furanyl)-2-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-28-6 CAPLUS

CN Propanamide, N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(4-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-29-7 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 856172-31-1 CAPLUS

CN Propanamide, N-[6-(2-furanyl)-2-(4-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-33-3 CAPLUS


CN Propanamide, N-[6-(2-furanyl)-2-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-34-4 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[6-(2-furanyl)-2-(2-thiazolyl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 856172-35-5 CAPLUS

CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-2-(2-furanyl)-6-(1H-pyrazol-1-yl)-
(CA INDEX NAME)


RN 856172-36-6 CAPLUS

CN 1-Propanol, 2-[[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]amino]-,
(2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 856172-37-7 CAPLUS


CN 1-Propanol, 3-[[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]amino]-
(CA INDEX NAME)

RN 856172-38-8 CAPLUS

CN 1,2-Ethanediamine, N1-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 856172-39-9 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-N-[2-(4-methoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)-
(CA INDEX NAME)




RN 856172-40-2 CAPLUS

CN 4-Pyrimidinamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(2-furanyl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856172-41-3 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-6-(1H-pyrazol-1-yl)-N-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856172-42-4 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-6-((1H-pyrazol-1-yl)-N-[2-(3-pyridinyl)ethyl])- (CA INDEX NAME)




RN 856172-43-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-N-(3-phenylpropyl)-6-((1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856172-44-6 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-N-[3-((1H-imidazol-1-yl)propyl)]-6-((1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 856172-45-7 CAPLUS

CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-6-(1H-pyrazol-1-yl)-2-(2-thienyl)-
(CA INDEX NAME)

RN 856172-46-8 CAPLUS


CN 1-Propanol, 2-[[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]amino]-,
(2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856172-47-9 CAPLUS

CN 1-Propanol, 3-[[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]amino]-
(CA INDEX NAME)




RN 856172-48-0 CAPLUS

CN 1,2-Ethanediamine, N1-[6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-
(CA INDEX NAME)




RN 856172-49-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-(4-methoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)- (CA INDEX NAME)




RN 856172-50-4 CAPLUS


CN 4-Pyrimidinamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)- (CA INDEX NAME)




RN 856172-51-5 CAPLUS
 CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-N-[2-(3-pyridinyl)ethyl]-2-(2-thienyl)- (CA INDEX NAME)



RN 856172-52-6 CAPLUS
 CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-N-[2-(2-pyridinyl)ethyl]-2-(2-thienyl)- (CA INDEX NAME)




RN 856172-53-7 CAPLUS

CN 4-Pyrimidinamine, N-(3-phenylpropyl)-6-(1H-pyrazol-1-yl)-2-(2-thienyl)-
(CA INDEX NAME)Ph-(CH₂)₃-NH


RN 856172-54-8 CAPLUS

CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-(1H-pyrazol-1-yl)-2-(2-thienyl)- (CA INDEX NAME)



RN 856172-55-9 CAPLUS


CN Carbamic acid, [6-(1H-pyrazol-1-yl)-2-(2-thienyl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 856172-56-0 CAPLUS


CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-[(1R,2S)-2-phenylcyclopropyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 856172-57-1 CAPLUS

CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-propyl- (CA INDEX NAME)




RN 856172-58-2 CAPLUS


CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 856172-59-3 CAPLUS


CN Urea, N-cyclopentyl-N'-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 856172-60-6 CAPLUS

CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-(4-methoxyphenyl)-
(CA INDEX NAME)


RN 856172-61-7 CAPLUS

CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-(2-phenylethyl)-
(CA INDEX NAME)




RN 856172-62-8 CAPLUS

CN Urea, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 856172-63-9 CAPLUS

CN Butanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methyl- (CA INDEX NAME)




RN 856172-64-0 CAPLUS

CN Butanamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,3-dimethyl- (CA INDEX NAME)




RN 856172-65-1 CAPLUS

CN Cyclopentanecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-66-2 CAPLUS

CN Benzeneacetamide, α -chloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)


RN 856172-67-3 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-68-4 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-69-5 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methoxy- (CA INDEX NAME)




RN 856172-70-8 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2-methoxy- (CA INDEX NAME)




RN 856172-71-9 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-72-0 CAPLUS

CN 1,3-Benzodioxole-5-acetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-73-1 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-dihydroxy- (CA INDEX NAME)




RN 856172-74-2 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2,5-dimethoxy- (CA INDEX NAME)




RN 856172-75-3 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methyl- (CA INDEX NAME)




RN 856172-76-4 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,5-dimethoxy- (CA INDEX NAME)




RN 856172-77-5 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-4-methoxy-3-(phenylmethoxy)- (CA INDEX NAME)




RN 856172-78-6 CAPLUS

CN Benzeneacetamide, 4-(cyclobutyloxy)-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methoxy- (CA INDEX NAME)




RN 856172-79-7 CAPLUS

CN Benzeneacetamide, 4-(difluoromethoxy)-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3-methoxy- (CA INDEX NAME)




RN 856172-80-0 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4,5-trimethoxy- (CA INDEX NAME)




RN 856172-81-1 CAPLUS

CN Benzeneacetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-dimethoxy-α-methyl- (CA INDEX NAME)




RN 856172-82-2 CAPLUS

CN Benzamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-83-3 CAPLUS


CN Benzamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 856172-84-4 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-85-5 CAPLUS
 CN 2-Furancarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-86-6 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-87-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-88-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)


RN 856172-89-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-90-2 CAPLUS


CN 2-Quinolinecarboxamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 856172-91-3 CAPLUS


CN 2-Propenamide, 3-(3,4-dimethoxyphenyl)-N-[6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(2-furanyl)-4-pyrimidinyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 856172-94-6 CAPLUS

CN Propanamide, N-[2-(2-furanyl)-6-(2H-1,2,3-triazol-2-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856172-95-7 CAPLUS


CN Benzeneacetamide, N-[2-(2-furanyl)-6-(2H-1,2,3-triazol-2-yl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)



RN 856172-96-8 CAPLUS


CN Propanamide, N-[2-(2-furanyl)-6-(1H-1,2,3-triazol-1-yl)-4-pyrimidinyl]-
(CA INDEX NAME)

RN 856172-98-0 CAPLUS


CN Propanamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX
NAME)

RN 856172-99-1 CAPLUS


CN Benzenepropanamide, N-[2-(2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-3,4-
dimethoxy- (CA INDEX NAME)




RN 856173-01-8 CAPLUS
 CN Benzeneacetamide, N-(2,6-di-2-furanyl-4-pyrimidinyl)-3,4-dimethoxy- (CA INDEX NAME)



RN 856173-02-9 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-benzothiazolyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 856173-04-1 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-thiazolyl)-2-(2-thienyl)- (CA INDEX NAME)




RN 856173-05-2 CAPLUS

CN Benzeneacetamide, N-[6-(2-furanyl)-2-(2-thiazolyl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 856173-06-3 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)- (CA INDEX NAME)




RN 856173-07-4 CAPLUS

CN Benzeneacetamide, N-[6-(1H-pyrazol-1-yl)-2-(2-thiazolyl)-4-pyrimidinyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 856173-08-5 CAPLUS

CN 4-Pyrimidinamine, 2-(2-furanyl)-N-methyl-6-(2-thiazolyl)- (CA INDEX NAME)




RN 856173-09-6 CAPLUS


CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-2-(2-furanyl)-6-(2-thiazolyl)-
(CA INDEX NAME)

RN 856173-10-9 CAPLUS


CN 4-Pyrimidinamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(2-furanyl)-6-(2-thiazolyl)- (CA INDEX NAME)




RN 856173-11-0 CAPLUS

CN 4-Pyrimidinamine, N-(cyclopropylmethyl)-6-(2-furanyl)-2-(2-thiazolyl)-
(CA INDEX NAME)

RN 856173-12-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-6-(2-furanyl)-2-(2-thiazolyl)-
(CA INDEX NAME)


RN 856173-13-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-furanyl)-N-[2-(3-pyridinyl)ethyl]-2-(2-thiazolyl)-
(CA INDEX NAME)

RN 856173-14-3 CAPLUS


CN 4-Pyrimidinamine, 6-(2-furanyl)-N-[(1R,2S)-2-phenylcyclopropyl]-2-(2-thiazolyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 856173-15-4 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 856173-16-5 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, cyclopentylmethyl ester (9CI) (CA INDEX NAME)




RN 856173-17-6 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 856173-18-7 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, (3,4-dimethoxyphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 856173-19-8 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, 3-pyridinylmethyl ester (9CI) (CA INDEX NAME)




RN 856173-20-1 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 856173-21-2 CAPLUS

CN Carbamic acid, [2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-, 3,4-dimethoxyphenyl ester (9CI) (CA INDEX NAME)




RN 856173-74-5 CAPLUS

CN Acetamide, N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]-2-(methoxycarbonyl)- (CA INDEX NAME)




RN 856173-75-6 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-76-7 CAPLUS

CN Acetamide, 2-(methoxycarbonyl)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-77-8 CAPLUS
 CN Acetamide, 2-(methylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 856173-76-7
 CME C15 H15 N5 O2 S



CM 2
 CRN 76-05-1
 CME C2 H F3 O2



RN 856173-79-0 CAPLUS
 CN Acetamide, 2-(dimethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 856173-78-9
 CME C16 H17 N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 856173-80-3 CAPLUS

CN 3-Pyridineacetamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-81-4 CAPLUS

CN 3-Pyridinepropanamide, N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-82-5 CAPLUS

CN Propanamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 856173-83-6 CAPLUS

CN Acetamide, 2-(diethylamino)-N-[2-(5-methyl-2-furanyl)-6-(2-thiazolyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 1000004-63-6 CAPLUS


CN 4-Pyrimidinamine, 6-(2-furanyl)-2-(3-pyridinyl)- (CA INDEX NAME)




IT 856173-66-5P, N-[6-(1,3-Benzothiazol-2-yl)-2-(2-furyl)pyrimidin-4-yl]acetamide 912940-72-8P 959628-36-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminopyrimidines as adenosine receptor antagonists)
 RN 856173-66-5 CAPLUS
 CN Acetamide, N-[6-(2-benzothiazolyl)-2-(2-furanyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 912940-72-8 CAPLUS
 CN Acetamide, 2-chloro-N-[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 959628-36-5 CAPLUS
 CN Carbamic acid, N-[2-[[2-(2-furanyl)-6-(1H-pyrazol-1-yl)-4-pyrimidinyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:451376 CAPLUS

DN 142:482069

TI Preparation of quinoxazolines and related derivatives vanilloid-1 receptor antagonists for treating pain

IN Hollingworth, Gregory John; Jones, Brian A.; McIver, Edward Giles; Moyes, Christopher Richard; Rogers, Lauren

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

not available under 102(e)


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005047279	A1	20050526	WO 2004-GB4719	20041109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289518	A1	20050526	AU 2004-289518	20041109
CA 2545384	A1	20050526	CA 2004-2545384	20041109
US 20050197342	A1	20050908	US 2004-984336	20041109
EP 1685124	A1	20060802	EP 2004-798442	20041109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007510706	T	20070426	JP 2006-538935	20041109
CN 101035780	A	20070912	CN 2004-80039870	20041109
IN 2006DN02615	A	20070824	IN 2006-DN2615	20060510
FRAI GB 2003-26217	A	20031110		
GB 2004-7748	A	20040405		
US 2004-617134P	P	20041008		
WO 2004-GB4719	W	20041109		
OS CASREACT 142:482069; MARPAT 142:482069				
AB Title compds. Y-J-L-Z [L = amino, O, S, CH ₂ ; J = 6-membered heterocycle, etc.; Y = naphthalene, etc.; Z = Ph, naphthyl, etc.; I] are prepared For instance, 4-(Quinolin-8-yl)-N-(4-trifluoromethylphenyl)pyrimidin-2-amine is prepared from 2-Chloro-4-(quinolin-8-yl)pyrimidine (preparation given) and 4-trifluoromethylaniline. I are vanilloid-1 receptor antagonists [no data] useful for the treatment of pain, cough, GERD and depression.				
IT 852062-98-7P, 6-(Quinolin-7-yl)-2-(1H-tetrazol-5-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine trifluoroacetate				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)				
RN 852062-98-7 CAPLUS				
CN 4-Pyrimidinamine, 6-(7-quinolinyl)-2-(2H-tetrazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)				

claims entitled to the priority date of 10/5/04

CM 1

CRN 852062-97-6

CMF C21 H13 F3 N8



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OSC.G 1

RE.CNT 2

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:465821 CAPLUS

DN 137:47211

TI Substituted 2-aryl-4-arylamino-pyrimidines and analogs as activators of caspases and inducers of apoptosis, their preparation, and the use thereof as, e.g., anticancer agents

IN Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin, Azra

PA Cytovia, Inc., USA

SO PCT Int. Appl., 210 pp.

CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 1

all disclosed compounds
excluded by proviso

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047690	A1	20020620	WO 2001-US47498	20011212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002028922	A	20020624	AU 2002-28922	20011212
	US 20030069239	A1	20030410	US 2001-12444	20011212
	US 6716851	B2	20040406		
	EP 1351691	A1	20031015	EP 2001-990048	20011212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 20040097503	A1	20040520	US 2003-704448	20031110
	US 7226927	B2	20070605		
PRAI	US 2000-254581P	P	20001212		
	US 2001-12444	A3	20011212		
	WO 2001-US47498	W	20011212		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:47211

AB The invention is directed to substituted 2-aryl-4-(arylamino)pyrimidines I and analogs thereof [Ar1, Ar2 = (independently) optionally substituted aryl or heteroaryl; A = N or C-R2; R1, R2 = (independently) H, halo, haloalkyl, aryl, fused aryl, carbocyclic, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, OH, SH, acyloxy, N3, alkoxy, aryloxy, arylalkoxy, haloalkoxy, CO2H, carbonylamido, or alkylthio; and R3 = H, optionally substituted alkyl or cycloalkyl]. The invention also relates to the discovery that compds. I are activators of caspases and inducers of apoptosis. I may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. In particular, a method of treating disorders responsive to the induction of apoptosis, comprising administration of I, or a pharmaceutically acceptable salt or prodrug thereof, is claimed. Over 200 specific examples of I are described. For instance, condensation of 4-chloro-6-methyl-2-(2-pyridinyl)pyrimidine with 2-chloro-5-methoxyaniline gave title compound II in 44% yield. This compound induced apoptosis and

activated caspase cascade in human breast cancer cell lines T-47D and ZR-75-1. Another compound I also showed marked selectivity for human breast cancer cells over other, non-breast cancer cell lines.


IT 438248-44-3P, 4-(3-Methoxyanilino)-2,6-di(2-pyridinyl)pyrimidine
 438248-45-4P, 4-(2,5-Dimethoxyanilino)-2,6-di(2-pyridinyl)pyrimidine 438248-46-5P,
 4-(5-Methoxy-2-methylanilino)-2,6-di(2-pyridinyl)pyrimidine
 438248-47-6P, 4-(2-Methoxy-5-methylanilino)-2,6-di(2-pyridinyl)pyrimidine 438248-48-7P,
 4-(2-Chloro-5-methoxyanilino)-2,6-di(2-pyridinyl)pyrimidine
 438248-49-8P, 4-(2,5-Dimethylanilino)-2,6-di(2-pyridinyl)pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)

RN 438248-44-3 CAPLUS


CN 4-Pyrimidinamine, N-(3-methoxyphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)



proviso

RN 438248-45-4 CAPLUS


CN 4-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)




proviso

RN 438248-46-5 CAPLUS


CN 4-Pyrimidinamine, N-(5-methoxy-2-methylphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)




RN 438248-47-6 CAPLUS
 CN 4-Pyrimidinamine, N-(2-methoxy-5-methylphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)



RN 438248-48-7 CAPLUS
 CN 4-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)



RN 438248-49-8 CAPLUS
 CN 4-Pyrimidinamine, N-(2,5-dimethylphenyl)-2,6-di-2-pyridinyl- (CA INDEX NAME)



OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:531965 CAPLUS

DN 135:107340

TI Preparation of (6-heteroarylpyrimidin-4-yl)oxyacetamides or
-aminoacetamides having selective affinity to peripheral benzodiazepine
receptor BZ α 3

IN Murata, Akiya; Kondo, Masanori; Furukawa, Kiyoshi; Oka, Makoto

PA Dainippon Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001199982	A	20010724	JP 2000-5585	20000114
PRAI	JP 2000-5585		20000114		
OS	MARPAT 135:107340				

AB The title comps. [I; X = O, NR₄; R₁ = H, lower alkyl, lower alkenyl, cycloalkyl-lower alkyl; R₂ = Ala, cycloalkyl, (un)substituted Ph-lower alkyl, (un)substituted Ph, (un)substituted heteroaryl; R₃, R₄ = H, lower alkyl; R₅ = H, lower alkyl, halo; R₆ = (un)substituted heteroaryl; A = (un)substituted heteroaryl or Ph] are prepared. These comps. are useful for the treatment and prevention of anxiety-related diseases, depression, and epilepsy. Thus, a mixture of 4-chloro-2-phenyl-6-(3-pyridyl)pyrimidine, 2-amino-N-methyl-N-phenylacetamide, and Et₃N was stirred under reflux at 150° for 3 h to give N-methyl-N-phenyl-2-[(2-phenyl-6-(3-pyridyl)-4-pyrimidinylamino]acetamide (II). 2-[6-(2-Furyl)-2-(4-pyridyl)-4-pyrimidinylamino]-N,N-dipropylacetamide showed IC₅₀ of 2.9 µg/mL for inhibiting the binding of [3H]4'-chlorodiazepam to benzodiazepine receptor BZ α 3. Pharmaceutical formulations, e.g. tablet containing II, were described.


IT 350490-96-9P 350490-97-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (heteroarylpyrimidinyl)oxyacetamides or -aminoacetamides having selective affinity to peripheral benzodiazepine receptor BZ α 3 for treatment and prevention of anxiety-related diseases, depression, and epilepsy)

RN 350490-96-9 CAPLUS


CN Acetamide, 2-[[6-(2-furanyl)-2-(4-pyridinyl)-4-pyrimidinylamino]-N,N-dipropyl- (CA INDEX NAME)



RN 350490-97-0 CAPLUS

CN Acetamide, 2-[[6-(2-thienyl)-4-pyrimidinylamino]-N-methyl-N-phenyl-

(CA INDEX NAME)



OSC.G 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L22 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1999:639710 CAPLUS

DN 132:12548

TI Amine reactivity changes in imide formation from heterocyclic bases

AU Hawthorne, D. G.; Hodgkin, J. H.

CS CSIRO Molecular Science, Clayton South, 3169, Australia

SO High Performance Polymers (1999), 11(3), 315-329

CODEN: HPPOEX; ISSN: 0954-0083

PB Institute of Physics Publishing

DT Journal

LA English

AB The inclusion of aza-heterocyclic di- or tri-amines in aromatic polyimide formulations can hinder the formation of high mol. weight products. Model studies using the reactions of pyridine, pyrimidine and triazine polyamines with phthalic anhydride and substituted phthalic anhydrides have shown that the combined deactivating effects of multiple aza-substitution and successive imidization of the amino groups can be sufficient to seriously impede or even prevent the formation of fully imidized derivs. Model co-polyimides incorporating 2,4,6-triaminopyrimidine were found to have lowered mol. wts. and to contain persistent free amino groups. Other polyimides containing these amines could be expected to have similar non-ideal structures (defects), which could extend into the structures of products formed from these resins, thereby potentially lessening the extent of any beneficial effects arising from use of the heterocyclic amines.


IT 251349-36-7P 251349-45-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(model compound; amine reactivity changes in imide formation from heterocyclic bases in relation to polyimide formation)


RN 251349-36-7 CAPLUS

CN 1H-isoindole-1,3(2H)-dione, 2,2'-(6-amino-2,4-pyrimidinediyl)bis- (9CI)
(CA INDEX NAME)




RN 251349-45-8 CAPLUS

CN 1H-isoindole-1,3(2H)-dione, 2,2'-(6-amino-2,4-pyrimidinediyl)bis[5-nitro- (9CI) (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1967:443794 CAPLUS
 DN 67:43794
 OREF 67:8235a,8238a
 TI Heterocycles from carboxylic acid derivatives. II. Substituted
 4-hydroxy- and 4-aminopyrimidines
 AU Kabbe, Hans J.
 CS Farbenfabriken Bayer A.-G., Leverkusen, Fed. Rep. Ger.
 SO Justus Liebigs Annalen der Chemie (1967), 704, 144-9
 CODEN: JLACBF; ISSN: 0075-4617
 DT Journal
 LA German
 OS CASREACT 67:43794
 AB cf. preceding abstract Acetic acid alkyl ester and arylacetic acid alkyl
 esters, R'CH₂CO₂R" (R' = H, Ph, substituted phenyl, 1-triazolyl, and
 3-indolyl), react with nitriles RCN (R = 2-, 3-, and 4-pyridyl, and
 2-furyl) (mole ratio 1:2) in the presence of NaOMe to give the
 corresponding 4-hydroxypyrimidines (I). Similarly, acetonitrile and
 arylacetoneitriles, R'CH₂CN (R' = H, Ph, substituted phenyl, 2-furyl, and
 1-naphthyl methyl) react with nitriles, RCN (R = 2-, 3-, and 4-pyridyl,
 2-furyl, and Ph), to give the corresponding 4-aminopyrimidines (II).
 IT 14757-20-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 14757-20-1 CAPLUS
 CN 4-Pyrimidinamine, 2,6-di-4-pyridinyl- (CA INDEX NAME)



proviso

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

10/582,704

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

165.68

362.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-23.80

-23.80

STN INTERNATIONAL LOGOFF AT 21:32:27 ON 02 MAR 2010